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Diabetes is a syndrome caused by lack of insulin and is characterised by
hyperglycaemia and deranged metabolism. The non-physiological doses of insulin
that are used in standard treatment regimens often leads to a mismatch between blood
glucose and plasma insulin concentrations, resulting in hypoglycaemia. The human
brain is dependent upon glucose as its main source of energy and rapidly
malfunctions if deprived of this substrate. Controlled hypoglycaemia can be induced
experimentally using the hyperinsulinaemic glucose clamp technique and this
method can be used to examine the effects of acute hypoglycaemia on cognitive
performance. In general, tests that involve attention, concentration, psychomotor
skill and the ability to ignore distracting information tend to deteriorate when blood
glucose declines below about 3.0 mmol/L. Memory, the cognitive process of storing,
encoding and retrieving information, is one of the most crucial domains of cognition,
yet memory function has seldom been examined during acute hypoglycaemia, and
the few studies that have attempted to do this have provided inconsistent results.
To protect the function and integrity of the central nervous system from
hypoglycaemia and restore homeostasis as rapidly as possible, a hierarchy of
responses are activated when blood glucose falls below 4.0 mmol/1. The rise in
blood glucose is mediated by the secretion of counterregulatory hormones, of which
adrenaline is one of the major components. Sympatho-adrenal stimulation provokes
significant haemodynamic changes, including an increased heart rate and stroke
volume, increased myocardial contractility and a rise in cardiac output. In addition,
peripheral blood pressure is affected with an increase in systolic and decrease in
diastolic pressure, while mean arterial pressure remains unchanged. Pressure values
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in the peripheral circulation are an inaccurate measure of central pressure because of
amplification of the pressure pulse between central and peripheral arteries. Central
systolic and diastolic pressures in the aorta are determinants of cardiac loading and
perfusion and directly influence cardiac function.
The aims of this research project were to examine the effects of acute
hyperglycaemia on cognitive function and mood, the effects of acute hypoglycaemia
on memory function, and to examine the central haemodynamic responses to acute
hypoglycaemia.
Study 1
The effects of experimentally-induced acute moderate hypoglycaemia on
memory function will be examined in 16 non-diabetic humans. It is hypothesised
that memory function will be significantly impaired during hypoglycaemia. Each
subject will participate in two laboratory sessions, representing two different
experimental conditions, that will be separated by at least 2 weeks. A modified
hyperinsulinaemic glucose clamp will be used to maintain the blood glucose at a
predetermined level. In the euglycaemia condition, the arterialised blood glucose
concentration was maintained at 4.5 mmol/L and hypoglycaemia will not be induced.
In the hypoglycaemia condition, the glucose concentration will be lowered to 2.5
mmol/L. The subjects will not be informed which experimental arm of the study is
being performed on each occasion and will undergo the two experimental sessions in
a randomised and counterbalanced fashion. Validated tests of immediate and
delayed verbal memory, immediate and delayed visual memory, and tests of working
memory will be administered during the study conditions. A general linear model
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(repeated measures analysis of variance) will be used to analyse the results with
order of session (euglycaemia-hypoglycaemia or hypoglycaemia-euglycaemia) as a
'between subjects' factor, and condition (euglycaemia or hypoglycaemia) as a
'within subjects' factor. A p value < 0 .05 will be considered to be significant, and
effect size will be calculated using Eta squared.
Study 2
An identical study design will be used to assess memory function during
acute hypoglycaemia in 16 young adults with type 1 diabetes. Identical methods will
be used to assess this separate group and the hypothesis is the same. Subjects
recruited for the study will not have any clinical evidence of microvascular disease,
will have a short duration of diabetes (<10 years) and will have normal symptomatic
awareness of hypoglycaemia.
Study 3
Cognitive function and mood will be examined during acute hyperglycaemia
in 20 subjects with type 2 diabetes. A hyperinsulinaemic glucose clamp will be used
to precisely control the arterialised blood glucose concentration. Two studies will be
performed at two week intervals. In one study, the arterialised blood glucose
concentration will be maintained at 4.5 mmol/1 (euglycaemia), and in the other study
hyperglycaemia will be induced (16-19 mmol/1). Studies will be performed in a
randomised and counterbalanced fashion, and the subjects will be blinded to their
blood glucose concentration at all times. A broad battery of cognitive tests,
including tests of memory and attention, will be administered during the studies. A
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mood questionnaire will also be administered. It is hypothesised that hyperglycaemia
will be associated with impairment of cognitive function and change in mood state.
Study 4
The central haemodynamic effects of acute insulin-induced hypoglycaemia
will be examined in 10 non-diabetic subjects. Pulse wave analysis allows the
measurement of central arterial pressure and the degree of its augmentation by pulse
wave reflection to be studied reliably and non-invasively using applanation
tonometry, with the external application of a micromanometer-tipped probe to record
peripheral pulse waveforms. The radial artery is usually used for these measurements
because of its close proximity to, and support provided by, nearby bony structures.
The pressure contour changes as it travels from the aorta to more peripheral sites so
that pressures at the radial artery cannot be used directly as a surrogate for central
pressure in the aorta. However, it is possible to estimate the central aortic pressure
wave from measurements of radial artery tonometry with the use of a mathematical
transformation. Acute hypoglycaemia will be induced by a continuous intravenous
infusion of insulin. The infusion will be continued until the onset of the autonomic
reaction associated with the induction of hypoglycaemia. The autonomic reaction is
identified as an abrupt rise in heart rate (15% above baseline), the rapid onset of
symptoms of hypoglycaemia (such as sweating and tremor), and an increase in
systolic blood pressure as measured peripherally. As soon as the autonomic reaction
has been reached hypoglycaemia will be reversed to restore normoglycaemia within
30 minutes. Serial measurements of radial artery pressure will be recorded by
applanation tonometry using a hand held tonometer. Heart rate will be monitored
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continuously throughout the study using precordial electrodes. Peripheral blood
pressure will be recorded every 10 minutes using a digital automated
sphygmomanometer.
Study 5
A similar study design will be used to examine the central haemodynamic
responses to insulin-induced hypoglycaemia in ten subjects with short duration (<10
years) type 1 diabetes.
Study 6
A further study, using an identical study design, will be used to measure the
central haemodynamic changes in response to acute hypoglycaemia in ten subjects
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Aim: To examine the effects of acute insulin-induced hypoglycaemia on short-term-,
delayed- and working memory in healthy adults.
Research Design and Methods: A hyperinsulinaemic glucose clamp was used to
maintain arterialised blood glucose at either 4.5 (euglycaemia = E) or 2.5
(hypoglycaemia = H) mmol/1 on two occasions in 16 non-diabetic human volunteers.
Tests of immediate and delayed verbal memory, immediate and delayed visual
memory and working memory were administered during each experimental
condition. Two tests of general cognitive ability, the Trail Making B and Digit
Symbol tests, were also administered.
Results: Immediate verbal memory was assessed by the Auditory Verbal Learning
Test (AVLT) and Logical Memory test. Scores deteriorated from a mean (SD) of
43.6 (7.0) and 27.7 (5.9) during E to 33.9 (7.7) (p=0.001) and 24.4 (5.0) (p=0.004)
during H, respectively. The Benton Visual Retention Test, a test of immediate visual
memory, deteriorated from 6.3 (1.7) (E) to 5.3 (1.6) (H) (p=0.041). The effect of
hypoglycaemia on working memory was very powerful. Four-term Order
deteriorated from 11.5 (4.9) (E) to 2.5 (1.9) (H) (p<0.0001). Three other tests of
working memory showed an equivalent degree of decrement during H. Delayed
memory, assessed by AVLT Delayed, deteriorated from 10.3 (2.1) (E) to 4.5 (1.6)
(H) (p<0.0001). Logical Memory Delayed deteriorated from 15.1 (4.0) (E) to 8.1
(2.9) (H) (p=0.001) and Visual Reproduction Delayed deteriorated from 21.5 (16.5)
(E) to 7.6 (5.5) (H) (p=0.001). Performance in the Trail Making B and Digit Symbol
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tests deteriorated from a mean (SD) of 41.5 (7.9) seconds and 70.1 (13.0) during E to
62.6 (11.0) seconds (p<0.0001) and 59.6 (14.4) (p=0.001) during H respectively.
Conclusions: All memory systems are impaired during acute hypoglycaemia, with
working memory and delayed memory being particularly susceptible. These findings
are of importance to people with insulin-treated diabetes, in whom mild (self-treated)
hypoglycaemia is common, and in whom such effects of hypoglycaemia on memory
will interfere with many daily activities.
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Study 2
Aim: To examine the effects of acute insulin-induced hypoglycaemia on short-term,
delayed and working memory in people with type 1 diabetes.
Research Design and Methods: A hyperinsulinaemic glucose clamp was used to
maintain arterialized blood glucose at either 4.5 (euglycaemia = E) or 2.5
(hypoglycaemia = H) mmol/1 on two separate occasions in 16 adults with type 1
diabetes. The participants completed tests of immediate and delayed verbal memory,
immediate and delayed visual memory, and working memory during each
experimental condition. Two other mental tests, the Trail Making B and Digit
Symbol tests, were also administered.
Results: Performance in tests of immediate verbal and immediate visual memory
was significantly impaired during hypoglycaemia. The effect of hypoglycaemia on
working memory and delayed memory was more profound. Performance in the non-
memory tests, the Trail Making B and Digit Symbol Tests, also deteriorated during
hypoglycaemia.
Conclusions: All of the memory systems examined in the present study were
affected significantly by acute hypoglycaemia, particularly working memory and
delayed memory. As mild (self-treated) hypoglycaemia is common in people with
insulin-treated diabetes, these observed effects of hypoglycaemia on memory are of
potential clinical importance, as they could interfere with many everyday activities.
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Study 3
Aim: To examine the effects of acute hyperglycaemia on cognitive function and
mood in people with type 2 diabetes.
Research Design and Methods: 20 subjects with type 2 diabetes (median (range)
aged 61.5 (53.1-72.0) years with Body Mass Index 29.8 (22.0-34.6) kg/m2, duration
of diabetes 5.9 (2.8-11.2) years and HbAlc 7.5 (6.7-8.4) %) were recruited to the
study. A hyperinsulinaemic glucose clamp was used to maintain arterialised blood
glucose at either 4.5 (euglycaemia) or 16.5 (hyperglycaemia) mmol/1 on two
occasions in a randomised and counterbalanced fashion. Tests of information
processing, immediate and delayed memory, working memory and attention were
administered with a mood questionnaire during each experimental condition.
Results: Performance in complex tests of cognitive function was impaired during
acute hyperglycaemia. For example, the Four Choice Reaction Time test, a test of
information processing, deteriorated from a mean (SD) score of 710 (116)
milliseconds during euglycaemia to 775 (122) milliseconds during hyperglycaemia
(p<0.0001, eta2=0.56). Mood was also significantly affected during hyperglycaemia,
with a decrease in energetic arousal and hedonic tone, and an increase in tense
arousal.
Conclusions: Acute hyperglycaemia causes impairment of cognitive function and
alteration of mood state in people with type 2 diabetes. These findings are of
practical importance to people with type 2 diabetes, in whom mild hyperglycaemia is
common, and in whom such effects of hyperglycaemia on cognitive function and
mood may interfere with many daily activities.
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Studies 4, 5 and 6
Aim: To examine the effects of intravenous insulin and acute hypoglycaemia on
arterial wall stiffness and central haemodynamic responses in adults with and without
type 1 diabetes.
Research Design and Methods: In thirty young male volunteers (10 non-diabetic;
10 with type 1 diabetes <5 years duration; 10 with type 1 diabetes >15 years
duration) intravenous insulin was administered to provoke an acute autonomic
reaction (R) to hypoglycemia. Heart rate, peripheral blood pressure and pulse wave
analysis (radial artery) were monitored. Augmentation index (AIx), a measure of
arterial wall stiffness and wave reflection, and central arterial pressure were
recorded.
Results: At baseline no significant differences were observed between Groups 1 and
2 in either AIx or in central arterial pressure but in Group 3 both measures were
significantly higher. All three groups exhibited similar responses to intravenous
infusion of insulin and to hypoglycaemia: AIx fell progressively from baseline to R,
peripheral systolic blood pressure increased, while central systolic pressure
decreased
Conclusions: When compared to age- and sex-matched non-diabetic controls,
people who had type 1 diabetes of long duration had increased stiffness of vessel
walls. The opposing responses in peripheral and central systolic pressures during
hypoglycaemia may be related to the reduction in AIx, which causes diminished
amplification of the systolic pressure wave. Changes in AIx are probably mediated
by a direct action of insulin on arterial endothelium, or changes in heart rate. These
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functional changes may contribute to the increased cardiovascular morbidity that is






Pathophysiological and Clinical Aspects of Hypoglycaemia
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INTRODUCTION
Hypoglycaemia is a common side-effect of treatment with insulin and affects
most people with insulin-treated diabetes (1). Hypoglycaemia is also associated with
sulphonylurea therapy, but occurs much less frequently. Physiological insulin secretion
requires transient peaks of plasma insulin associated with meals and with a relatively
constant and low basal level of insulin secretion during periods of fasting. Most current
methods of insulin replacement therapy for people with diabetes are far from
physiological, and intra- and inter-individual absorption of insulin is highly variable.
Despite improvements in insulin formulations, methods of insulin delivery and treatment
regimens, fluctuations in blood glucose are common and it remains difficult to match the
administration of exogenous insulin to an individual's energy requirements on a daily
basis. Occasional and unpredictable hypoglycaemia is therefore almost an inevitable
consequence of effective insulin therapy. Hypoglycaemia can be extremely unpleasant,
is associated with acute and chronic morbidity (2), and can impinge on every aspect of
everyday life. Severe hypoglycaemia is greatly feared and is the major limiting factor to
achieving and maintaining good glycaemic control.
The Diabetes Control and Complications Trial (DCCT) (3) and the Stockholm
Diabetes Intervention Study (SDIS) (4) in type 1 diabetes, and the UK Prospective
Diabetes Study (UKPDS) (5) in type 2 diabetes evaluated the effect of strict glycaemic
control on the incidence and progression of diabetic complications and documented the
frequency of adverse effects of treatment. These studies have shown unequivocally that
strict glycaemic control limits the development and progression of diabetic
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microangiopathy, but is accompanied by a higher rate of severe hypoglycaemia,
particularly in type 1 diabetes. Current therapeutic policies that attempt to achieve
continuous normoglycaemia with intensive insulin regimens, and the increasing use of
insulin at an earlier stage of management in type 2 diabetes, are likely to promote more
frequent hypoglycaemic events of varying severity. It is important that physicians
recognise the potential risks associated with hypoglycaemia, as deliberate avoidance of
this problem influences modern therapeutic strategies for the clinical management of
diabetes.
MAINTENANCE OF NORMOGLYCAEMIA IN HUMANS
The human brain is dependent upon glucose as its main source of energy and
rapidly malfunctions if deprived of this substrate. To protect the function and integrity
of the central nervous system and restore homeostasis as quickly as possible, a hierarchy
of responses are activated when the blood glucose concentration falls (6-10).
Continuous adjustment of blood glucose is controlled through a blood glucose
sensor mechanism in the portal circulation, with central feedback to the brain, which
modifies insulin secretion (11). This system responds to, and controls, the normal
physiological fluctuations in blood glucose in response to the ingestion of food and the
energy demands of exercise, but is unable to cope with a significant decline in blood
glucose associated with the hyperinsulinaemia caused by administration of exogenous
insulin. Insulin inhibits hepatic and renal glucose production, and stimulates glucose
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uptake and utilisation by peripheral tissues, especially skeletal muscle, causing a fall in
blood glucose. The initial response to a decline in blood glucose is the suppression of
endogenous insulin secretion, which commences at an arterialised blood glucose
concentration of approximately 4.6 mmol/1, well within the normal physiological range.
The subsequent prevention and correction of hypoglycaemia is dependent on the
secretion of various counterregulatory hormones, the principal ones being glucagon,
adrenaline, growth hormone and Cortisol. Glucagon works only in the liver and
stimulates hepatic glucose production, while adrenaline stimulates hepatic and renal
glucose production and limits peripheral glucose utilisation. Adrenaline is not essential
for the correction or prevention of hypoglycaemia, but its role becomes critical when
glucagon is deficient or absent. Growth hormone and Cortisol also restrict glucose
utilisation and support glucose production, but have a lesser role in the hierarchy of
acute counterregulatory activity as their actions occur more slowly than glucagon and
adrenaline, and they have greater importance in the counterregulatory response to
prolonged hypoglycaemia.
Studies in animals have indicated that counterregulatory responses are initiated
by the stimulation of glucose sensors within the hypothalamus in the brain (7), in
addition to the the peripheral sensor mechanism in the portal vein (11), and glucopenia
appears to have a direct effect on the alpha cells of the pancreatic islets to promote
glucagon secretion (7). Central activation of the autonomic nervous system results in
stimulation of the peripheral sympatho-adrenal system and includes a profuse secretion
of adrenaline, equivalent to that observed in major medical emergencies such as acute
myocardial infarction. While adrenaline has a prominent counterregulatory role, it also
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augments physiological responses that occur as a consequence of autonomic arousal,
such as characteristic haemodynamic changes (e.g. tachycardia) and sweating. These
changes invoke subjective sensations that are interpreted by the brain as symptoms of
hypoglycaemia. Thus, generation of these warning symptoms alert the individual to the
potential threat that hypoglycaemia poses to the brain and so stimulate an appropriate
behavioural response (the ingestion of food).
The glycaemic thresholds at which the secretion of the counterregulatory
hormones commences, are just below the normal physiological range of blood glucose
(arterial blood glucose concentration 3.8 mmol/1). By contrast, the glycaemic thresholds
for the onset of symptoms of hypoglycaemia (3.0 mmol/1) and the development of
cognitive impairment (2.7 mmol/1) occur at lower blood glucose concentrations.
Glycaemic thresholds are reproducible in non-diabetic individuals (12) (Figure 1.1), but
are dynamic in people with diabetes and can be altered by external factors such as very
strict glycaemic control or recent preceding (antecedent) hypoglycaemia (13).
30
Figure 1.1: Hierarchy of endocrine, symptomatic and neurophysiological responses to
acute hypoglycaemia in non-diabetic subjects. Reproduced from Textbook ofDiabetes,



































The development of subjective symptoms of hypoglycaemia is fundamental to
the early detection and treatment of hypoglycaemia. Perception and interpretation of the
symptoms is crucial to this process, and is inherent to the concept of 'awareness' of
hypoglycaemia. Symptoms are idiosyncratic with considerable individual variation in
their nature and intensity in adults, and can be classified as autonomic, neuroglyopenic
or non-specific (Table 1.1) (14). Autonomic symptoms, such as tremor, palpitations and
sweating, are generated through activation of the sympatho-adrenal system. Because
glucose is the principal energy source for the brain, hypoglycaemia rapidly affects and
impairs neuronal function through neuroglycopenia, that is manifested by symptoms
such as confusion, drowsiness and incoordination. The range of symptoms of
hypoglycaemia is age-specific. In children features of behavioural change are common
(15,16), while in the elderly neurological symptoms are prominent (17,18). Both the
character and the intensity of symptoms may change over time and are affected by
numerous biological and psychosocial modifiers. Factors that affect the magnitude of
the physiological responses to hypoglycaemia include the depth and duration of
hypoglycaemia, the rate of decline of blood glucose, and, in a person with diabetes, the
duration of diabetes, the quality of glycaemic control and history of previous exposure to
hypoglycaemia. The symptoms of hypoglycaemia are also modified by posture (the
intensity of autonomic symptoms is greater when standing compared to lying) (19),
medications, such as sedatives and beta-adrenoceptor blockers (20), and alcohol (21).
Circumstances and activities can also affect the identification of symptoms. Diminished
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perception of warning symptoms may be associated with the syndrome of impaired
awareness ofhypoglycaemia (see Chapter 1.2).
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Table 1.1: Common symptoms of hypoglycaemia in humans (based on Deary et al,
1999)
Autonomic Neuroglycopenic Non-specific
Sweating Confusion General malaise
Palpitations Drowsiness Headache





Because blood glucose excursions are very tightly controlled in the non-diabetic
state, spontaneous hypoglycaemia is very rare, whereas episodic hypoglycaemia is
common in people with insulin-treated diabetes (1). An episode of hypoglycaemia is
classified as mild, if the individual is able to self-treat, and severe if the individual
requires the assistance of another person. Severity is not classified either by the nature
or intensity of the symptom response, the effect on conscious level, or the type of
treatment required.
Causation is often multifactorial and no definite cause can be identified in many
episodes of severe hypoglycaemia, which usually result from a mismatch between the
absorption of food and insulin, and may be aggravated by a failure to perceive a
symptomatic warning.
Common causes of hypoglycaemia are listed in Table 1.2. These include:
Dosage errors: In addition to failure to adjust insulin dosage appropriately for
premeditated exercise or reduced or delayed intake of food, mistakes occur in the
measurement of insulin doses, particularly in people with visual impairment or those
with a faulty injection technique. The impact of a small error in insulin dose is much
greater in young children.
Exercise: If plasma insulin concentrations are low, exercise stimulates increased hepatic
glucose production and promotes hyperglycaemia. However, if they are high, hepatic
glucose production and peripheral glucose utilisation are inhibited and, unless more
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carbohydrate is consumed, hypoglycaemia will ensue. The absorption of insulin is
accelerated if exercise commences shortly after the insulin injection (particularly when
the insulin has been injected into an exercised limb, such as the leg), and enhances the
risk of hypoglycaemia.
Renal Failure: Insulin requirements are lower in people whose renal function is
impaired, as their metabolic clearance of insulin is reduced. People with renal
impairment have a five-fold higher incidence of severe hypoglycaemia compared to
matched subjects with normal kidney function (22).
Co-existent endocrine disease: Any condition which decreases the concentration of anti-
insulin hormones will increase insulin sensitivity and predispose to the development of
hypoglycaemia. Endocrine disorders which result in Cortisol deficiency, such as
Addison's disease and hypopituitarism, are associated with a higher frequency of
hypoglycaemia.
Malabsorption and gastroparesis: Malabsorptive conditions, such as coeliac disease
(which is associated with type 1 diabetes), and delayed gastric emptying or frank
gastroparesis resulting from autonomic neuropathy, can decrease or delay carbohydrate
digestion and absorption, and promote hypoglycaemia (23).
Factitious hypoglycaemia-. Deliberate induction of hypoglycaemia is associated with
psychological or psychiatric disorders and is often difficult to detect or confirm. It
should be suspected if repeated severe hypoglycaemia occurs with no obvious cause.
This problem is sometimes observed in young women who are recognised to have
unstable glycaemic control, and is sometimes referred to as 'brittle' diabetes.
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Sulphonylurea therapy is also associated with hypoglycaemia (5), although it
occurs less frequently than with insulin and is seldom as severe. It is commoner with
many of the long-acting sulphonylureas, such as glibenclamide (24). Advanced age and
fasting have been identified as major risk factors associated with sulphonylurea-induced
hypoglycaemia (25), and others are listed in Table 1.3. Adverse drug interactions are
recognised to occur between sulphonylureas and other commonly prescribed
medications that may increase the risk of sulphonylurea-induced hypoglycaemia. In one
comprehensive review, 15% of patients who had developed sulphonylurea-induced
hypoglycaemia were simultaneously taking medications known to increase the risk of
hypoglycaemia (25). Drugs that can potentiate the biological activity of sulphonylureas
include aspirin, warfarin, non-steroidal anti-inflammatory drugs and alcohol.
The risk factors for severe hypoglycaemia in adults with insulin-treated diabetes
are listed in Table 1.4, and include:
Strict glycaemic control. Within the last decade, the results ofmajor prospective studies
have confirmed that strict glycaemic control in type 1 diabetes is associated with a three¬
fold greater risk of hypoglycaemia (3,4,26), as the margin for error is small.
Impaired awareness ofhypoglycaemia-. Perception of the onset of warning symptoms of
hypoglycaemia is either diminished or absent in approximately 25% of people with type
1 diabetes (27,28), but this is uncommon in people with insulin-treated type 2 diabetes
(29). In this syndrome, the early onset of hypoglycaemia is not detected and a six-fold
higher frequency of severe hypoglycaemia is reported (30).
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Sleep: Most people do not experience symptoms of hypoglycaemia during sleep when
catecholamine responses to hypoglycaemia are diminished (31), and are seldom
wakened by a low blood glucose. Sleep is therefore a true physiological cause of
impaired awareness of hypoglycaemia. Nocturnal hypoglycaemia is common in people
treated with insulin.
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Table 1.3: Risk factors associated with sulphonylurea therapy (e.g. glibenclamide,
glipizide) in type 2 diabetes
• Age (not dose)
• Previous history of cardiovascular disease or stroke
• Impaired renal function
• Reduced food intake
• Gastrointestinal disease e.g. diarrhoea
• Alcohol ingestion
• Interaction with other drugs
Table 1.4: Risk factors for severe hypoglycaemia
• Strict glycaemic control
• Impaired hypoglycaemia awareness
• Previous history of severe hypoglycaemia
• Increasing age
• Sleep
• Excessive consumption of alcohol or binge drinking
• Lower social class
• C-peptide negativity; serum ACE concentration
• Renal impairment





People with type 1 diabetes who attempt to achieve strict glycaemic control
generally experience an undetermined number of episodes of asymptomatic biochemical
hypoglycaemia; blood glucose concentrations have been estimated to be below 3.3
mmol/1 around 10% of the time (32). Mild episodes of symptomatic hypoglycaemia are
usually quickly forgotten by the individual and can only be recalled with accuracy for up
to one week (33). The recollection of episodes of severe hypoglycaemia is more robust,
but total amnesia of an event is not uncommon, and enquiries may have to be made of
relatives or friends to obtain an accurate estimate.
Several studies have examined how often hypoglycaemia occurs in people with
type 1 diabetes. There is some disparity between reported frequencies, which is
principally related to differences in definition of severity of hypoglycaemia,
heterogeneity of diabetic populations studied, the quality of glycaemic control, and
accuracy of the methods of ascertainment (prospective vs. retrospective). A multicentre
study that was performed in Denmark and England recorded the annual frequency of
hypoglycaemia prospectively in over 1000 people with type 1 diabetes (34). Mild
hypoglycaemia was common with an incidence of 2.0 episodes/patient/week, and the
incidence of severe hypoglycaemia was 1.3 episodes/patient/year. The frequency of
episodes of severe hypoglycaemia was noted to increase with duration of diabetes, and
with a rising prevalence of impaired awareness of hypoglycaemia. These figures are
similar to the results of a previous study (33), performed more than a decade earlier,
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when different insulin regimens and formulations were in use. The incidence of severe
hypoglycaemia was similar to those reported by other studies of unselected patient
cohorts in various northern European countries (1.0-1.7 episodes/patient/year) in which
the same definitions ofhypoglycaemia were used (2,4,33,35,36).
In the large prospective DCCT study, a lower incidence of severe hypoglycaemia
of 0.6 episodes/patient/year was recorded in the group with strict glycaemic control (26),
but this was still three fold higher than the group with conventional treatment and less
strict control. However, in the DCCT the participants were a highly selected and
atypical group of young, healthy, motivated individuals of above average intelligence,
who had type 1 diabetes of short duration, and the cohort did not include people with a
history of preceding severe hypoglycaemia. German surveys which have recorded lower
rates of severe hypoglycaemia (37) used a more rigorous definition for severe
hypoglycaemia (coma and/or requiring parenteral therapy), whereas when the consensus
definition of 'requiring external assistance' was applied, their frequency was similar to
other studies (38).
These rates of severe hypoglycaemia have been derived in Western European
and North American populations and may not be comparable in other parts of the world,
where the frequency of insulin-treated diabetes and the treatment regimens may differ
considerably.
Type 2 diabetes
Iatrogenic hypoglycaemia is widely considered to be less frequent in type 2
diabetes than type 1 diabetes (5,39,40). It is principally associated with insulin
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treatment and the frequencies recorded with different treatment modalities in the
UKPDS are shown in Table 1.5. Several other studies have also examined the frequency
of hypoglycaemia in people with insulin-treated type 2 diabetes. A large 12-month
retrospective, cross-sectional study of African Americans with type 2 diabetes revealed
that mild hypoglycaemia occurred in 30% of patients treated with insulin and in 16% of
those on oral hypoglycaemic agents; severe hypoglycaemia occurred only in those
taking insulin (41). As is observed in type 1 diabetes, the incidence of hypoglycaemia in
people with type 2 diabetes is greater with intensive therapy. However, the event rates
of severe hypoglycaemia were approximately 10-fold lower in type 2 diabetes even
during aggressive therapy with insulin (5). People with advanced type 2 diabetes (i.e.
who are insulin-deficient) have deficient hormonal counterregulation (42), analogous to
what is observed in type 1 diabetes. Hypoglycaemia becomes progressively more
frequent with an increase in duration of insulin-treatment for type 2 diabetes, and when
they are matched for duration of insulin therapy the rates of severe hypoglycaemia begin
to approach those recorded in people with type 1 diabetes (29). Thus people with type 2
diabetes progressively resemble those with type 1 diabetes with respect to risk of
hypoglycaemia.
Hypoglycaemia is a side-effect of sulphonylurea therapy. A study of
sulphonylurea-induced hypoglycaemia that was of sufficient severity to require hospital
treatment recorded an annual incidence of 4.2 per 1000 patients (43), but other European
studies have estimated the frequency of severe hypoglycaemia to be much lower at 0.19-
0.25 per 1000 patient years (44,45). A 2-year prospective trial that involved 321
subjects with type 2 diabetes, receiving treatment with either chlorpropramide or
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glibenclamide, recorded an incidence of symptomatic hypoglycaemia of 19 episodes per
1000 patient years (46). Many studies have recorded higher rates of hypoglycaemia
with long-acting sulphonylureas. A 12-year study in Switzerland demonstrated that
treatment with long-acting sulphonylureas was three times more likely to precipitate
admission to hospital with severe hypoglycaemia than the use of short-acting
sulphonylureas (24). However, not all long-acting sulphonylureas provoke
hypoglycaemia. The incidence of hypoglycaemia was reported to be low with the use of
glimepiride which is administered once daily and stimulates insulin production primarily
in response to meals (47). Almost all sulphonylurea drugs are metabolised in the liver to
metabolites that are subsequently excreted in the urine. While most of these metabolites
either have minimal or no metabolic activity, the two major hepatic metabolites of
chlorpropramide do possess hypoglycaemic activity. Renal impairment prolongs the
biological activity of many sulphonylureas and treatment should then be with a
sulphonylurea that is metabolised mainly in the liver, such as gliclazide.
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Table 1.5: Annual percentage (95% CI) of patients reporting at least one hypoglycemic
episode in relation to demographic characteristics and therapy. Data derived from the
UKPDS, 1998 (5).
N Any Severe
Diet alone 756 0.8 (0.6 to 1.0) 0.1 (0.1 to 0.2)
Sulphonylurea 1418 7.0 (5.1 to 11.9) 1.2 (0.4 to 3.4)
Metformin 290 1.7(1.0 to 3.0) 0.3 (0.1 to 1.1)
Basal insulin alone 1036 21.2 (14.6 to 29.8) 3.8 (1.2 to 11.1)
Basal plus prandial insulin 38 32.6 (21.8 to 45.6) 5.5 (2.0 to 14.0)
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MORBIDITY AND MORTALITY
Effects on the Cardiovascular System (Table 1.6)
Acute hypoglycaemia provokes pronounced haemodynamic changes that include
an increase in heart rate, stroke volume, myocardial contractility and cardiac output, and
widening of pulse pressure (48,49). Regional changes in circulation occur during
hypoglycaemia to increase the blood flow to vital organs such as the brain, and to the
liver and skeletal muscle for the delivery of gluconeogenic precursors, while perfusion
of non-essential organs such as the kidneys and spleen is reduced (49). Acute
hypoglycaemia also has significant transient effects on peripheral blood, which
encourage haemostasis and increase blood viscosity (49). These changes influence
capillary blood flow and in some tissues may predispose to intravascular stasis during
hypoglycaemia. The haemodynamic and haematological changes that occur during
acute hypoglycaemia do not appear to compromise vascular perfusion in the normal
healthy vasculature, but they may have potentially adverse effects in people with
diabetes, in whom endothelial dysfunction and vascular disease are common, and in
whom premature atherosclerosis and macrovascular disease are often present.
Hypoglycaemia may precipitate an acute vascular event or a dysrhythmia (49,50)
in people who have pre-existing coronary heart disease or may compromise myocardial
contractility in people who have the specific heart disease of diabetes. The secretion of
adrenaline causes a rapid fall in plasma potassium (51), which could promote
prolongation of ventricular repolarisation. Electrocardiographic changes, including
prolongation of the QT interval, T wave flattening and inversion, and ST segment
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depression, have been demonstrated during experimentally-induced hypoglycaemia (52),
and transient cardiac arrhythmias have occasionally been demonstrated in non-diabetic
and diabetic subjects during hypoglycaemia (50). These electrophysiological changes
may lead to the generation of a serious cardiac arrhythmia, especially in the presence of
occult coronary heart disease. Angina, myocardial infarction, acute cardiac failure and
cardiac arrest have been described, albeit infrequently and anecdotally, as the direct
consequences of acute hypoglycaemia (50,53). The true incidence of these events is
unknown but may be underestimated in clinical practice because the precipitating factor
of acute hypoglycaemia is either overlooked, may already have been treated, or
counterregulation may have raised the blood glucose by the time the patient receives
medical attention.
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Table 1.6: Cardiovascular effects of acute hypoglycaemia
Physiological changes Potential pathological sequelae
• Increased heart rate • Silent myocardial ischaemia
• Widening ofpulse pressure • Angina; myocardial infarction
• Increased cardiac output • Arrhythmias




Physical injury occurring as a result of severe hypoglycaemia is relatively
common. In a retrospective survey of people with insulin-treated diabetes (2),
approximately 10% had suffered a physical injury related to severe hypoglycaemia at
some time during their treatment with insulin. These included skeletal injuries with
fractures and joint dislocations, head injuries and burns in addition to the more frequent
minor soft tissue injuries of bruises, cuts and lacerations. Injuries may occur as a result
of falls following dizziness, inco-ordination, drowsiness, loss of consciousness, or
convulsions (54) and may be a consequence of driving-related accidents associated with
hypoglycaemia.
Effects on the Central Nervous System
The effects of hypoglycaemia on the central nervous system are discussed in
Chapter 1.2.
Potential effect on microvascular disease
The profound haemodynamic changes that occur in response to acute
hypoglycaemia may have functional effects on vascular flow and may damage
capillaries that are already abnormal. The sudden changes in arterial pressure and
capillary blood flow may expose the microvasculature to fluctuating stress of varying
magnitude. It has been postulated that these changes, in combination with increased
plasma viscosity and coagulability, may affect the capillary circulation, reducing
capillary blood flow, encouraging stasis, thrombosis and capillary closure and so
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producing localised ischaemia and hypoxia in vulnerable tissues such as the retina and
renal glomeruli (55). This may lead to capillary closure in tissues already affected by
diabetic microvascular disease.
Anecdotal reports have associated nocturnal hypoglycaemia with acute vitreous
haemorrhage in patients who had untreated proliferative diabetic retinopathy (56,57).
The cause may be related to the sudden fall in intra-ocular pressure which occurs in
response to acute hypoglycaemia (58), with the effects of sudden mechanical stress and
changes in perfusion pressure causing rupture of delicate new vessels in the retina and
vitreous humour. However, rapid improvement in glycaemic control in people with
longstanding type 1 diabetes who have established background diabetic retinopathy is
associated with a worsening of retinopathy (59). While the principal cause for the
development of retinal ischaemia during strict glycaemic control is presumed to be the
rapid reduction in the retinal hyperperfusion that is associated with chronic
hyperglycaemia, it is tempting to speculate that recurrent acute hypoglycaemia may have
a contributory role. Hypoglycaemia also causes an acute reduction in renal plasma flow
and glomerular filtration (60), and theoretically may influence progression of glomerular
and arteriolar sclerosis in patients with diabetic nephropathy, although at present there is
no evidence to support this premise.
Mortality
Severe hypoglycaemia has been implicated in 2-4 % of deaths in the insulin-
treated diabetic population (61,62). The number is difficult to estimate with accuracy
because of the difficulty of identifying and confirming that death has directly resulted
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from hypoglycaemia (61), particularly in the fatal outcome of an acute vascular event.
The risk of sudden death in people with insulin-treated diabetes is higher than that of a
non-diabetic population of equivalent age, and in younger people this is principally
attributable to metabolic causes, ofwhich severe hypoglycaemia predominates (62).
Hypoglycaemia has been implicated in the 'dead in bed' syndrome (63-65), in
which young people with type 1 diabetes, who have been in good health and have been
sleeping alone, are found dead in an undisturbed bed. The 'dead in bed' syndrome
accounts for 6% of deaths amongst individuals with type 1 diabetes under 40 years of
age, occurring at a rate of two to six events per 100,000 patient years (65).
Hypoglycaemia-induced cardiac arrhythmia, acute respiratory arrest with impaired
baroreflex sensitivity (66) or undetected autonomic dysfunction (67), have been
suggested as possible causative mechanisms. The sudden development of a fatal cardiac
arrhythmia is the most likely explanation as death following neuroglycopenic cerebral
damage is relatively slow and produces characteristic histopathological changes in the
brain.
The manifestations of hypoglycaemia are unpleasant and frightening (68) and the
consequences of severe hypoglycaemia can be serious. Severe hypoglycaemia is very
disruptive and can impinge on every aspect of daily life. It can occur at any time of the
day or night and is frequently unpredictable. The ever-present risk of hypoglycaemia
and its possible ramifications often causes long-term emotional distress. Psychological
PSYCHO-SOCIAL EFFECTS OF HYPOGLYCAEMIA
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manifestations include decreased happiness, chronic anxiety and depression (69,70), and
rarely may induce a phobia (71). Such is the fear of hypoglycaemia and its potential
outcomes, that many people with diabetes regard it with the same degree ofworry as the
development of serious long-term complications of diabetes, such as sight-threatening
retinopathy or renal failure (33) (Figure 1.2). Hypoglycaemia may also cause significant
psychological upset in family members, particularly spouses or partners (72) and the
parents of diabetic children (73). This can influence the approach to self-care of
diabetes by the individual or by carers and relatives and may encourage poor or
suboptimal glycaemic control in an attempt to avoid severe hypoglycaemia (74).
Hypoglycaemia is a potential hazard when driving (75,76), and can affect
employment prospects. In most Western countries, vocational driving licences (for
large goods vehicles and passenger carrying vehicles) are not permitted for drivers with
diabetes taking insulin, and the development of impaired awareness of hypoglycaemia or
recurrent severe hypoglycaemia can cause the revocation of an ordinary driving licence.
Because hypoglycaemia is a potential risk in the workplace, in Europe and North
America insulin-treated diabetic patients are excluded from dangerous or high-risk
occupations, and occasionally may suffer discrimination by employers. The risk and
development of hypoglycaemia at work can result in enforced changes in, and
sometimes loss, of employment. In the longer-term, all of these problems may enforce
lifestyle changes.
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Figure 1.2: Results on a visual analogue scale, showing attitudes and concerns towards
different aspects of diabetes, as indicated by patients with Type 1 diabetes. Reproduced











Not worried Very worried
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TREATMENT
Insulin-treated patients who are conscious and able to swallow should be given
oral carbohydrate. Guidelines exist for the self-treatment of mild symptomatic
hypoglycaemia, and suggest the initial consumption of 10-15 grams of fast-acting
carbohydrate, preferably as glucose (e.g. 2-3 dextrose tablets) followed by longer-acting
carbohydrate in the form of starch. Unconscious patients should receive 50% dextrose
as an intravenous bolus of 20-50 ml and, if hypoglycaemia is protracted, an intravenous
infusion of 10-20% dextrose may be required to maintain euglycaemia. Intramuscular or
intravenous glucagon may also be given, but if the hypoglycaemia has been precipitated
by, or is associated with, excessive alcohol intake, glucagon may be ineffective as
alcohol blocks the glycogenolytic action of glucagon to convert hepatic glycogen into
glucose. Glucagon is not recommended for the treatment of sulphonylurea-induced
hypoglycaemia on the theoretical basis that it can stimulate further endogenous insulin
release. Patients who are being treated with sulphonylureas may need admission to
hospital for the treatment of severe hypoglycaemia. A long-acting sulphonylurea such
as glibenclamide has a long half-life and the hypoglycaemia may therefore persist or
recur, necessitating maintenance of a dextrose infusion for 3 to 5 days.
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PREVENTION
Prevention is better than cure and it is essential that newly diagnosed patients
with type 1 diabetes, and people with type 2 diabetes who are commenced on insulin
therapy, receive adequate education about the potential risks of hypoglycaemia, its
treatment and prevention. Instruction on the prevention and emergency treatment of
hypoglycaemia should embrace the patient's relatives and friends, and if in employment,
the employer and colleagues at work should also be informed. Because the symptoms of
hypoglycaemia are idiosyncratic, early familiarisation of patients with the symptoms that
are peculiar to themselves is important. Because the nature and intensity of symptoms
may alter with time, the symptoms of hypoglycaemia should be reviewed at regular
intervals (14). The relationships between insulin administration and timing of meals
must be explained, and specific advice is required for driving, premeditated exercise,
including sport, and holidays. Specific subgroups, such as people who have impaired
awareness of hypoglycaemia (Table 1.7), and those who have a history of recurrent
nocturnal hypoglycaemia (Table 1.8) may require additional advice. There is some
evidence that some individuals who have developed impaired awareness of
hypoglycaemia may regain their symptomatic awareness if hypoglycaemia can be
strictly avoided (77-80), although this is often very difficult to achieve in clinical
practice. However, it may be possible with the utilisation of newer treatments and
technology such as a wider range of insulin analogues, insulin pumps (continuous
subcutaneous insulin infusion) and the imminent prospect of methods of continuous
blood glucose monitoring.
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Short-acting insulin analogues, which have a rapid onset and short duration of
action, are effective in reducing the incidence of hypoglycaemia in people with type 1
diabetes (81). They are of particular benefit in people with unpredictable lifestyles, as
they allow greater flexibility in timing and dosage of insulin and timing of meals. The
long-acting insulin analogue, insulin glargine, has been shown in some studies to be
beneficial in reducing the incidence of hypoglycaemia, particularly at night (81).
Other important prophylactic measures include the choice of appropriate insulin
regimens and dose schedules, or anti-diabetic drugs in type 2 diabetes, and the
establishment of appropriate therapeutic goals. Intensive insulin therapy is
contraindicated in people with impaired awareness of hypoglycaemia and in those with a
history of recurrent severe hypoglycaemia, because of the risks of strict glycaemic
control in these conditions. For people with type 2 diabetes, precautions need to be
undertaken to avoid hypoglycaemia associated with sulphonylurea therapy (Table 1.9).
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Table 1.7: Treatment strategies for people with impaired awareness of hypoglycaemia
• Frequent blood glucose monitoring
• Avoid blood glucose values < 4.0 mmol/1
• Avoid maintenance ofHbAlc within non-diabetic range
• Use predominantly short-acting insulins (e.g. basal-bolus regimen; use of insulin
analogues
• Consume regular snacks between meals and at bedtime
Table 1.8: Measures to avoid nocturnal hypoglycaemia
• Measure blood glucose at bedtime
• Bedtime snack containing long-acting carbohydrate
• Do occasional blood glucose measurements during the night
• Take care with timing of evening meals and timing of insulin administration
• Defer administration of intermediate-acting insulin until bedtime
• Use rapid-acting insulin analogue before evening meal
• Use long-acting insulin analogue (taken in morning)
• Take care with consumption of alcohol and strenuous exercise during evening
• Keep rapid acting carbohydrate at bedside for emergency treatment
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Table 1.9: Avoidance of hypoglycaemia associated with anti-diabetic drugs
• Use short-acting drugs (e.g. gliclazide, glipizide) or long-acting derivative
glimepiride (lower risk of hypoglycaemia)
• Check renal, hepatic and cardiac function
• Consider discontinuing anti-diabetic drugs if HbAlc is within the
non-diabetic range
• Reduce dose or discontinue antidiabetic drugs if food intake is substantially
reduced (e.g. intercurrent illness)
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Chapter 2
Effects of Hypoglycaemia on the Brain
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Electrophysiological manifestations of cerebral dysfunction accompany the
cognitive and mood changes associated with acute hypoglycaemia. Characteristic
electroencephalographic (EEG) changes occur during acute hypoglycaemia in the
waking state. A decrease in alpha waves is accompanied by an increase in delta and
theta waves, which are more pronounced over anterior parts of the brain (82,83).
These changes are more prominent in people with type 1 diabetes in whom EEG
evidence of epileptiform activity during hypoglycaemia has been recorded more
commonly than in non-diabetic subjects (84). Acute neuroglycopenia is a recognised
cause of focal or generalised convulsions, and in an individual treated with insulin it
is important to exclude acute hypoglycaemia as the cause of a seizure. EEG changes
often persist for several days after a hypoglycaemia-induced convulsion, so
neurophysiological investigations should be deferred for at least a week, and blood
glucose should be estimated at the time of performing an EEG. Permanent EEG
changes are present in many people who have a history of recurrent severe
hypoglycaemia (82).
Cerebrovascular Events
Transient hemiplegia is another alarming manifestation of acute
hypoglycaemia (85), although it is unclear whether the mechanism is the direct effect
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of neuroglycopenia or whether altered regional blood flow causes localised
ischaemia within the brain. In older persons, acute changes in regional
cerebrovascular perfusion may precipitate an acute vascular event such as a transient
ischaemic attack or even a stroke.
Coma
Coma is relatively uncommon and constitutes about one third of all episodes
of severe hypoglycaemia. Fortunately, prolonged neuroglycopenia associated with
hypoglycaemic coma is rare but, when it is associated with the development of
cerebral oedema, the mortality is high. Many of these fatal cases are associated with
a deliberate overdose of insulin in an individual with suicidal intent (86) or are
associated with the ingestion of an excessive quantity of alcohol (87). The few
individuals who survive such protracted, profound neuroglycopenia often have
extensive and permanent neurological damage, associated with severe cognitive
impairment and memory loss, and they may remain in a chronic vegetative state (88).
In cases with such a disastrous outcome, neuroimaging usually demonstrates cortical
and hippocampal atrophy with secondary ventricular enlargement.
Mechanisms of hypoglycaemia-induced brain injury may involve the release
of toxic neuro-excitatory amino acids, such as glutamate and aspartate (89,90), and
localised cerebral ischaemia. In humans, the duration of severe hypoglycaemia is
probably more important than the depth in causing damage to the brain.
Neuropathological observations have confirmed the rostrocaudal direction of
vulnerability of the brain to neuroglycopenia. The cerebral cortex and hippocampus
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are most sensitive while the hindbrain and spinal cord are relatively resistant to
neuroglycopenia (91,92).
EFFECTS OF HYPOGLYCAEMIA ON COGNITIVE FUNCTION
Acute
The human brain is the most important organ to be affected by acute
hypoglycaemia, because of its dependence on a continuous supply of glucose.
Progressive neuroglycopenia causes cognitive impairment (93,94), manifested
initially as reduced speed of cerebration and difficulty concentrating, but proceeding
to drowsiness, confusion, and ultimately loss of consciousness. Complex tasks that
require rapid decision-making, sustained attention and planning capabilities
deteriorate during mild to moderate hypoglycaemia, whereas simple cognitive and
motor tasks are more resistant and may be relatively unaffected (94). Considerable
inter-subject variability exists in the neuropsychological responses of individuals to
hypoglycaemia. Some people may develop severe cognitive impairment during
hypoglycaemia, while others are relatively unaffected at a similar blood glucose
concentration. Individual differences in susceptibility to the cognitive effects of acute
hypoglycaemia are mediated by a large number of interacting factors, some of which
have been determined (94-99). These include male gender, high IQ and having type
1 diabetes, with or without impaired awareness of hypoglycaemia. Mood changes
are also common during acute hypoglycaemia and include tense-tiredness, anger,
depression, anxiety and pessimism. Denial that hypoglycaemia is present is common,
and irrational and aggressive behaviour may sometimes occur. Occasionally a state
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of automatism is said to develop, although there have been no scientific studies of
this phenomenon. Recovery of cognitive function is usually fairly rapid after the
blood glucose concentration returns to normal with most aspects of intellectual
function returning to normal within 45-90 minutes (100,101). Even after severe
hypoglycaemic coma, recovery of cognition is complete within 24 hours (101).
However, disturbance of mood and memory and a feeling of general malaise may
persist for longer (102), and amnesia of severe hypoglycaemia may occur.
Chronic
In recent years, evidence has accumulated to suggest that diabetes per se may
be associated with the gradual emergence ofmodest cognitive impairment (103-106).
This presumably develops as a result of prolonged exposure to hyperglycaemia and
other metabolic abnormalities, and is compounded by the effects of hypertension and
vascular disease on the brain. Potential causes of cognitive impairment in diabetes
are listed in Table 2.1. Among these, repeated exposure to severe hypoglycaemia has
been postulated to cause progressive cognitive dysfunction in some people with type
1 diabetes. This premise is controversial and is therefore reviewed in some detail.
Occasional non-diabetic patients who have been subjected to chronic
neuroglycopenia as a result of an insulinoma have been reported to develop
significant and permanent deterioration in intellectual function (107). Anecdotal case
reports in people with insulin-treated diabetes have suggested that recurrent exposure
to severe hypoglycaemia may have lasting consequences, resulting in a chronic
deterioration of cognitive function with reduced intellectual ability, impaired social
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skills and behaviour, inability to maintain employment and increasing dependence on
a spouse or carer (69). The age of onset of diabetes is an important determinant of the
potential effects that recurrent hypoglycaemia may have on cognitive function and
intellectual ability, with children being the most susceptible.
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Table 2.1: Putative causes of cognitive impairment in diabetes.
Chronic hyperglycaemia
Recurrent severe hypoglycaemia




Psychosocial impact of chronic disease
Alcohol, drug abuse
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Effects ofrecurrent hypoglycaemia in childhood
The developing and immature brain of the young child is particularly
vulnerable to the effects of neuroglycopenia. The deleterious influence of
hypoglycaemia on intellect and cerebral function has been shown to be greatest in
children who have developed diabetes before the age of five years and who have
been exposed to multiple episodes of severe hypoglycaemia in early childhood,
especially when these have provoked convulsions (108-110). Cognitive dysfunction
may become manifest later in childhood or adolescence with demonstrable learning
difficulties, and occasionally with abnormal behaviour (111).
Several retrospective, cross-sectional (108,109), and prospective studies
(111,112) have shown an association between the early onset of type 1 diabetes in
childhood and lower than expected powers of attention and psychomotor efficiency
in adolescence, when compared to non-diabetic peer groups (113). A direct
correlation has been demonstrated between the frequency of hypoglycaemia-induced
convulsions at this age and evidence of cognitive dysfunction later in life (110,114).
Children with onset of diabetes after the age of five years also perform less well than
their non-diabetic peer group on many tests of cognitive function, especially on
assessment of verbal IQ. However, this is considered to be a consequence of the
psychosocial and educational effects of diabetes, with factors such as interrupted
school attendance through ill-health or intermittent metabolic disturbances playing a
significant role, rather than a direct pathophysiological effect of repetitive
hypoglycaemia on the brain (110).
66
Effects of recurrent hypoglycaemia in adulthood
The relationship between cognitive dysfunction and the frequency of
exposure to severe hypoglycaemia has been examined in adults with insulin-treated
diabetes but with less definitive results than those observed in children. Two major
prospective studies, the DCCT (115) and the SDIS (36), have not shown an
association between the frequency of severe hypoglycaemia and measures of
cognitive function (116). Both of these studies were designed to evaluate the effect
of strict glycaemic control on limiting the complications of diabetes. The participants
were subdivided into intensively-treated and conventionally-treated subgroups,
achieving either strict or moderate glycaemic control respectively; the incidence and
progression of diabetic complications and the frequency of adverse effects of
treatment were monitored prospectively. Both studies have shown unequivocally that
strict glycaemic control limits the development and progression of diabetic
microangiopathy, but is accompanied by a higher rate of severe hypoglycaemia.
In the DCCT, a comprehensive battery of tests of cognitive function was
applied, whereas the cognitive tests used in the SDIS were much more limited, and a
clear separation of the groups was not achieved in terms of exposure to severe
hypoglycaemia (36). However, in both studies the higher frequency of severe
hypoglycaemia in the patients with strict glycaemic control was not associated with
any evidence of intellectual decline.
While these results are reassuring and suggest that mental ability is not being
affected adversely by repeated exposure to severe hypoglycaemia, they need to be
interpreted with caution. Both the DCCT and SDIS had stringent recruitment criteria.
The participants, and the extent of medical support available to them, were not
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representative of the insulin-treated diabetic population in general. They were
relatively young and had diabetes of short duration. They were above average
intelligence, were highly motivated and were well educated in self-care of their
diabetes. People who had a history of multiple episodes of severe hypoglycaemia
were excluded. This criterion is likely to have excluded anyone with impaired
hypoglycaemia awareness, so that few, if any, patients were recruited to participate
in these studies who were at high risk of developing severe hypoglycaemia. It would
be imprudent, therefore, to extrapolate the conclusions from these studies to the
archetypal population with type 1 diabetes which is much more heterogeneous, and
includes people who have impaired awareness of hypoglycaemia and other risk
factors for severe hypoglycaemia. The rate of severe hypoglycaemia in unselected
populations is double that observed in the DCCT group who had strict glycaemic
control (1,33). Furthermore, cognitive decline may be a late manifestation of the
cumulative effects of severe hypoglycaemia, emerging after 20 years or more of
treatment with insulin, and the causes may be multifactorial. The timescale of the
follow-up (less than 10 years) of these two major prospective studies may not have
been long enough to reveal the development of an intellectual deficit.
By contrast, studies in adult patients with type 1 diabetes which have relied
on a retrospective estimate of the frequency of exposure to recurrent severe
hypoglycaemia have demonstrated a significant correlation with evidence of
impaired intellectual function. In an early study, measures of global intelligence in
100 adults with insulin-treated diabetes were compared with demographically
matched, non-diabetic controls (117). Intellectual function was impaired in the
diabetic group compared to the control group and the cognitive decrement appeared
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to be related to the estimated number and severity of previous episodes of
hypoglycaemia (117). An association between the estimated number of previous
severe hypoglycaemic events and the neuropsychological test performance of adults
with type 1 diabetes has been observed in other studies (118,119). In a Swedish study
of a small group of 17 adults with type 1 diabetes all of whom had a history of
recurrent severe hypoglycaemia, deficits were demonstrated in tests of problem
solving, motor ability, visuospatial skills and in tasks which assess frontal lobe
functions (119). However, the study design did not preclude the possibility that the
patients who had a history of recurrent hypoglycaemia may have been those who had
a lower pre-morbid IQ and, being less adept in their self-management of diabetes,
had therefore experienced a higher frequency of severe hypoglycaemia.
This possibility was avoided in a study in Edinburgh (120), in which the
degree of intellectual impairment was estimated as the difference between measures
of premorbid and current IQ. A significant correlation was demonstrated between the
degree of cognitive impairment and the frequency of severe hypoglycaemia in a
group of 100 adults who had developed type 1 diabetes in adulthood (i.e. after full
maturation of the brain and attainment of intellectual ability). Partial correlation
analysis showed that the observed correlations were not related to age, duration of
diabetes or blood glucose measured at the time of cognitive testing. The group could
be divided approximately into quartiles on the basis of their previous experience of
severe hypoglycaemia. These subgroups were matched for age, duration of diabetes,
education, social class and premorbid IQ. Comparison of the quartile who had a
history of five or more episodes of severe hypoglycaemia with the quartile with no
previous severe hypoglycaemia, revealed significant differences in IQ deficit (Figure
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2.1), performance IQ and reaction time (121). Individual differences in the
experience of severe hypoglycaemia were not related to differences in premorbid
intelligence.
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Figure 2.1: Comparison of premorbid (red bars) and present (blue bars) IQ levels
between a group of individuals with Type 1 diabetes with no history of previous
severe hypoglycaemia (group A) and a group of individuals with Type 1 diabetes
with a history of five or more previous episodes of severe hypoglycaemia (group B).
Premorbid versus present IQ comparison for group A is not significant, for group B it
is significant at p < 0.001. Reproduced from Langan et al, 1991 (120), with the
permission ofDiabetologia.
Group A Group B
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While this study indicated a relationship between the frequency of severe
hypoglycaemia and cognitive impairment (119,120), it could not exclude the
possibility that diabetes per se was influencing cognitive function. The subjects with
type 1 diabetes were therefore compared with a group of non-diabetic controls,
matched for pre-morbid IQ, age and educational experience. This demonstrated that
the performance and verbal IQs of the diabetic participants were lower than the non-
diabetic controls (121). Within the group of subjects with diabetes, the effect of
previous severe hypoglycaemia was associated specifically with a deficit in
performance IQ, and decision-making and response initiation skills were affected
adversely in preference to processes that involved the encoding and storage of
information (122). The lower verbal IQ in the subjects with type 1 diabetes may
therefore be the consequence of other factors, such as the social and educational
impact of having this disorder. A different study which used an identical protocol
and selection criteria for a group of 70 subjects with type 1 diabetes, was performed
subsequently in Nottingham and reported very similar findings (123)
These studies have shown the existence of a positive correlation between the
frequency of severe hypoglycaemia and a modest degree of intellectual impairment.
Although the mean decrement in intellectual ability resulting from recurrent severe
hypoglycaemia in the Edinburgh study was small (approximately 6 IQ points), this
deficit is significant (equivalent to half a standard deviation) and potentially
important (120-122). It would be sufficient to influence competence in tasks that
require intellectual dexterity and could adversely affect individuals who have
intellectually demanding occupations, in terms of job performance and capability.
While this mean decrement represented the average effect of recurrent severe
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hypoglycaemia on performance IQ in the group, some individuals were affected to a
greater degree. It is also pertinent to emphasise that the participants had developed
type 1 diabetes in adulthood, after full intellectual ability had been achieved, and that
very strict inclusion criteria were applied to avoid confounding variables that could
have affected cognitive function adversely, such as hypertension, previous head
injury, psychiatric illness and alcohol abuse. In most people with type 1 diabetes, the
modest cognitive deficits indicated by the retrospective studies are unlikely to be
obvious in the performance of everyday tasks as the decline in intellectual function is
small and appears to be slowly progressive. In older people intellectual decline may
be attributed to the ageing process and disregarded.
While these retrospective studies suggest that recurrent exposure to severe
hypoglycaemia may cause a modest decline in cognitive function, a major criticism
is that they are limited by the accuracy of recall of previous hypoglycaemic events.
However, in some studies (120,121,123) the accuracy of individual reporting was
enhanced by interviewing relatives and by scrutiny of medical records. In addition,
the cohort with type 1 diabetes in the original Edinburgh study (120) was reassessed
within a period of 18 months, and their estimated frequency of severe hypoglycaemia
showed good reliability with the rate that had been reported previously (122), so
helping to validate the method used to estimate the frequency of previous severe
hypoglycaemia.
A further piece of supportive evidence comes from clinical and experimental
observations of people with type 1 diabetes who have chronic impairment of
awareness of hypoglycaemia (see later section) who have a high frequency of severe
hypoglycaemia. In these individuals cognitive dysfunction is more profound during
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acute hypoglycaemia (124,125), and persists for longer following restoration of
normoglycaemia than in unaffected people with type 1 diabetes who have normal
awareness of hypoglycaemia. In a population study, a modest decline in intellectual
function was noted to be associated with impaired awareness of hypoglycaemia
(126). In addition, a study of the speed of recovery of cognitive function following a
single episode of severe hypoglycaemic coma in a group of people with type 1
diabetes, suggested that cognitive decrements and altered mood states in those with a
history of recurrent severe hypoglycaemia were persistent and were probably a
consequence of previous repeated exposure to severe neuroglycopenia (101). This
suggests that the frequent exposure to severe hypoglycaemia suffered by people with
type 1 diabetes who have impaired awareness of hypoglycaemia may have a long-
term detrimental effect on intellectual function.
In conclusion, it is possible that repeated episodes of severe hypoglycaemia
may have a deleterious effect on cognitive function that is cumulative over time and
is akin to the chronic intellectual impairment associated with repeated exposure to
other acute neurotoxic insults, such as alcohol abuse, hypoxia (sleep apnoea) and
repetitive head injury (boxing). Individuals may vary in their susceptibility to
hypoglycaemic injury, and a wide spectrum of abnormality is likely, with only a few
individuals developing severe intellectual impairment (69). However, although the
results of studies are suggestive that recurrent hypoglycaemia in adults may have a
deleterious long-term effect on cognitive function, the evidence is still equivocal and
remains unproven.
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STRUCTURAL CHANGES IN THE BRAIN IN DIABETES: ROLE OF
HYPOGLYCAEMIA
If cognitive impairment is a permanent consequence of recurrent severe
hypoglycaemia, could this cause structural changes in the brain in people with
diabetes? Most neuroimaging studies of the brain have been performed in people
with type 2 diabetes and have shown that structural degenerative changes are more
common than in non-diabetic controls of similar age (127). The clinical significance
of these neuroimaging abnormalities is not yet known, but is suggestive of a
premature ageing of the brain. Cortical atrophy is present in 36-53% of subjects with
type 2 diabetes compared to 12% of matched non-diabetic controls, occurs earlier in
life and is more extensive in people with diabetes (127). Leukoaraiosis, a patchy area
of either focal or diffuse demyelination and gliosis, is a non-specific, age-related
finding and is associated with several pathological conditions, including
hypertension, vascular disease, demyelination and dementia (128). It has been
identified in 69% of subjects with diabetes compared to 12% of non-diabetic controls
of similar age (129). A significantly higher incidence of degenerative changes in the
brain has also been reported in subjects with type 1 diabetes compared to age-
matched non-diabetic controls (130,131) but the cause is unknown.
A few studies have tried to identify whether structural changes in the brains
of diabetic subjects are associated with deficits in intellectual performance (132-134)
and to date the results have been inconclusive. Magnetic Resonance Imaging (MRI)
scans of the brain were performed in a subgroup of subjects who had participated in
the major Edinburgh study described earlier (120-122) and an association was
observed between the presence of cortical atrophy and a history of recurrent severe
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hypoglycaemia (131). However, the number of people in this study was too small to
demonstrate any significant correlation with impaired cognitive function.
Furthermore, it is possible that type 1 diabetes per se could be an important
pathogenetic factor. This premise has been supported by the preliminary results of
another large study in our centre of young patients who had developed type 1
diabetes in childhood or adolescence, and in whom any abnormalities demonstrated
by neuroimaging (using MRI) were related to an assessment of their cognitive
function (135). No correlation has been observed between structural changes in the
brain and any abnormality of cognitive function, but MRI changes were more
common in a subgroup of patients who had diabetic retinopathy. This would suggest
that exposure to chronic hyperglycaemia may be of greater importance than
hypoglycaemia in causing cerebral changes in young people with type 1 diabetes.
This interpretation is consistent with observations from recent studies by Wessels et
al (136,137), and from the results of the Epidemiology of Diabetes Interventions and
Complications (EDIC) study (138). Wessels et al (136,137) have shown that people
with Type 1 diabetes, who, as a consequence of chronic hyperglycaemia, had
developed advanced retinopathy, had also developed evidence of microvascular
damage in the brain, and the results of the EDIC study, an 18-year follow-up of the
DCCT cohort, have indicated that higher glycated HbAlc values, and not frequency
of severe hypoglycaemia, were associated with psychomotor impairment (138). An
earlier American study of young adults with type 1 diabetes (139), demonstrated that
impaired cognitive function was associated with peripheral neuropathy (a surrogate
marker of chronic hyperglycaemia) and not with previous severe hypoglycaemia per
se. However, when the effects of peripheral neuropathy and severe hypoglycaemia
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were combined, a significant correlation with cognitive dysfunction was observed
suggesting that exposure to severe hypoglycaemia compounds the adverse effect of
poor glycaemic control on cerebral function. Similar results have been reported in a
recent study by Musen et al (140), who have demonstrated that both persistent
hyperglycaemia and exposure to acute severe hypopglycaemia have an impact on
brain structure.
It is likely that when cognitive dysfunction does develop in people with
insulin-dependent diabetes, this has a multifactorial pathogenesis. Several metabolic
factors, including chronic hyperglycaemia (possibly with intermittent exposure to
diabetic ketoacidosis) and recurrent hypoglycaemia, may interact to affect
neurological function. In addition, evidence is accumulating for the existence of a
central neuropathy (or encephalopathy) in people with type 1 diabetes of long
duration (103-106), which is presumed to have a multifactorial pathogenesis, and to
which severe hypoglycaemia may contribute.
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ACQUIRED HYPOGLYCAEMIA SYNDROMES
Hypoglycaemia is associated with the development of acquired clinical
syndromes that are specific to insulin-treated diabetes, which may be the
consequence of recurrent exposure to hypoglycaemia per se. A single protracted
episode of hypoglycaemia lasting for more than an hour is associated with
diminished magnitude of the symptomatic and neuroendocrine responses to a further
episode of hypoglycaemia occurring within the ensuing 48 hours (141) (Figure 2.2).
Recurrent exposure to hypoglycaemia, through the pathogenetic role of antecedent
hypoglycaemia, may induce these acquired hypoglycaemia syndromes, in which the
glycaemic thresholds for symptomatic and neuroendocrine responses are modified as
a result of cerebral adaptation.
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Figure 2.2: Schematic diagram to represent the effect of antecedent hypoglycaemia
on symptomatic and neuroendocrine responses to subsequent episodes of
hypoglycaemia. From Hypoglycaemia in Clinical Diabetes, 1999 (eds Frier BM,
Fisher BM), with the permission of the publishers.
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Impaired awareness of hypoglycaemia
Various mechanisms have been proposed to underlie the aetiology of
impaired awareness of hypoglycaemia and it is possible that several co-existing
factors are important in inducing this condition (Table 2.2). Recurrent
hypoglycaemia appears to be of particular importance in the development of
impaired awareness of hypoglycaemia (28). Although impaired awareness of
hypoglycaemia is associated with strict glycaemic control in the short term, it may
also be a long-term consequence of recurrent exposure to hypoglycaemia. People
with type 1 diabetes of long duration who have developed impaired awareness of
hypoglycaemia, irrespective of the quality of glycaemic control, have been shown to
have an altered glycaemic threshold for autonomic symptoms, which is set at a lower
than usual blood glucose concentration (27,28,142). Neuroglycopenia develops
before autonomic symptoms are generated, thus interfering with subjective
perception ofwarning symptoms and ability to self-treat the low blood glucose.
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Table 2.2: Possible pathogenetic mechanisms of impaired awareness of
hypoglycaemia. From Hypoglycaemia in Clinical Diabetes, 1999 (eds Frier BM,
Fisher BM).
CNS adaptation
Chronic exposure to low blood glucose
• Strict glycaemic control in people with diabetes




• Hypoglycaemia associated central autonomic failure
Peripheral nervous system dysfunction
• Peripheral autonomic neuropathy
• Reduced peripheral adrenoceptor sensitivity
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Counterregulatory hormonal deficiencies
The magnitude of counterregulatory hormonal responses to hypoglycaemia
often declines with increasing duration of diabetes. Hypoglycaemia-induced
secretion of glucagon becomes deficient in most people within five years of onset of
type 1 diabetes (143,144), and may be followed within a few years by attenuation of
the adrenaline response to hypoglycaemia (144,145). People with type 1 diabetes
who have counterregulatory deficiencies are at greater risk of progressing to severe
hypoglycaemia if their blood glucose falls, particularly if they are subjected to
intensive insulin therapy (146). Similar counterregulatory hormonal deficiencies
have been demonstrated in people with insulin-treated type 2 diabetes who have
progressed to pancreatic beta cell failure (147).
In some people with longstanding type 1 diabetes, peripheral autonomic
neuropathy may contribute to a subnormal adrenaline secretory response. However,
in people who have counterregulatory hormonal deficiencies, the blood glucose
threshold at which the adrenaline secretory response to hypoglycaemia is triggered is
altered, so that a lower blood glucose (i.e.. a more profound hypoglycaemic stimulus)
is required to initiate secretion of adrenaline (148,149). This shift in glycaemic
threshold is probably a consequence of cerebral adaptation to exposure to recurrent
hypoglycaemia.
Cerebral adaptation: altered glycaemic thresholds
Cerebral adaptation can occur following short and longer term exposure to
hypoglycaemia, which causes elevation of the glycaemic thresholds at which the
secretion of counterregulatory hormones and the onset of symptoms of
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hypoglycaemia occur (i.e. a lower blood glucose has to be reached and a more
profound hypoglycaemic stimulus is therefore necessary) (150-152). The putative
mechanism appears to be an ability of the brain to adapt to function normally despite
chronic exposure to a low blood glucose concentration (153,154). Attenuation of the
neuroendocrine and symptomatic responses occurs in type 1 diabetes when the
glycated haemoglobin concentration is within or near to the non-diabetic range (155).
Such patients can maintain normal glucose uptake by the brain during
hypoglycaemia (154), so preserving cerebral metabolism and delaying the
neuroendocrine and symptomatic responses to hypoglycaemia, and so blunting
symptomatic awareness of hypoglycaemia. Although these changes initially protect
the brain from a greater degree of neuroglycopenia, they are thought to be
maladaptive responses, as the normal symptomatic warning is suppressed, narrowing
the margin for corrective action to be taken and so risking the development ofmore
severe neuroglycopenia. In people with well controlled type 2 diabetes (on diet or
antidiabetic agents), the counterregulatory and symptomatic responses occurred at
higher blood glucose concentrations than in type 1 diabetes and in non-diabetic
controls (156,157), but this glycaemic threshold was altered when people with type 2
diabetes required treatment with insulin (158). The phenomenon of cerebral
adaptation to strict glycaemic control in type 1 diabetes appears to be related to the
use of insulin therapy, but is also associated with insulin deficiency. The glycaemic
threshold for cognitive dysfunction is probably also susceptible to cerebral
adaptation, but this remains a controversial issue. Some studies of people with type 1
diabetes have shown that despite strict glycaemic control or exposure to antecedent
hypoglycaemia, cognitive function remains preserved during experimental
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hypoglycaemia with a shift in glycaemic threshold for the onset of cognitive
dysfunction (29,159-162). However, in other studies, cerebral adaptation to protect
cognitive function did not appear to occur, and it became impaired at the same blood
glucose threshold irrespective of preceding glycaemic experience (152,163-165).
Such an outcome would allow cognitive dysfunction to occur at a higher plasma
glucose concentration than that required to trigger the warning symptoms, thereby
increasing the risk of severe neuroglycopenia and limiting the scope for intensive
insulin therapy.
A preceding (antecedent) episode of hypoglycaemia can also promote
cerebral adaptation, by altering the glycaemic thresholds for symptomatic and
neuroendocrine responses to hypoglycaemia (166). Recurrent exposure to
hypoglycaemia may therefore, through the pathogenetic role of antecedent
hypoglycaemia causing cerebral adaptation, induce the acquired hypoglycaemia
syndromes, with modification of the glycaemic thresholds for symptomatic and
neuroendocrine responses.
Cerebral adaptation: altered regional blood flow
A permanent redistribution of regional cerebral blood flow occurs in people
with type 1 diabetes who have a history of recurrent severe hypoglycaemia, with a
relative but persistent increase in blood flow to the frontal lobes (167). This mirrors
the normal physiological response to hypoglycaemia (168), and may represent a
chronic adaptive response to protect the most vulnerable parts of the brain from the
effects of further severe hypoglycaemia. However, it has been observed that the
changes in regional cerebral blood flow in response to controlled hypoglycaemia
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occur independently of the state of awareness of hypoglycaemia in people with type
1 diabetes (169), so this is presumably an adaptive response to hypoglycaemiaper se.
Hypoglycaemia-associated autonomic failure
It has been suggested by Cryer that the acquired hypoglycaemia syndromes
represent a form of'hypoglycaemia-associated autonomic failure' (170) (Figure 2.3),
implicating recurrent severe hypoglycaemia as the central problem that causes the
development of these clinical syndromes. It is proposed that recurrent exposure to
severe hypoglycaemia promotes cerebral adaptation, with resultant alteration of
glycaemic thresholds, and the emergence of counterregulatory hormonal deficiencies
and sympatho-adrenal insufficiency, culminating in a chronically impaired awareness
of hypoglycaemia. Repetitive episodes of hypoglycaemia may lead to
'downregulation' of the central mechanisms that normally would respond to a low
blood glucose to activate glucoregulatory responses and produce the warning
symptoms of hypoglycaemia. As a result, a vicious circle is established so that
hypoglycaemia promotes further episodes of severe hypoglycaemia, so perpetuating
the problem.
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Figure 2.3: Schematic diagram to demonstrate the model of hypoglycaemia-
associated autonomic failure, derived from Cryer (1992), from Hypoglycaemia in
Clinical Diabetes, 1999 (eds Frier BM, Fisher BM), with the permission of the publishers.
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Chapter 3




Hypoglycaemia is a common side-effect of insulin treatment (1,33), which
can impact upon all aspects of everyday life (171). Several important prospective
studies have confirmed the long-term beneficial effects of strict glycaemic control,
both in type 1 (3,4) and type 2 diabetes (172), so encouraging the use of intensive
insulin therapy. However, this is associated with an increased risk of severe
hypoglycaemia (3,4,173), which has recognised mortality and morbidity (2,50,174),
and is feared by people with insulin-treated diabetes (171) and their relatives.
Acute hypoglycaemia induces a series of hormonal, symptomatic,
neurophysiological and cognitive changes, which occur at different and defined
blood glucose levels (glycaemic thresholds) (12). These thresholds are reproducible
in non-diabetic individuals, but are dynamic in people with diabetes and can be
altered by external factors such as very strict glycaemic control or recent preceding
(antecedent) hypoglycaemia. The glycaemic thresholds at which the secretion of the
counterregulatory hormones commences are just below the normal physiological
range of blood glucose (arterial blood glucose concentration 3.8 mmol/1). By
contrast, the glycaemic thresholds for the onset of symptoms of hypoglycaemia (3.0
mmol/1) and the development of cognitive impairment (2.7 mmol/1) occur at lower
blood glucose concentrations. Because the human brain is critically dependent on
glucose as its principal source of fuel, acute hypoglycaemia results in impaired
cognitive function with potential clinical consequences and many studies have
examined the effects of hypoglycaemia on different cognitive domains (94,175).
However, in humans, not all cognitive and motor functions are affected equally
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during hypoglycaemia (Table 3.1). Complex tasks that require rapid decision¬
making, sustained attention and planning capabilities deteriorate during mild to
moderate hypoglycaemia whereas simple cognitive and motor tasks are more
resistant and remain relatively unaffected (94,175). A substantial degree of
variability exists among the neuropsychological responses of individuals to
hypoglycaemia in adult humans, whether or not they have type 1 diabetes (93-
99,176,177). Some people develop severe cognitive impairment during
hypoglycaemia, while others are unaffected by a similar decline in blood glucose
concentration. The susceptibility of an individual to the detrimental effects of acute
hypoglycaemia may be influenced by several different factors, and various
moderators of cognitive performance during acute hypoglycaemia have been
proposed.
The search for moderators that predict individual vulnerability assumes that
this clinical response to hypoglycaemia is consistent across time and equivalent
degrees of hypoglycaemia, and that it does not simply reflect individual variation
within a population. Gonder-Frederick et al (178) have demonstrated that individual
differences in cognitive responses to hypoglycaemia are consistent (178). In their
study, 26 subjects with type 1 diabetes performed a battery of cognitive tests during
euglycaemia (blood glucose 6.3 mmol/1), mild hypoglycaemia (blood glucose 3.6
mmol/1), moderate hypoglycaemia (blood glucose 2.6 mmol/1), and these were
repeated following restoration of euglycaemia. To assess the temporal reliability of
individual differences of performance deterioration during hypoglycaemia, 15 of the
subjects were retested three months later. This study (178) demonstrated
considerable variations between the subjects' responses to hypoglycaemia of varying
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severity. At a blood glucose of 3.6mmol/l, 19% of the subjects exhibited a
significant deterioration in cognitive performance, while almost half showed little or
no deterioration. At a blood glucose of 2.6 mmol/1, a significant deterioration
occurred in more than 50% of the subjects; only 15% showed little or no disruption
in performance. On re-testing three months later, these individual variations in
vulnerability to the development of cognitive dysfunction, and the degree of
impairment that was observed in most tests, were very similar in individual subjects,
indicating that the individual differences to hypoglycaemia were stable and did not
occur at random. This would suggest that hypoglycaemia has no uniform effect on
causing cognitive dysfunction, and infers that some individuals are more susceptible




Cognitive impairment is most evident in tasks requiring:
• Selective attention
• Rapid decision-making
• Analysis of complex visual stimuli
• Mental flexibility
• Memory of recently learned information
• Hand-eye co-ordination
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MODERATORS OF COGNITIVE FUNCTION DURING ACUTE
HYPOGLYCAEMIA
The factors that moderate the individual differences in glycaemic thresholds
for the onset of hypoglycaemia-induced cognitive dysfunction are of clinical
relevance to people with type 1 diabetes. Moderators that have been investigated
include: age, gender, intelligence, the presence or absence of diabetes, the duration of
diabetes, the magnitude of counterregulatory hormonal responses to hypoglycaemia,
quality of glycaemic control, exposure to antecedent hypoglycaemia, the state of
awareness of hypoglycaemia, a history of previous severe hypoglycaemia, the
duration of hypoglycaemia and a variety ofpharmacological agents.
Age
Age influences the counterregulatory responses to hypoglycaemia and
modifies the symptoms that are experienced. With increasing age, the magnitude of
responses of adrenaline and glucagons is lower, autonomic warning symptoms are
less profound and neuroglycopenic symptoms predominate (18,179) (Figure 3.1). To
examine the effects of ageing on the glycaemic thresholds for cognitive impairment,
one study utilised a single test of cognitive function, the four-choice reaction time
test, during controlled hypoglycaemia in two groups of non-diabetic men (17). One
group consisted of seven older men between the ages of 60-70 years, and the second
group comprised seven young men aged between 22-26 years. A hyperinsulinaemic
glucose clamp was used to lower the blood glucose concentration from 5.0 to 2.4
mmol/1 in a stepwise fashion, and the four choice reaction time, a test of general
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neuropsychological co-ordination and psychomotor speed, was administered. The
counterregulatory hormonal responses to hypoglycaemia, symptoms of
hypoglycaemia, and choice reaction time were assessed at each glucose plateau. The
study demonstrated that cognitive function, as assessed by this single test,
deteriorated at a higher blood glucose concentration (3.0 vs. 2.6 mmol/1), and to a
greater degree, in the older group compared to the younger subjects. In the younger
group, the symptoms of hypoglycaemia commenced at a higher blood glucose
concentration (3.6 vs. 3.0 mmol/1) and were more intense, such that in the older men
there was no perceptible difference between the blood glucose levels for the warning
symptoms of hypoglycaemia and the development of cognitive impairment. This
provides a very limited opportunity to detect the onset of hypoglycaemia and take
appropriate action before more disabling neuroglycopenia supervenes. Thus, these
age-related changes in the glycaemic thresholds for the symptomatic responses and
for development of cognitive dysfunction during hypoglycaemia render older people
at greater risk of not responding to hypoglycaemia and allowing progression to more
severe hypoglycaemia.
In contrast to these findings (17), other studies that have examined the effect
of age on cognitive function during hypoglycaemia have shown no consistent
correlation between age and the degree of cognitive impairment during
hypoglycaemia (97,98,178), although in these studies the age differences of the
subjects was limited. In the study by Cox et al (97), only 10 people with type 1
diabetes were studied with ages ranging from 26-52 years of age, in the study by
Draelos et al (98) the patients were aged between 18-44 years, and in the study by
Gonder-Frederick et al (178) the patients were between 23 and 48 years of age. It is
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probable that the age ranges of the subjects in these studies are too narrow to have
allowed any significant effects of age on cognitive function during acute
hypoglycaemia to have been elicited.
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Figure 3.1
The difference between the glycaemic threshold for subjective awareness of
hypoglycaemia and that for the onset of cognitive dysfunction may be absent in the

















Significant gender differences in cognitive performance during acute
hypoglycaemia were demonstrated in a study of 20 men and 22 women with type 1
diabetes by Draelos et al (98), in which a wide range of cognitive abilities were
tested. These included sensory perceptual processing, simple motor abilities,
attention, learning and memory, language, and spatial and constructional abilities,
which were examined at plasma glucose levels of 2.2, 5.6, 8.9, 14.4, and 21.1
mmol/1. All aspects of cognitive performance were impaired at a plasma glucose of
2.2 mmol/1 when compared with the baseline performance at euglycaemia (plasma
glucose 5.6 mmol/1). However, at this degree of hypoglycaemia cognitive
impairment was less in women than in men in tests which examined selective and
sustained attention and mental flexibility. This difference persisted after adjustment
for other potential confounding factors. No gender differences were observed with
tests of other aspects of cognitive function, nor were this discrepancy evident in the
cognitive test scores obtained at lesser levels of hypoglycaemia. Other studies have
shown that women have less intense counterregulatory hormonal and symptomatic
responses to hypoglycaemia compared with men (180-182). Women may therefore
be more able to tolerate hypoglycaemia than men and be more resistant to cognitive
impairment.
The indication of a gender difference in cognitive susceptibility to
hypoglycaemia is supported by a further study that demonstrated that women
performed better on cognitive function testing than men during mild hypoglycaemia
(venous plasma glucose 3.6 mmol/1) (178). However, in this study, the degree of
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cognitive impairment was similar in both sexes during more profound
hypoglycaemia (blood glucose 2.6 mmol/1).
Intelligence
It has been suggested that individuals with greater intelligence as measured
by a higher IQ level, possess more 'brain reserve capacity' for cognitive processing
that may be utilised if cognitive function is compromised, and that this will confer a
degree of protection from various cerebral insults, such as hypoglycaemia (183). A
study by Gold et al (184) sought to identify whether IQ level exerts a differential
effect on the impairment of cognitive performance that is caused by acute
hypoglycaemia. In this study, 24 healthy non-diabetic volunteers were divided into
high and average IQ groups according to their performance in two standard tests of
general intelligence (the Alice Heim 4 test and the National Adult Reading Test).
Cognitive function was measured during euglycaemia (plasma glucose 4.5 mmol/1)
and hypoglycaemia (plasma glucose 2.5 mmol/1). As anticipated, the high IQ group
had a significantly better performance at baseline in most of the cognitive tasks.
Cognitive function deteriorated during hypoglycaemia irrespective of IQ and very
few differences in deterioration in performance were observed between the two
groups. However, multiple univariate analysis of variance revealed an IQ effect on
two of the cognitive tests. The group with average IQ deteriorated significantly less
than the high IQ group during hypoglycaemia in tests of attention and information
processing (Paced Auditory Serial Addition Test (PASAT) and Rapid Visual
Information Processing). These results suggest that individuals with a higher IQ are
not protected from the adverse effects of hypoglycaemia on cognitive function, and
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that they may in fact be more vulnerable to the detrimental effects of
neuroglycopenia on intellectual ability.
However, studies performed in people with diabetes have failed to
demonstrate a relationship between intelligence (or a surrogate marker, such as the
number of years of education) and changes in cognitive performance during
hypoglycaemia (97-99,178).
Diagnosis of Diabetes
The question of whether the presence or absence of diabetes per se influences
cognitive performance during hypoglycaemia was addressed in a study by Wirsen et
al (185). Cognitive function was measured using a neuropsychological test battery
before, during, and after acute insulin-induced hypoglycaemia (arterialised blood
glucose 1.8-2.0 mmol/1) in 10 men with type 1 diabetes and in 12 non-diabetic men
(185). The two groups were matched for age and educational level, and no
differences between the two groups in neuropsychological test performance were
apparent at euglycaemia. The reported symptoms of hypoglycaemia were
comparable between the two groups, and significant deterioration of cognitive
function occurred in both groups during hypoglycaemia. However, the group of
subjects with diabetes demonstrated a greater degree of cognitive impairment during
hypoglycaemia than the non-diabetic group. This would suggest that people with
type 1 diabetes are more susceptible to the effects of neuroglycopenia. It is possible
that this may represent some form of sub-clinical effect of diabetes on the brain (a
diabetic 'encephalopathy'), either as a consequence of repeated exposure to severe
hypoglycaemia or from the long-term effects of chronic hyperglycaemia (104,186).
98
However, no difference in cognitive function was observed between the two groups
at baseline and the subjects with diabetes had higher blood glucose concentrations
before the induction of hypoglycaemia, which may influence cognitive performance.
The results of the study by Wirsen et al (185) should be interpreted with caution. It
is possible that the difference in cognitive performance during hypoglycaemia that
was observed between the two groups may have been related to the greater absolute
reduction in blood glucose that was required to achieve a determined level of
hypoglycaemia in the diabetic group.
In contrast to these observations, no differences between diabetic and non-
diabetic subjects were noted in cognitive performance during acute hypoglycaemia in
two earlier studies (96,152). In a third study which included diabetic and non-
diabetic subjects (187), differences in cognitive performance between the groups
were observed at baseline, which precluded interpretation of the effects of diabetes
on responses during hypoglycaemia.
Other Diabetes-Related Clinical Variables
No relationship has been observed between the degree of cognitive
dysfunction during hypoglycaemia and variables such as duration of diabetes
(96,98,178,188), age of onset of diabetes (99,178) and the magnitude of
counterregulatory hormonal responses to hypoglycaemia (96-98). In one study
(178), a greater deterioration in cognitive performance during acute hypoglycaemia




Strict glycaemic control alters the blood glucose thresholds at which the
symptomatic and counterregulatory hormonal responses to hypoglycaemia are
initiated, in that a lower blood glucose is required to trigger these responses
(150,151). While it would seem likely that the threshold for the onset of cognitive
dysfunction during hypoglycaemia would also be modified by the level of previous
glycaemic control, this proposal has aroused controversy and the evidence is
conflicting.
A study by Widom and Simonson (152) compared neuropsychological
function during hypoglycaemia in a group of eight subjects with type 1 diabetes who
had good glycaemic control (mean HbAlc 8.0%) and a group of nine subjects who
had much poorer glycaemic control (mean HbAlc 11.8%). A battery of cognitive
tests was administered during a hyperinsulinaemic glucose clamp in which blood
glucose was lowered in a stepwise fashion from 5.0 to 2.2 mmol/1. The median
glucose threshold for the onset of cognitive dysfunction did not differ statistically
between those with better glycaemic control diabetes from those with poorer control.
Similar results were observed by Maran and colleagues (164) in an examination of
the glycaemic thresholds for the deterioration of four-choice reaction time during
acute hypoglycaemia in eight subjects with intensively-treated type 1 diabetes (mean
HbAlc 7.7%) and ten subjects on conventional therapy who had sub-optimal
glycaemic control (mean HbAlc 10.1%) (164). Their results are in concordance
with those of several other studies (95-97,176,177,183,189) that have failed to
demonstrate any correlation between the quality of glycaemic control and cognitive
performance during acute hypoglycaemia.
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A link between glycaemic control and neuropsychological test performance
has been demonstrated during acute hypoglycaemia in a study by Holmes and
colleagues (176). In subjects with type 1 diabetes who had strict glycaemic control
(mean HbAlc 6.9%), a significantly poorer performance in an auditory reaction time
test was observed when compared with subjects with less strict glycaemic control
(mean HbAlc 8.8%) (176). However, these results need to be interpreted with some
caution as the subjects with strict glycaemic control had a history of experiencing a
significantly greater number of episodes of coma caused by severe hypoglycaemia
which may have influenced their performance and the number of subjects in the
study (n=15) was small.
Neuropsychological studies that have examined the effects of acute
hypoglycaemia on sensory evoked potentials (P300 event-related potentials) gave
results that are consistent with the findings of Holmes et al (94). Measurement of
event-related potentials provides an objective quantitative assessment of cognitive
function. The P300 component of these potentials is generated endogenously when a
subject is required to discriminate and memorise a specific task-specific stimulus. Its
latency reflects the speed of information processing and correlates with attention and
short-term memory. Ziegler et al (159) addressed the issue of whether the quality of
preceding glycaemic control will modify cognitive function during acute
hypoglycaemia by measuring P300 event-related potentials during hypoglycaemia.
Eighteen people with type 1 diabetes were studied, seven of whom had good
glycaemic control (mean HbAlc 6.3%) and 11 of whom were less well controlled
(mean HbAlc 9.1%). No significant difference between the two groups was present
at baseline with regard to P300 latency but the glycaemic threshold at which a
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significant increase of P300 latency was first detected was 1.6 mmol/1 in subjects
with strict glycaemic control, and 3.5 mmol/1 in those with poorer control.
Comparable results have been reported in another study that examined the effect of
hypoglycaemia on P300 potentials in people with intensively and conventionally-
treated diabetes (160).
Antecedent Hypoglycaemia
The thresholds for counterregulatory hormonal responses to hypoglycaemia
are attenuated by preceding exposure to hypoglycaemia (antecedent hypoglycaemia)
(141,190). A number of studies have tried to identify whether the glycaemic
threshold for cognitive dysfunction during hypoglycaemia also changes in response
to antecedent hypoglycaemia. However, the impact of antecedent hypoglycaemia on
cognitive function is difficult to quantify; different degrees and durations of
antecedent hypoglycaemia have been studied, and the duration of the time period
between the episode of antecedent hypoglycaemia and the subsequent
hypoglycaemia study varies considerably between studies.
Mellman et al studied the effects of antecedent hypoglycaemia in nine non-
diabetic volunteers (191). Antecedent hypoglycaemia (arterialised blood glucose 3.2
mmol/1) or euglycaemia (blood glucose 5.2 mmol/1) was maintained for two hours,
90 minutes before performing to a stepped hypoglycaemic clamp, during which
cognitive function was assessed. Two tests of cognitive function were administered:
Logical Memory, a test of immediate verbal memory, and the Digit Symbol
Substitution Test, a test of general psychomotor performance. It was found that the
Digit Symbol Substitution test scores deteriorated equally during hypoglycaemia,
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irrespective of whether antecedent hypoglycaemia or euglycaemia had been present,
but the performance during hypoglycaemia in the memory task was preserved
following antecedent hypoglycaemia. This suggests that the preservation of Logical
Memory function during hypoglycaemia following a recent episode of antecedent
hypoglycaemia may have resulted from adaptation of the central nervous system to
low blood glucose.
Asymptomatic nocturnal hypoglycaemia is a very common problem amongst
people with type 1 diabetes (192,193). Veneman et al (42) and Fanelli et al (162)
have studied the impact of antecedent nocturnal hypoglycaemia on cognitive
function during hypoglycaemia the following day. Veneman et al measured
cognitive function during hyperinsulinaemic hypoglycaemic glucose clamps in 10
healthy volunteers on two occasions; once after induction of asymptomatic nocturnal
hypoglycaemia (plasma glucose 2.4 mmol/1) for two hours, and once after a
euglycaemic control study in which saline instead of insulin was infused overnight
(42). The deterioration of cognitive function during hypoglycaemia the following
day was significantly less after the asymptomatic antecedent nocturnal
hypoglycaemia, compared to antecedent nocturnal euglycaemia. In addition, the
plasma glucose concentration at which cognitive dysfunction developed was
significantly lower following antecedent hypoglycaemia. Fanelli et al (162) also
demonstrated that a single episode of moderate asymptomatic antecedent nocturnal
hypoglycaemia diminished cognitive dysfunction during a subsequent episode of
controlled hypoglycaemia the following day. In this study, the effect of antecedent
nocturnal hypoglycaemia (arterialised plasma glucose 2.8 mmol/1) was examined in
fifteen people with type 1 diabetes. The subjects were exposed for 3.5 hours to either
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nocturnal hypoglycaemia or euglycaemia. After nocturnal hypoglycaemia, overall
cognitive dysfunction was less in comparison with nocturnal euglycaemia when
cognitive tests were applied during hypoglycaemia induced on the following day.
The results of these three studies suggest that the glycaemic thresholds for
hypoglycaemic cognitive dysfunction shift to lower plasma glucose concentrations
after recent antecedent hypoglycaemia, both in non-diabetic people and in those with
type 1 diabetes. By contrast, a study by Hvidberg et al (165) of 16 non-diabetic
subjects reported that the glycaemic thresholds for cognitive dysfunction during
hypoglycaemia did not shift to lower plasma glucose concentrations after a period of
antecedent hypoglycaemia. In the afternoon, the subjects were exposed for two
hours either to moderate hypoglycaemia (mean blood glucose 2.6 mmol/1) or, on a
separate occasion, to euglycaemia. The following morning, cognitive function tests
were administered during a hypoglycaemic clamp. No significant overall effect of
exposure to antecedent hypoglycaemia was observed on subsequent hypoglycaemic
cognitive dysfunction. However, when performance of individual tasks at specified
blood glucose concentrations was considered, less deterioration in tasks of attention
and pattern recognition was observed when plasma glucose concentrations were
reduced from 2.8 to 2.5 mmol/1.
Several other studies have not shown any effect of antecedent hypoglycaemia
on hypoglycaemia-induced neuropsychological dysfunction. Dagogo-Jack et al
exposed 16 people with type 1 diabetes to either antecedent afternoon hypoglycaemia
or antecedent afternoon euglycaemia (149). Cognitive function during
hypoglycaemic clamps carried out on the following morning was not significantly
affected by the antecedent hypoglycaemia. Indeed, some aspects of cognition
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(attention) were actually worse following antecedent hypoglycaemia. In another
study by George et al (194), eight people with type 1 diabetes were exposed to
antecedent hypoglycaemia (arterialised blood glucose 2.8 mmol/1) or antecedent
euglycaemia (blood glucose 5.0 mmol/1), which was followed, after an interval of
two days, by a further episode of hypoglycaemia with use of the four-choice reaction
time test. The results showed that the decrement in cognitive performance induced
by hypoglycaemia was unaffected by exposure to antecedent hypoglycaemia. In
addition, studies by Bendtson et al (195) and King et al (102) detected no effect of
antecedent nocturnal hypoglycaemia on cognitive test performance the following
day.
Finally, a study by Ovalle et al (161) investigated the impact of recurrent
antecedent hypoglycaemia on subsequent cognitive performance during a stepped
hypoglycaemic clamp. In this study, six patients with type 1 diabetes were exposed
to either two hours of recurrent hypoglycaemia (blood glucose 2.8 mmol/1) twice a
week for a period of one month, or to two hours of hyperglycaemia (8.3 mmol/1)
twice a week for a month. Recurrent antecedent hypoglycaemia was found to cause
a significant reduction in overall cognitive dysfunction during hypoglycaemia.
Duration of hypoglycaemia (short-term cerebral adaptation)
Cerebral adaptation can occur following exposure to low blood glucose
concentrations resulting in a change in the glycaemic thresholds for secretion of
counterregulatory hormones and for the generation of symptoms of hypoglycaemia
to lower blood glucose levels (i.e. a more profound hypoglycaemic stimulus is
required). The brain appears to have an inherent ability to adapt so as to be able to
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function normally despite a diminished supply of glucose. The glycaemic threshold
for the onset of cognitive dysfunction may also be affected by cerebral adaptation,
but this remains uncertain. The putative mechanism underlying cerebral adaptation
is unknown but may involve upregulation of glucose transporters which control the
rate of glucose transporters into neurones.
In two studies by Kerr et al, performance in a single choice reaction time test
was studied during prolonged hypoglycaemia in people with (196) and without (197)
type 1 diabetes. Arterialised blood glucose concentration was clamped at 3.5 mmol/1
for one hour then reduced to, and maintained at, 2.8 mmol/1 (196) and 3.0 mmol/1
(193) for 90 (196) and 60 (197) minutes, respectively. Reaction times were
measured at baseline, and twice at the glucose plateaus. Counterregulatory hormone
levels and symptomatic awareness of hypoglycaemia were also documented. The
reaction times initially slowed when the blood glucose concentration was lowered
from 3.5 mmol/1 to the blood glucose nadir, compared to the baseline scores.
However, after prolonged hypoglycaemia the reaction times improved towards
baseline scores. The improvement in reaction time performance during prolonged
hypoglycaemia occurred in parallel with a reduction of symptomatic awareness of
hypoglycaemia. Meanwhile, counterregulatory hormone levels remained elevated
during prolonged hypoglycaemia. Therefore, as hypoglycaemia continued, the
symptom score declined and cognitive function improved, while levels of
counterregulatory hormones remained elevated. Although alternative cerebral fuels
have been shown to be used by the brain during hypoglycaemia (ketones, amino
acids, free fatty acids), it is unlikely that the utilisatation of ketone bodies could be
used by the brain in these circumstances as ketone body formation would be
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suppressed by the hyperinsulinaemic clamp. The findings of these studies (196,197)
have been interpreted as demonstrating some degree of cerebral adaptation occurring
during mild hypoglycaemia. However, this study is fundamentally flawed in that a
separate euglycaemia study in the subjects studied indicated that there was a practice
effect for the reaction time task, which therefore improved with increasing
application. No statistical comparison of the results from the hypoglycaemia and
euglycaemia clamps was reported. It should be noted that a blood glucose nadir of
2.8 or 3.0 mmol/1 is not very low and that most cognitive functions become impaired
at glucose levels below this.
In contrast to these findings, Gold et al found no evidence of cerebral
adaptation in 24 non-diabetic subjects following exposure to 40-60 minutes of
hypoglycaemia (arterialised blood glucose 2.5 mmol/1) (198). This is a much more
scientifically robust study in that an extensive test battery was utilised, with
statistical adjustment for potential practice effects by comparing the hypoglycaemia
clamp results with those obtained during a separate euglycaemic clamp. However,
the duration of hypoglycaemia was relatively short, and it is likely that a more
prolonged period of exposure to hypoglycaemia is required to induce cerebral
adaptation.
The effect of protracted, prolonged hypoglycaemia on cerebral adaptation
was investigated by Boyle et al by exposing a group of 12 non-diabetic volunteers to
hypoglycaemia for a period of four days (153). On the first day, a stepped
hypoglycaemic clamp was performed, lowering blood glucose concentration from
4.72 to 2.5 mmol/1. At each plateau of blood glucose, symptomatic awareness of
hypoglycaemia, counterregulatory hormone levels and cognitive function were
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measured and brain glucose uptake was also calculated. The arterialised blood
glucose concentration was maintained at 2.9 mmol/1 for 56 hours. On the final day
the stepped glucose clamp procedure was repeated, starting with a blood glucose
concentration of 4.16 mmol/1, and the same measurements were repeated. The
glycaemic thresholds at which subjects developed symptoms of hypoglycaemia and
at which cognitive function declined occurred at much lower blood glucose levels
during the final clamp compared to the results obtained on the first day. The
threshold for counterregulatory hormone secretion was also modified. On the first
day, brain glucose uptake became impaired at a blood glucose concentration of 3.61
mmol/1, but on the final day it remained preserved throughout the hypoglycaemic
clamp. This would suggest that following prolonged exposure to a low blood
glucose level adaptation had occurred within the brain to preserve and protect brain
glucose uptake and maintain cerebral function during hypoglycaemia. However, the
results of this study should be interpreted with caution since potential practice effects
of the cognitive tasks were not evaluated, and the statistical analysis compared
cognitive performance at each blood glucose level within a clamp with its own
baseline. Interaction analyses between the clamps were not performed, thereby
increasing the risk of a spurious effect emerging in line with the experimental
hypothesis.
Impaired awareness of hypoglycaemia
Scientific assessment of the impact of impaired awareness of hypoglycaemia
on cognitive function during acute hypoglycaemia is hampered to some extent by the
lack of a validated, non-subjective means of defining symptomatic awareness.
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Moreover, it is difficult to separate out the confounding influences of recent
antecedent hypoglycaemia and of strict glycaemic control, which are inter-related. In
a study by Heller et al (187), the effects of insulin-induced hypoglycaemia on
subjective detection of hypoglycaemia and on cognitive function using the four-
choice reaction time test were studied in 15 people with type 1 diabetes. Blood
glucose was lowered progressively using a stepped hypoglycaemic clamp to 2.5
mmol/1, and maintained at this level for 30 minutes. Subjects were asked "Do you
feel hypoglycaemic?" and a hypoglycaemia symptom questionnaire was applied.
This showed that, at a blood glucose concentration of 2.5 mmol/1, only four of the
fifteen subjects recognised that the blood glucose was low. The subjects were not
matched for IQ, and those who had impaired awareness of hypoglycaemia had a
longer duration of diabetes and a lower mean glycated haemoglobin concentration
than the subjects who had normal awareness. Cognitive performance was affected to
the same degree during hypoglycaemia in the subgroup of people with intact
symptomatic awareness compared to the larger number with apparent impaired
awareness. What this study shows is that the glycaemic threshold for generation of
symptoms varies between individuals, and is influenced by glycaemic control and
other factors such as duration of type 1 diabetes, but actual impairment of
hypoglycaemia awareness was not demonstrated.
A recent study by Zammitt et al (199) has shown a reduced decrement in
cognitive ability during hypoglycaemia in people with impaired awareness compared
to subjects with normal awareness of hypoglycaemia. Twenty subjects with type 1
diabetes and normal self-assessed hypoglycaemia awareness (12 male, median HbAic
8.7%, median age 30 years) and 15 subjects with impaired hypoglycaemia awareness
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(6 male, median HbA]c 8.2%, median age 34) underwent two hyperinsulinaemic
glucose clamps, during euglycaemia (blood glucose 4.5 mmol/1) and during
hypoglycaemia (2.5 mmol/1). The hypoglycaemia-aware group suffered impairment
of short-term verbal memory at 2.5 mmol/1, whereas the unaware group did not. This
finding is consistent with cerebral adaptation having developed in the unaware
group.
By contrast, Gold et al (125) demonstrated that people with type 1 diabetes
with impaired awareness of hypoglycaemia (estimated using a validated self-rating
scale (30) exhibited a trend towards greater cognitive dysfunction during acute
hypoglycaemia, which persisted for longer following restoration of euglycaemia,
compared to subjects with normal awareness (199). The aware and unaware subjects
in this study were matched for pre-morbid IQ, duration of diabetes, HbAlc and
exposure to previous episodes of hypoglycaemia. There was, however, a difference
in IQ between the two groups (0.5 standard deviation), with the unaware subjects
having lower mean scores on the Alice Heim 4 task (a test of general intelligence).
Although this difference was not statistically significant, it is possible that this
difference may have confounded the study results.
Symptomatic awareness of hypoglycaemia may be restored in people who
have impaired awareness of hypoglycaemia if hypoglycaemia is strictly avoided (77).
The effect of the restoration of hypoglycaemia awareness on the glycaemic
thresholds for the development of cognitive dysfunction during acute hypoglycaemia
has been examined, and the results are conflicting. Cranston et al (78) investigated
the effects of strict avoidance of hypoglycaemia on symptomatic, cognitive and
hormonal responses to hypoglycaemia in 12 men with type 1 diabetes. The subjects
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were aged between 28-55 years, had a duration of diabetes between 11 and 32 years,
and all had impaired awareness of hypoglycaemia. Six subjects had good overall
glycaemic control (mean HbAlc 6.5%) and six had relatively poor control (mean
HbAlc 8.2%). After strict avoidance of hypoglycaemia for three consecutive weeks
(which took a mean duration of four months to achieve), hormonal and symptomatic
responses to controlled hypoglycaemia during a hyperinsulinaemic hypoglycaemic
clamp increased in magnitude. However, the glycaemic threshold for cognitive
dysfunction (assessed by performance in the four choice reaction time test) did not
change, with a deterioration in cognitive function occurring at similar blood glucose
concentrations (2.8 mmol/1) in all patients, both before, and after the period of
hypoglycaemia avoidance. Contrary to these findings, in a study by Fanelli et al
(79), restoration of awareness of hypoglycaemia was associated with a change in the
glycaemic threshold for cognitive dysfunction during acute hypoglycaemia. Sixteen
people with type 1 diabetes were studied, all of whom had impaired awareness of
hypoglycaemia. Exposure to hypoglycaemia was avoided for a period of two weeks.
Cognitive function during, and symptomatic awareness of, hypoglycaemia were
measured during a stepped hypoglycaemic clamp before, and after the period of
avoidance of hypoglycaemia. Counterregulatory hormonal and symptomatic
responses to hypoglycaemia improved following hypoglycaemia avoidance.
Moreover, the blood glucose concentration at which cognitive dysfunction
commenced was higher following the period of avoidance of hypoglycaemia. In
addition, the degree of cognitive dysfunction at a given glucose concentration was
less (79). These changes were maintained following a year of hypoglycaemia
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avoidance (79), and were also observed in subjects with impaired awareness of
hypoglycaemia who had type 1 diabetes of short duration (80).
Mitrakou et al examined the effects of reversibility of hypoglycaemia
unawareness on cognitive function during hypoglycaemia in people with insulinomas
(200). Autonomic and neuroglycopenic symptoms, counterregulatory hormonal
responses and cognitive function were measured during hypoglycaemia in six people
with insulinomas using a stepped hypoglycaemic clamp before and approximately
six months after curative surgery and in 14 normal subjects matched for age, sex and
weight. Before surgery, the patients with insulinomas had lower scores than the
control subjects for autonomic and neuroglycopenic symptoms, had impaired
counterregulatory hormonal responses and exhibited less cognitive dysfunction
compared to normal subjects during hypoglycaemia. Surgical cure reversed all these
abnormalities.
Pharmacological agents
The effect of a various pharmacological agents on cognitive performance
during acute hypoglycaemia has been examined, principally in non-diabetic
volunteers..
Agents that alter membrane channels for potassium adenosine triphosphate
(KATP) in pancreatic beta cells have been shown to improve cognitive function
during acute neuroglycopenia. In a study of 10 healthy males (201), performance in
the four-choice reaction time test deteriorated at a glycaemic threshold of 2.5 mmol/1
during treatment with glibenclamide, compared to a glucose level of 3.0 mmol/1 in
subjects treated with diazoxide and 2.9 mmol/1 in subjects treated with placebo (201).
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Structural similarities exist between the pancreatic beta cell and glucose sensitive
neurones within the hypothalamus, and sulphonylurea receptors have been found to
be widely distributed in neuronal cells throughout the brain.
Evidence also exists that some aspects of cognitive function may be protected
by the administration of alanine during acute hypoglycaemia. In a study by Evans et
a/ (202), a hyperinsulinaemic glucose clamp was used to lower the concentration of
plasma glucose to 2.5 mmol/1 in the presence of an infusion of either intravenous
alanine or intravenous saline in seven healthy male volunteers. Cognitive function,
assessed by the Stroop colour-word test, deteriorated less in the presence of the
alanine infusion compared to saline, although performance in several other cognitive
tests showed no benefit. It is possible that during hypoglycaemia alanine can be
utilised by the brain as a metabolic fuel instead of glucose, or can do so by enabling
an increased availability of lactate.
Smith et al studied the effects ofmodafinil on cognitive function during acute
hypoglycaemia (203). Modafinil inhibits the release of the inhibitory
neurotransmitter gamma-aminobutyric acid (GABA). Nine healthy male volunteers
were randomly assigned to take either 200mg of modafinil or a placebo, following
which a hyperinsulinaemic glucose clamp was used to maintain euglycaemia or
reduce plasma glucose to 2.4 mmol/1. Modafinil had no effect on cognitive
performance during euglycaemia. However, during hypoglycaemia, performance in
two cognitive function tasks (the Stroop colour-word test and simple reaction time)
deteriorated less in the modafinil-treated group.
Alcohol and hypoglycaemia independently affect cognitive function
adversely. Cheyne et al (204) have demonstrated that the combined effects of both
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hypoglycaemia and alcohol are additive. In this study, a hyperinsulinaemic clamp
was used in 17 healthy subjects who were studied during euglycaemia (blood glucose
4.5 mmol/1) with placebo, euglycaemia with alcohol, hypoglycaemia (2.8 mmol/1)
with placebo and hypoglycaemia with alcohol. The blood alcohol concentration
during the euglycaemia and hypoglycaemia arms was identical at 43 mg/dl.
Cognitive function was assessed using the Four-Choice Reaction Time test, the Trail
Making B test and the Digit Symbol Substitution Test. The administration of alcohol
during euglycaemia was associated with a deterioration in performance in the Four-
Choice Reaction Time and Trail Making B tests, and the hypoglycaemia and placebo
arm was associated with a deterioration in performance in the Four-Choice Reaction
Time test only. However, when alcohol was combined with hypoglycaemia the
deterioration in performance was significantly greater in all of the cognitive function
tests.
Several studies have also looked at the potential effect of caffeine on
cognitive function during hypoglycaemia. Caffeine has been shown to augment the
symptomatic and counterregulatory responses to hypoglycaemia, thereby increasing
recognition of hypoglycaemia. However, with the exception of one study by Watson
et al (205) who demonstrated only a small improvement in performance in a single
cognitive test (the Four-Choice Reaction Time test) during hypoglycaemia, other
studies have shown that caffeine has no effect on cognitive function (206-208).
Mood
The short-term impact of hypoglycaemia on mood has attracted much less
attention than the effects on cognitive function. Acute hypoglycaemia has a
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profound effect on mood (94,209-213). Changes in various emotions are common
and this may influence cognitive performance during hypoglycaemia. Moderate
hypoglycaemia may induce a state of anxious tension, unhappiness and low energy,
and even irritability and anger. As for cognitive function per se, considerable
interindividual differences are observed in the effects of hypoglycaemia on mood and
it would appear that an idiosyncratic relationship exists in individual subjects
between mood and a low blood glucose. It could be speculated that this discrepant
effect between individuals may have a direct influence on their cognitive
performance during acute hypoglycaemia.
CONCLUSIONS
Individual differences in susceptibility to the effects of acute hypoglycaemia
on cognitive function may therefore be mediated by a large number of interacting
factors (Table 3.2). Increasing age and male gender may make people more
susceptible to the effects of hypoglycaemia on intellectual function and, less
convincingly, the presence of diabetes per se and a higher intelligence may also
confer a greater predilection for cognitive impairment in the presence of
neuroglycopenia. However, for those who have type 1 diabetes, the duration of the
disorder, the age of onset and the integrity of the hormonal counterregulatory
responses to hypoglycaemia do not appear to be important determinants of the nature
or degree of cognitive decrements during hypoglycaemia, and evidence exists that
prolonged or repeated exposure to moderate hypoglycaemia induces cerebral
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adaptation with a subsequent improvement in cognitive performance or no apparent
effect on intellectual abilities at the same degree of hypoglycaemia.
Controversy continues to surround the impact of impaired awareness of
hypoglycaemia, strict glycaemic control and antecedent hypoglycaemia on the ability
of the brain to adapt to frequent exposure to neuroglycopenia. Some studies have
supported the premise that the glycaemic thresholds for the impairment of differing
domains of cognitive function are shifted to commence at lower blood glucose
concentrations in people who are exposed to recurrent hypoglycaemia because of
these conditions or circumstances in a manner analogous to the well-recognised shift
in glycaemic thresholds for counterregulatory hormonal responses and the generation
of warning symptoms. However, a shift in glycaemic thresholds for cognitive
dysfunction has not been demonstrated in other studies in similar groups of patients.
It is possible that methodological differences between the studies, and in particular
small sample size giving insufficient statistical power, may be responsible for these
discrepant results. After discounting investigations which have obvious
methodological limitations, it is noticeable that those studies which have
demonstrated a shift in cognitive thresholds have utilised either a battery of cognitive
function tests or neurophysiological changes of sensory evoked potentials. By
contrast, the studies that did not demonstrate any change in glycaemic thresholds
have often utilised only a solitary or, at most, two cognitive tasks (175,212). It is
likely that not all cognitive tests are affected to a similar degree by conditions such as
impaired awareness of hypoglycaemia, strict glycaemic control or recurrent
antecedent hypoglycaemia, so that very small batteries of cognitive tests are
inadequate to demonstrate an effect on glycaemic thresholds (214).
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The psychometric test performance impairments observed during
experimental studies of acute hypoglycaemia are clinically relevant. While it is
difficult to evaluate the direct relevance ofmost experimental cognitive tests to tasks
performed in everyday life, driving is an important activity that involves many
cognitive processes and has been studied during hypoglycaemia. Studies using a
driving simulator have examined the effect of hypoglycaemia on driving
performance, although results have been inconsistent between groups of
investigators. For example, Hoffman et al found no effect of hypoglycaemia (venous
blood glucose 2.7 mmol/1) on driving (80), while studies by Cox et al have
consistently demonstrated that driving performance is significantly impaired when
arterialised plasma glucose concentration declines below 3.8 mmol/1 (76,215). In
addition, they demonstrated interindividual differences in driving performance
during hypoglycaemia which have been shown to be reproducible and stable on re-
testing after an interval of three months. Moderators of cognitive performance
during hypoglycaemia may have important implications for people with insulin-
treated diabetes in relation to their performance at work which would become
impaired if they were exposed to hypoglycaemia.
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Table 3.2
Factors increasing degree of cognitive dysfunction during acute hypoglycaemia:
• Increasing age
• Male gender
• Presence ofType 1 diabetes
• Recent antecedent hypoglycaemia





Memory is the subject concerning the concepts that the brain employs to store
and retrieve information, or the process referred to as remembering. It is the
cognitive process of storing, encoding and retrieving information and pervades
everyday functioning.
CLASSIFICATION OF MEMORY SYSTEMS
A useful classification recognised three main memory systems: sensory,
short-term and long-term memory (216). Sensory memory is memory in which
representations of the physical features of a stimulus are stored for a very brief time,
perhaps for a second or less, and it is difficult to distinguish from the process of
perception. Although the measurement of sensory memory presents practical
problems, the effect of hypoglycaemia on this memory system has been examined
previously (217-219). The function of sensory memory appears to be to retain
information for a sufficient length of time for it to be transferred to short-term
memory. Short-term memory refers to the function that temporarily retains stimuli
that have just been perceived from the environment or retrieved from long-term
memory. Its capacity is limited in terms of the number of items that can be stored.
Short-term memory lasts for a duration measured in seconds. Information may be
transferred from short-term memory to long-term memory by the process of
consolidation (220). Through rehearsal, the neural activity corresponding to sensory
stimulation can be sustained, which causes permanent structural changes in the brain
that are responsible for the formation of long-term memory (221,222). Long-term
memory refers to information that is represented on a permanent or near permanent
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basis. Unlike short-term memory, long-term memory has no known limits and is
relatively durable.
WORKING MEMORY
Memory has been clinically and experimentally well studied, and has been
shown to involve brain regions such as the hippocampus. It is thought to be mediated
by changes in cell functioning. Early psychological work in the 1950's and 1960's
led to the hypothesis of 'short term memory'; a process of limited capacity and only
operative over a few seconds. The concept of 'working memory' is an extension of
this idea, with the added idea that short term memory is woven together with higher
cognitive processes, such as learning, reasoning, and comprehension.
Working memory, a short-term memory system which allows the retention
and manipulation of information concurrently, is vital for daily activities. Working
memory comprises a phonological loop (a store of phonetic, verbal information), a
visuospatial scratchpad (a store of spatial information and memories for movement),
and a central executive, which supervises and updates the content of working
memory (223-225). Working memory allows the short-term retention and
manipulation ofmaterial. Working memory, therefore, is used to think about what is
already known and to come to conclusions on the basis of that knowledge. It is used,
for example, to remember what has been said at the beginning of a sentence and
retain this until the sentence has been completed, it allows a telephone number to be
remembered long enough for it to be dialled, and enables the calculation of simple
mental arithmetic. Multivariate modelling and computer simulation studies show
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that working memory is almost indistinguishable from reasoning, and that individual
differences in working memory correlate almost perfectly with individual differences
in the general factor derived from a battery of psychometric intelligence tests (226-
229).
Unlike long term memory, which has a large clinical body of research,
working memory has only recently become the focus of intense clinical study. It is
often assayed in intelligence or cognitive examinations using span tests, in which
patients are asked to repeat a set of digits in reverse order (if I read "8-9-3-2-1-9",
you would say "9-1-2-3-9-8") or repeat in the correct alphabetical order a group of
words that had been read aloud. Studies indicate that working memory is not one
process; rather, it is made up of several separable processes.
The simplicity and fundamental nature of working memory systems, and the
adaptability ofworking memory experiments, make it suitable for new brain imaging
technologies. Both Positron Emission Tomography (PET) and Functional Magnetic
Resonance Imaging (fMRI) capitalise on properties of cerebral blood flow to make
inferences about underlying neural activity. Founded upon Baddeley's model of
working memory, investigators have begun to explore neural correlates of working
memory. Several neuroimaging studies provide evidence for a distinct neurological
basis for a phonological loop, as well as separate processes for storage of items and
retrieval (230). During the storage phase of verbal working memory tasks, activity is
found in Broca's area (involved in speech production) in addition to supplementary
and premotor areas (involved in movement) in frontal cortex, and is strongly
consistent with activity in areas involved in preparation of speech from other
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neuroimaging studies. In addition, different networks are involved in retrieval as
compared with storage in the left lateralised frontal cortex (230,231).
The neural correlates of spatial or object storage, in pursuit of the visuospatial
scratchpad, is somewhat more tenuous. Neuroimaging studies yield that there are
different areas activated in spatial or object memory tasks compared to those in
verbal working memory tasks. Neuroimaging studies also suggest a difference in
storage systems compared with retrieval systems in spatial or object working
memory, indicating that there are again separate networks at work (230).
The most fascinating line of inquiry confronts the idea of a 'central executive',
a control system that mediates attention and regulation of processes occurring in
working memory. The idea of a central executive was first postulated by Baddeley
(224). Many investigators have seen evidence supporting the idea of a central
executive; they have observed higher cognitive activity in an area in the prefrontal
cortex, called DLPFC (Dorsolateral Prefrontal Cortex), during difficult tasks (231).
This area shows activity during object working memory, and what are termed
'executive processes', such as planning, focusing attention on an object, switching
between tasks, and 'inhibition' of short term storage. One powerful design to study
executive processes is to tax working memory systems to its capacity, or to present
the subject with two tasks to perform simultaneously. An example of such a difficult
task is the Stroop task, where colour names are presented in different colours ("red",
for example, might be presented in green text). Neuroimaging studies using these
difficult tasks support the notion of a central executive control system (230). In
addition to neuroimaging studies, there is converging evidence from animal models
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and cellular studies. Electrophysiological studies of monkeys allow the
interconnections of individual circuits to be mapped out. Many of these circuits are
focused in the prefrontal cortex (232).
The pharmacology of working memory also proves fascinating. Dopamine, a
largely inhibitory neurotransmitter with many functions, is thought to play a major
role in working memory (233,234). The frontal cortex has many dopaminergic
pathways, which may modulate the activity of the pyramidal cells in the frontal
cortex (233). Again, although much evidence has been conducted in monkeys, the
relationship to human working memory systems is unclear.
Despite the current intensive inquiry into how we remember things on a short
time scale, the components of working memory remain poorly understood. Further
research on the systems of working memory will result in greater understanding of
this fundamental system that we use almost every moment of our lives, providing





STUDIES 1 AND 2
Acute hypoglycaemia is a common side effect of treatment with insulin in
people with diabetes (1). The non-physiological doses of insulin that are used in
standard treatment regimens often leads to a mismatch between blood glucose and
plasma insulin concentrations, resulting in hypoglycemia. A recent study has
confirmed the high frequency of hypoglycemia amongst people with type 1 diabetes
(33). The mean rate of mild hypoglycaemia was 2.0 episodes/patient/week, and of
severe hypoglycaemia was 1.3 episodes/patient/year.
The human brain is dependent on a continuous supply of glucose as its main
source of energy. Cerebral deprivation of glucose, therefore, rapidly causes cognitive
dysfunction through the direct effects of acute neuroglycopenia (106,235). Early
observations noted that blood glucose concentrations below 3.0 mmol/1, as a
consequence of either natural glucose fluctuations (236) or bolus injection of insulin
(237), were associated with impaired motor co-ordination and mental speed. Since
then, a large literature on the cognitive effects of acute hypoglycaemia has developed
with recent interest focusing on the particular cognitive domains that are affected and
the clinical relevance of the cognitive decrements that occur.
Two main techniques have been employed to induce hypoglycaemia
experimentally: the insulin infusion technique and the hyperinsulinaemic glucose
clamp. The former involves the intravenous infusion of insulin at various rates to
reach the desired blood glucose concentration, while the hyperinsulinaemic clamp
technique employs a fixed intravenous infusion rate of insulin with a variable
intravenous infusion of dextrose to maintain blood glucose concentrations at the
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determined level (238). However, in many clamp studies, a common methodological
error has been to induce hypoglycaemia by glucose clamp using a stepwise decline in
blood glucose with tests of cognitive function being administered during the final 30
minutes of each blood glucose plateau. This allows a practice effect to occur, which
is confounded with the level of hypoglycaemia.
Hypoglycaemia affords the opportunity to study cognitive processes under
controlled deprivation of the brain's energy supply. Memory is one of the most
important cognitive domains with respect to everyday function, yet it has seldom
been examined in detail during acute hypoglycaemia. To our knowledge, the effect
of hypoglycaemia on this key cognitive area has not explicitly been studied
previously, and there are no systematic studies involving short and longer-term
memory processes. There is a particular lack of information concerning the effect of
hypoglycaemia on working memory.
The present studies were designed to investigate the effects of experimentally
induced hypoglycaemia on verbal and non-verbal tests of short-term, delayed and
working memory in people with and without Type 1 diabetes. It was hypothesised
that performance in memory tasks would be significantly impaired during acute
hypoglycaemia in both diabetic and non-diabetic subjects.
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STUDY 3
Many studies have demonstrated the effects of acute hypoglycemia, on
cognitive function and on mood states, both in non-diabetic subjects and in people
with type 1 and type 2 diabetes mellitus. In contrast, considerably less information is
available on the effects of acute /zyperglycaemia on cognitive function and non-
cognitive functions, such as mood. Anecdotal descriptions by patients with either
type 1 or type 2 diabetes suggest that altered mood (such as increased irritability),
diminished well-being, and difficulties with rapid cerebration, occur when blood
glucose is elevated.
Published data is contradictory. An early study by Holmes et al (239)
examined verbal skills in 12 adults with type 1 diabetes under conditions of
controlled euglycaemia, hypoglycaemia (blood glucose concentration 3.0 mmol/1)
and hyperglycaemia (blood glucose 16.6 mmol/1). Word meaning and spelling skills
were significantly disrupted during hypoglycaemia, and a trend towards poorer
performance was observed during hyperglycaemia. A further study in 12 children
with type 1 diabetes (240) with a mean age of 12.4 years also demonstrated
impairment of cognitive function during acute hyperglycaemia. At a blood glucose
concentration of 20-30 mmol/1, there was a reduction in performance IQ of 9.5%
compared to euglycaemia.
Other studies do not support these data. A study of adolescents with type 1
diabetes (241) did not show any effect of hyperglycaemia on cognitive function, but
the assessment was limited to tests of reaction time and trail making. In a cohort of
42 adult patients with type 1 diabetes mellitus, under conditions of controlled
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hyperglycaemia (blood glucose 8.9, 14.4 and 21.1 mmol/1 in a stepped
hyperglycaemic insulin clamp), neither cognitive function (99), nor self-reported
mood (242) was significantly affected. However, it should be noted that the study
cohort had poor metabolic control (mean total HbAl 10.1%). Cerebral adaptation to
low blood glucose concentrations is a recognised phenomenon (167). There may
also be potential for cerebral adaptation in response to high prevailing blood glucose
concentrations, and acute hyperglycaemia in people with poor glycaemic control may
have different effects.
The short-term effects of hyperglycaemia on cognitive function and mood are
therefore an area worthy of further study, with implications for effects of
postprandial hyperglycaemia which is common in most patients treated with
conventional diabetes therapies, including insulin and oral hypoglycaemic agents.
The aim of this study was to test the hypothesis that, in people with type 2
diabetes mellitus, acute hyperglycaemia compared to euglycaemia will adversely
affect cognitive function and/or mood as measured by a medium effect (i.e. a mean
difference of 0.5 SD) on a range of validated tests.
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STUDIES 4, 5 AND 6
People with Type 1 diabetes are frequently exposed to acute hypoglycaemia,
which in humans is associated with profound haemodynamic changes, including an
increase in heart rate and stroke volume, increased myocardial contractility and a rise
in cardiac output (48,50). Changes in peripheral blood pressure include an increase
in systolic and a decrease in diastolic pressure, with no change in mean arterial
pressure. The effects on central arterial pressure are not known.
Arterial blood pressure is usually recorded non-invasively at the brachial
artery by sphygmomanometry. It is assumed that the pressure is the same throughout
the arterial tree and that it represents an accurate index of aortic peak pressure and of
left ventricular systolic pressure, and so of left ventricular afterload. However, blood
pressure measured in the peripheral circulation is not an accurate estimate of central
pressure because of amplification of the pressure pulse between central and
peripheral arteries (244,245). Normally, there is amplification of the pulse pressure
between the aorta and brachial artery (246). It is the aortic, rather than the brachial,
pressure which determines left ventricular workload (247,248).
Central arterial pressure and arterial wall stiffness, which are independent
predictors of cardiovascular morbidity (249-253), can be studied non-invasively
using pulse wave analysis (254-257), which requires the external application of a
micromanometer-tipped probe over a peripheral artery (258,259). Contraction of the
left ventricle generates a pressure wave which travels along the major arteries until it
meets sites of resistance (high resistance arterioles), then the wave is reflected back
to the heart (260). The stiffness of the arterial wall influences the velocity of the
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reflected wave. In healthy young people, the reflected wave reaches the heart during
diastole and, by increasing diastolic pressure, enhances coronary perfusion.
However, when arterial stiffening has developed, the increased pulse wave velocity
of the stiffened arteries leads to earlier reflection of the wave so that it returns to the
heart during late systole (249,261). The increase in systolic pressure that results
from this earlier reflection of the pressure wave is known as 'augmentation', with
augmentation index (AIx) measured as the augmentated pressure expressed as a
percentage of the pulse pressure. AIx increases with age, and in disease states such
as hypertension (262) and hypercholesterolaemia (263). It is also influenced by heart
rate; a decrease in AIx is observed with an increase in heart rate (264). Central
arterial pressure and waveform convey important information about cardiovascular
status (249,265,266).
The present study sought to measure arterial wall stiffness and the central
haemodynamic responses to the administration of intravenous insulin and the
induction of acute hypoglycaemia in people with Type 1 diabetes of varying duration
and in non-diabetic subjects. It was hypothesised that increased duration of type 1










In studies 1, 2 and 3 a hyperinsulinaemic glucose clamp was used to control
blood glucose concentrations (238).
Each session commenced at 08.00 hours following a 10-12 hour overnight
fast. An intravenous cannula was inserted retrogradely into a vein on the dorsum of
the non-dominant hand for regular blood sampling. The hand was placed in a heated
blanket to arterialise the venous blood. A second intravenous cannula was inserted
into a vein in the antecubital fossa of the same arm for infusion of human soluble
insulin (Humulin S; Eli Lilly) and 20% dextrose. Intradermal lignocaine (1%) was
used for insertion of each cannula. Insulin was infused at a constant rate of 60
mU/m2/min using an IMED Gemini PCI pump (Alaris Medical Systems, San Diego,
USA). A variable intravenous infusion of 20% dextrose was given simultaneously.
The rate of dextrose infusion was varied according to the arterialised blood glucose
concentration. This was measured at the bedside using the glucose oxidase method
(Yellow Springs Instrument 2300 Stat, Yellow Springs, Ohio, USA). Blood glucose
concentration was measured every three minutes initially and then every five minutes
once a stable level had been achieved.
In studies 1 and 2, the arterialised blood glucose concentration was stabilised
initially at 4.5 mmol/1 (baseline) for a period of 30 minutes. In the euglycaemia
condition, the blood glucose concentration was thereafter maintained at 4.5 mmol/1
throughout the study. In the hypoglycaemia condition, blood glucose was lowered
over a 20 minute period to 2.5 mmol/1. The blood glucose concentration was
maintained at the predetermined target level for a further 10 minutes before
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commencing the cognitive tests, and was maintained at this level for a further 70
minutes while the tests were administered. At the end of the hypoglycaemia study,
the blood glucose level was restored to 4.5 mmol/1. Subjects were provided with a
meal after completion of each study session.
In study 3, in each study condition the arterialised blood glucose
concentration was stabilised initially at 4.5 mmol/1 (baseline) for a period of 30
minutes. In the euglycaemia condition, the blood glucose concentration was
maintained thereafter at 4.5 mmol/1 throughout the study. In the hyperglycaemia
condition, blood glucose was raised over a 20 minute period to 16.5 mmol/1. The
blood glucose concentration was maintained at the predetermined target level for a
further 10 minutes before commencing the cognitive tests, and was maintained at this
level for a further 80 minutes while the tests were administered. At the end of the
hyperglycaemia study, the blood glucose was restored to 4.5 mmol/1. Subjects were




In studies 1, 2 and 3, tests of general cognitive function were administered to
the subjects. Theses included the Trail Making B and Digit Symbol Substitution
tests, and the Reaction Time test (study 3 only).
General Cognitive Tests
TrailMaking B
This is a test of complex visual scanning with a motor component, measuring
visual conceptual and visual motor tracking. The subject is presented with a grid
containing randomly positioned numbers and letters. The subject must connect
consecutive numbers in numerical order and consecutive letters in alphabetical order,
alternating between numbers and letters (267). The score is the time taken to
complete the task.
Digit Symbol Substitution Test
This is a test of motor persistence, sustained attention, response speed and
visuo-motor co-ordination. It consists of four rows containing, in all, 100 small
blank squares, each paired with a randomly assigned number from one to nine.
Above these rows is a printed key that pairs each number with a different symbol.
The subject is asked to fill in as many of the blank squares with the appropriate
symbol that matches the number above the box, in a time limit of 120 seconds (268).
The score is the number of squares that are successfully completed within the 120
second time limit.
Reaction Time Test
This test is a test of psychomotor speed and information processing. It
measures individuals' reaction time to a specific stimulus. In study 3, reaction time
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was measured using a portable device, originally designed for the UK Health and
Lifestyle survey (269). This has a LCD screen at the top with five response keys
arranged below. Two versions of the test were used. In the Simple Reaction Time
test, a zero was presented on the LCD screen at random intervals. Subjects were
instructed to press the response key as quickly as possible when they saw the zero.
In the Four-Choice Reaction time test, numbers 1, 2, 3 or 4 were presented randomly
on the screen. Subjects were required to press the key corresponding to the number
as quickly as possible. The time interval between a response and the display of the
next digit varied randomly between 1 and 3 seconds for both Simple and Four-
Choice Reaction Time tests. The mean scores for the tests were recorded in
milliseconds.
Memory tests
The following memory tests were used:
Verbal Memory Tests
Auditory Verbal Learning Test (A VLT) - immediate and delayed
The AVLT is a test of immediate memory span, retrieval efficiency and
learning. The delayed component measures longer-term retention (270). It consists
of a list of 15 random words that are read to the subject at a rate of one word per
second. The subject is asked to try and immediately recite the list as accurately as
possible. This procedure is repeated five times. The sum total of words remembered
correctly is designated the "immediate" score. Each subject is instructed to try to
remember the list and is informed that recall of the list will be requested after a
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period of one hour. The "delayed" score is the number of words that are recalled
correctly at that time.
LogicalMemory Test — immediate and delayed
Logical memory is a test of verbal learning. It measures immediate free
recall following auditory presentation, and delayed recall (271). The subject is asked
to recount a short story immediately after it is read to them, to remember the story
and to recall it again after a delay of one hour. The story incorporates a number of
specific points, each of which the subject must remember to achieve a score. The
immediate and delayed scores are the sum total of the number of points remembered
by the subject during immediate and delayed recall.
Visual Memory Tests
Visual Reproduction — immediate and delayed
This test measures immediate and delayed recall following visual
presentation (271). Five designs (line drawings) are presented to the subject in
sequence. The subject is allowed to study each design for ten seconds. The design is
then removed and the subject is instructed to draw the design from memory. They
are asked to draw the designs again after a delay of at least one hour. The designs
are scored according to their accuracy. The total score is the sum of the scores of all
five designs. Immediate and delayed scores are calculated separately.
Benton Visual Retention Test (BVRT)
This is a test of immediate visual recall. A series of ten designs of increasing
complexity are presented to the subject, the designs are removed and the subject is
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then asked to draw the designs from memory (272). The test is scored according to
the accuracy with which the designs are drawn. The total score is the sum of the
scores of all ten designs.
Working memory Tests
Digit Span - Forwards and Backwards
In the Digit Span test, a series of lists of random numbers is presented
verbally to the subject, who must then recall the numbers in ascending numerical
order (forwards) or reverse order (backwards) (271). The test score is the number of
lists that are remembered correctly.
Letter/Number Sequencing
In the Letter/Number Sequence test, a series of lists of random numbers
mixed with random letters is presented verbally. The subject must recall the list,
stating the numbers in ascending numerical order and the letters in alphabetical order
(271). The test score is the number of lists that are remembered correctly.
Four-term Order
Subjects are presented verbally with three commands, each command
determining the sequence of four separate words. Subjects must arrange the words in
the correct order according to the commands. Eight appropriate combinations of the
four words are then shown to the subjects for 15 seconds. One option lists the words
in the correct order; the other seven options are incorrect. Subjects are required to
try to identify the correct option. Twenty-four problems, each with three commands
and eight possible options, are presented to the subjects. The score achieved is the
number of problems that are answered correctly (273).
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Validation Span
In this test from Kyllonen's Cognitive Abilities Measurement battery (273),
the subject is presented visually with a simple arithmetical problem. The subject is
required to perform the calculation and to determine if the sum is correct or incorrect.
On the left side of the page, adjacent to the problem, is placed an isolated and
unrelated number. In addition to performing the simple mental arithmetic, the
subject must remember this isolated number. Each problem is presented for five
seconds. The problems are presented in sets of three, four and five. After
completion of each set, the subject must recall the isolated left-sided numbers in the
correct order. The score is based on how many of the isolated numbers are




For this example, the correct sequence of numbers is 5,2,3.
Parallel versions of the tests are available for Logical Memory, AVLT, Benton
Visual Retention Test, Four-term Order and Validation Span, and these were used to
minimise a learning effect between the study conditions. Throughout the studies,
tests were carried out in a predetermined fixed order.
Tests of Attention
In study 3, the Test of Everyday Attention (TEA) battery (274) was used to
measure attention. It gives a broad-based measure of the most important clinical and
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theoretical aspects of attention, and is the only test of attention based on everyday
materials.
Map Search
This is a test of visual selective attention. The subjects had to search for a
particular symbol, such as a sign that represented a garage, on a color map. The
score is the number of symbols circled out of a possible maximum of 80 in two
minutes. After the first minute had elapsed, the subjects were given a different
colored pen to circle the map signs, to enable the number of targets located in the
first minute to be identified and compared to the final total achieved.
Elevator Counting
This subtest was presented on audio-tape, and consisted of a simple counting
procedure. It is a test of sustained attention. Subjects were asked to pretend that
they were in an elevator whose floor-indicator was not functioning. They had to
ascertain at which 'floor' they had arrived by counting a series of tape-presented
tones.
Elevator Counting with Distraction
This subtest is similar to Elevator Counting, and was also presented on audio¬
tape. It differed in that subjects had to count the same tone that they had heard
previously, while ignoring a distracting tone which had a higher note. It is a test of
auditory selective attention.
Visual Elevator
In this subtest, the subject was asked to imagine that they were traveling up
and down in an elevator, which in this case was represented by a series of pictures of
elevator doors. Large arrows showed the direction of counting between pictures.
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This reversal task is a measure of attentional switching, and hence of cognitive
flexibility.
Elevator Counting with Reversal
This subtest was the same as the visual elevator subtest except that it was
presented at a fixed speed on audio-tape and is another test of auditory selective
attention.
Telephone Search
In this test, a test of visual selective attention, the subjects had to look for key
symbols while searching through pages in a telephone directory.
Telephone Search while Counting
In this task, the subject had again to search for key symbols in a (different)
telephone directory while simultaneously counting a series of strings of tones
presented on audio-tape. By combining the scores for this subtest, and the time per
target score for the previous telephone search, this test aims to provide a measure of
divided attention, a 'dual task decrement'. In the factor analysis of normal data, this
task loads on the sustained attention factor.
Lottery
In this final subtest of sustained attention, subjects had to listen for their
(predetermined) winning lottery numbers. To do this, they had to listen to a 10
minute series of audio-tape-presented numbers of the form 'BC143' i.e. two letters
followed by three numbers. The task was to write down the two letters preceding all
lottery numbers ending in certain numbers e.g. '55'.
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Parallel versions of the TEA battery are available and were used to minimise
a learning effect between study conditions. Throughout the studies, tests were carried
out in a predetermined fixed order.
Mood Questionnaire
In study 3, the UWIST mood adjective checklist, a validated subjective self-
rating questionnaire, was used to document changes in mood experienced by the
subjects during the euglycaemia and hyperglycaemia (275). There are three main
mood states: energetic arousal (feeling lively and active versus tired and sluggish),
tense arousal (feeling anxious and nervous versus relaxed and calm), and hedonic
tone (feeling happy versus sad). The questionnaire consists of a list of 24 symptoms
(e.g. cheerful, anxious, energetic). Each symptom can be categorized to one of the
three main mood states. Each mood state is represented by eight different symptoms.
The subject is required to score each symptom as Definitely, Slightly, Slightly Not,
or Definitely Not (scoring 4, 3, 2 and 1 points respectively), to reflect how they are





In studies 1 and 2, the Edinburgh Hypoglycaemia Scale (276), a validated
subjective self-rating questionnaire, was used to document the symptoms of
hypoglycaemia experienced by subjects during the two studies. The symptoms of
hypoglycaemia were classified as autonomic (hunger, palpitations, sweating,
shaking), neuroglycopenic (drowsiness, confusion, inability to concentrate, speech
difficulty, blurred vision) and non-specific (nausea, headache). Each symptom was




In studies 1, 2 and 3, the results were analysed independently for each
cognitive test. A general linear model (repeated measures analysis of variance) was
used with order of session (euglycaemia-hypoglycaemia or hypoglycaemia-
euglycaemia for studies 1 and 2, euglycaemia-hyperglycaemia or hyperglycaemia-
euglycaemia for study 3) as a 'between subjects' factor, and condition (euglycaemia
or hypoglycaemia for studies 1 and 2, and euglycaemia or hyperglycaemia for study
3) as a 'within subjects' factor. A p value < 0.05 was considered to be significant.
Effect size was calculated using the Eta squared test. All analyses were performed






Multiple Memory Functions are Impaired During Acute
Hypoglycaemia in Non-Diabetic Humans
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INTRODUCTION
The human brain is dependent on a continuous supply of glucose as its main
source of energy. Cerebral deprivation of glucose rapidly causes cognitive dysfunction
through the direct effects of acute neuroglycopenia (235). Acute hypoglycaemia is a
common side-effect of treatment with insulin in people with diabetes, and can adversely
affect their everyday activities (171,277).
In humans, controlled hypoglycaemia can be induced experimentally using the
hyperinsulinaemic glucose clamp technique (238) and the effects of acute
hypoglycaemia on cognitive performance has been examined in non-diabetic and
diabetic subjects. Tasks that are complex, attention demanding and require a rapid
response are more greatly impaired during neuroglycopenia, compared with simple
cognitive and motor tasks, which are relatively preserved. In general, tests that involve
attention, concentration, psychomotor skill, the accessing of long term memory and the
ability to ignore distracting information, tend to deteriorate when blood glucose declines
below 3.0 mmol/1 (6,82,152,185,196,278).
Memory is one of the most important cognitive domains, that has seldom been
examined during acute hypoglycaemia. Working memory is particularly important and
the effects of acute hypoglycaemia on this domain have never been examined
previously..
Previous studies of acute hypoglycaemia have used a heterogeneous assortment
of memory measures as part of a larger battery of cognitive tests. Published studies
suggest that short-term memory, as tested by word and story recall, can deteriorate
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during hypoglycaemia (93,99,152,185,279). Other tests which assess memory can be
identified in cognitive batteries that have been used to study the effects of acute insulin-
induced hypoglycaemia in subjects with, and without, diabetes. Some studies have
shown impaired memory functions (6,93,99,185,279), whereas in others, tests of
memory were unaffected (152,239,280). Variable results may relate to methodological
differences between studies. Many of the studies previously reported suffer from small
sample size, application of a limited selection of (often obscure) tests, an inadequate
ascertainment of biomedical and psychosocial variables that may affect the results,
which have then been over-interpreted. In addition, the method of induction of
hypoglycaemia has varied between studies, and the method of blood sampling (e.g.
arterialised or venous blood) has differed. A common methodological error has been to
induce hypoglycaemia by glucose clamp using a stepwise decline in blood glucose with
tests of cognitive function being administered during the final 30 minutes of each blood
glucose plateau, so allowing a prominent practice effect to occur. As a result of these
problems, definitive evidence regarding the effects of acute hypoglycaemia on learning
and memory is not available.
The present study was designed to investigate the effects of experimentally-




Sixteen (9 male) non-diabetic healthy volunteers were studied. Their median
(range) age was 29.2 years (26.8-34.2) with a median Body Mass Index of 23.0 (20.2-
24.1) kg/m . None of the participants had a history of chronic disease, previous head
injury, seizure, blackouts, psychiatric illness or a family history of diabetes. They had
no intercurrent illness and were taking no regular medication (with the exception of the
oral contraceptive pill). Ethical permission for the study was approved by the Lothian
Research Ethics Committee. All subjects gave written informed consent for the study.
Study Design
Each subject participated in two laboratory sessions, representing two different
experimental conditions that were separated by at least two weeks (Figure 7.1). The
studies were conducted in the Department of Diabetes at the Royal Infirmary of
Edinburgh. A modified hyperinsulinaemic glucose clamp was used to maintain the
blood glucose at a predetermined level (238). In the euglycaemia (E) condition, the
arterialised blood glucose concentration was maintained at 4.5 mmol/1 and
hypoglycaemia was not induced. In the hypoglycaemia (H) condition, the glucose
concentration was lowered to 2.5 mmol/1. The subjects were not informed which
experimental arm of the study was being performed on each occasion and underwent the




run-in baseline (30 mins)




Figure 7.1: Study design
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Procedure
Hypoglycaemia was induced using the hyperinsulinaemic glucose clamp
procedure (238), as discussed in Chapter 6.
Cognitive Function Tests
Tests of immediate and delayed verbal memory, immediate and delayed visual
memory, and tests of working memory were administered during the study conditions.
In addition to the memory tests, the Trail Making B and Digit Symbol tests were also
administered. These are validated tests of general cognitive ability and were used to
confirm the effect of hypoglycaemia on cognitive function, as has been shown in
previous studies (93,185,217,218,281).
Symptoms of Hypoglycaemia
The Edinburgh Hypoglycaemia Scale (276) was used to document the common
symptoms of hypoglycaemia experienced by the subjects during the two studies.
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RESULTS
A stable blood glucose plateau was achieved during both study conditions
(Figure 7.2). The mean (SD) blood glucose concentration during the euglycaemia
condition was 4.51 (0.21) mmol/1, and during the hypoglycaemia condition was 2.46
(0.11) mmol/1. Statistical analysis revealed that no significant order effects had occurred
for any of the outcome variables of this study, and no significant gender differences
were evident.
Symptoms
Results of the hypoglycaemia symptom questionnaires confirmed that scores for
autonomic (p<0.0001), neuroglycopenic (p<0.0001) and general malaise (p=0.05)
symptoms were all increased significantly during hypoglycaemia compared to baseline
euglycaemia, and were unchanged during the euglycaemia study condition.
Tests of General Cognitive Function
Considerable differences were observed during hypoglycaemia in the
performance of the Trail Making B and Digit Symbol tests. The time taken to complete
the Trail Making B test increased significantly from a mean (SD) of 41.5 (7.9) seconds
during euglycaemia to 62.6 (11.0) seconds during hypoglycaemia (p<0.0001, effect size
0.807). The mean (SD) score of the Digit Symbol test deteriorated from 70.1 (13.0)





The results of the memory function tests are summarised in Table 7.1.
Immediate Verbal Memory
Acute hypoglycaemia caused a significant deterioration in tests of immediate
verbal memory as assessed by the AVLT and Logical Memory tests (Figure 7.3). The
mean (SD) immediate AVLT score measured 43.6 (7.0) during euglycaemia and 33.9
(7.7) during hypoglycaemia (p=0.001, effect size=0.535). Immediate Logical Memory
also demonstrated a significant deterioration during hypoglycaemia, with a mean (SD)
of 27.7 (5.9) during euglycaemia, falling to 24.4 (5.0) during hypoglycaemia (p=0.004,
effect size=0.453).
Immediate Visual Memory
In the Benton Visual Retention Test, the achieved score declined from a mean
(SD) of 6.3 (1.7) during euglycaemia to 5.1 (1.6) during hypoglycaemia (p=0.041, effect
size=0.266) (Figure 7.3). By contrast, the results for the Visual Reproduction test did
not demonstrate a significant deterioration (Figure 7.3). The score fell from a mean
(SD) of 85.6 (8.3) during euglycaemia to 81.7 (8.0) during hypoglycaemia (p=0.059).
Despite failing to achieve significance, the effect size was moderate (effect size=0.232).
Delayed Verbal Memory
Both the AVLT Delayed and Logical Memory Delayed tests were affected by
hypoglycaemia (Figure 7.4). The scores deteriorated from a mean (SD) of 10.3 (2.1)
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and 15.1 (4.0) during euglycaemia to 4.5 (1.6) (p<0.0001, effect size=0.873) and 8.1
(2.9) (p=0.001, effect size=0.584) during hypoglycaemia respectively.
Delayed Visual Memory
The Visual Reproduction Delayed test demonstrated a significant decrement
during hypoglycaemia (Figure 7.4). The mean (SD) score was 21.5 (16.5) during
euglycaemia, and 7.6 (5.5) during hypoglycaemia (p=0.001, effect size=0.575).
Working Memory
In all tests of working memory the performance deteriorated during
hypoglycaemia. In the Digit Span Forwards test, mean (SD) score measured 10.2 (2.4)
during euglycaemia, compared to 9.3 (1.7) during hypoglycaemia (p=0.042, effect
size=0.263). In the Digit Span Backwards, scores deteriorated from a mean (SD) of 8.8
(1.9) during euglycaemia to 6.8 (1.2) during hypoglycaemia (p<0.0001, effect
size=0.674) (Figure 7.5), and in the Letter/Number Sequencing test total scores were
13.1 (3.1) during euglycaemia and 10.5 (1.8) during hypoglycaemia (p=0.008, effect
size=0.403) (Figure 7.5). The effects of hypoglycaemia on the Four-term Order and
Validation Span tests were also highly significant (Figure 7.5). Four-term order had a
mean (SD) score of 11.5 (4.9) during euglycaemia compared to 2.5 (1.5) during
hypoglycaemia (p<0.0001, effect size 0.8). A large decrement in performance in the
Validation Span was also observed during hypoglycaemia; mean (SD) during
euglycaemia measured 22.0 (2.3), and during hypoglycaemia measured 13.4 (2.5)
(p<0.0001, effect size 0.942).
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DISCUSSION
The present study has demonstrated the profound effect of acute hypoglycaemia
on impairing memory function in humans. The results indicate that all memory systems
were impaired during hypoglycaemia, with working memory and delayed memory being
particularly susceptible. Performance in tests of general cognitive ability, the Trail
Making B and Digit Span tests, were also significantly impaired during hypoglycaemia,
consistent with the results of previous studies (93,185,217,218,281). This demonstrates
that the degree of hypoglycaemia achieved was sufficient to impair other domains of
cognitive function simultaneously.
Memory is a crucial domain of cognition, and is fundamental to the successful
completion of many everyday tasks. At least three main memory systems - sensory,
short-term and long-term memory - are recognised (216). They are discussed in more
detail in Chapter 4. Working memory, often regarded as a short-term memory system, is
a discrete modality that allows the short-term manipulation of material, as opposed to
the storage ofmaterial in memory.
Few studies have examined the effects of acute hypoglycaemia on memory
function in people with and without diabetes (93,99,152,185,279), and earlier studies
have given inconsistent results. In view of the paucity of data on the effects of
hypoglycaemia on this important cognitive domain, the present study has attempted a
comprehensive examination of the effects of hypoglycaemia on short-term, delayed
(longer-term) and working memory.
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The present study has shown that short-term memory is significantly disrupted
by hypoglycaemia. The effect of hypoglycaemia on short-term verbal memory, assessed
by the AVLT and Logical Memory tests, was considerable, with performance in both
tests being significantly impaired. More importantly, the extent of the deterioration
induced by hypoglycaemia was substantial, as indicated by the large effect size. The
extent of deterioration was slightly greater in the AVLT compared to the Logical
Memory test. The capacity of short-term memory to retain verbal material depends on
how much meaning the information confers to the recipient. A list of random, unrelated
words is therefore more difficult to remember than a story in which the words are
organised into meaningful sentences with a structured and logical progression. Short-
term visual memory was also impaired during hypoglycaemia. The Benton Visual
Retention Test score decreased significantly during hypoglycaemia, although this test
was impaired to a lesser degree than tests of verbal memory. This may reflect an
integral difference in the degree of susceptibility to hypoglycaemia of these two
different modalities, or may indicate a relative insensitivity of this specific test in
detecting changes in cognitive performance. The immediate Visual Reproduction test
was not significantly affected by hypoglycaemia. Although a small decrement was
observed in the scores during hypoglycaemia as compared to euglycaemia, this
difference was not significant. However, the effect size was modest indicating that,
even though the effects of hypoglycaemia on this test did not achieve significance in this
study, hypoglycaemia caused an impairment of test performance.
All tests of delayed memory were greatly affected by hypoglycaemia.
Performance in the Delayed AVLT and Delayed Logical Memory tests decreased
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substantially, with the Delayed AVLT test being more vulnerable to the effects of
hypoglycaemia. The effects of hypoglycaemia on delayed visual memory were also
considerable. Working memory was very susceptible to the effects of hypoglycaemia,
with all tests being affected severely. The Digit Span Forwards test, the least difficult of
the working memory tests, was the least affected. Digit Span Backwards,
Letter/Number Sequencing, Four-term Order and Validation Span were all more
substantially impaired. The impact of hypoglycaemia on performance in these tests was
highly significant, and the extent of the decrements, as measured by effect size, was
large, especially for the Four-term Order and Validation Span tests.
Much of the knowledge about the brain mechanisms which underlie memory has
been derived from animal studies (282) or from studies of humans who have sustained a
preceding brain injury (283). Neuroimaging techniques in humans has confirmed the
importance of medial temporal lobe structures such as the hippocampus and adjacent
parahippocampal regions to memory function in normal individuals (284,285). Injury to
the medial temporal lobe yields global amnesia, a profound and pervasive inability to
remember new information. The hippocampus is susceptible to a wide variety of toxic
insults, including hypoglycaemia.
The brain is susceptible to neuroglycopenia in a rostrocaudal direction with the
cerebral cortex and hippocampus being most sensitive and the brainstem and spinal cord
being most resistant (35). The brains of human subjects who have suffered an episode
of severe hypoglycaemia have been studied and are shown to have areas of cortical
necrosis in the frontal lobes and hippocampus, with relative sparing of the hindbrain
(91,286). Anecdotal case reports of severe amnesia following an episode of severe
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hypoglycaemia have identified a specific structural lesion in the hippocampus in people
with insulin-treated diabetes (92,287).
The results of the present study would support the premise that the hippocampus
is very vulnerable to the adverse effects of hypoglycaemia. Working memory and
delayed memory appeared to be the most vulnerable components of memory to the
effects of hypoglycaemia. Many of the tests of working memory also engage other
cognitive processes, particularly attention. In the brain, the frontal lobes are important
for performance in tasks requiring attention (288,289), and these areas of the brain are
also very sensitive to the effects of neuroglycopenia (82,91). A recent study in our own
centre has confirmed the detrimental effects of acute hypoglycaemia on attention (290).
In the present study, it is possible that the marked disruptive effect of hypoglycaemia on
working memory is a combination of the simultaneous adverse effects of hypoglycaemia
on impairing memory and attention. The present study also demonstrated that other
domains of cognition are impaired during moderately severe hypoglycaemia, and it is
feasible that the impairment of memory performance observed in this study reflects a
transient global brain dysfunction induced by hypoglycaemia, rather than specific
vulnerability of memory processes to hypoglycaemia. The very large effect size
associated with the four-term order test test, in particular, may be a consequence of task
complexity.
The impact of hypoglycaemia on delayed memory was also profound. It is likely
that the normal pathways of hippocampal neural activity that are responsible for the
transfer of information from short-term memory to longer-term memory are disrupted by
neuroglycopenia, resulting in a propensity for disturbance in tests of delayed memory.
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The present study has revealed the adverse effects of hypoglycaemia on
impairment of memory in non-diabetic humans and, in particular, has demonstrated the
potentially deleterious immediate effects of hypoglycaemia on working and delayed
memory. We acknowledge that, with the administration of such an extensive battery of
cognitive tests, there is the potential for type 1 statistical error, and ideally this should
have been excluded by the use of bonferroni statistical analysis. It is not known whether
the effect of hypoglycaemia on memory functions is sustained or protracted, and this
requires further investigation. Many tasks of everyday life engage memory processes,
especially working memory. For example, working memory is used to remember
whether traffic is proceeding along a street after looking to either side before crossing,
taking rapid decisions while driving or operating machinery or computer equipment, and
is fundamental to following instructions or reading a map. It is difficult to quantify the
extent to which memory impairment during acute hypoglycaemia is manifest in
everyday life. There is considerable inter-individual variability of susceptibilty to the
adverse cognitive effects of acute hypoglycaemia and it is probable that some
individuals are more profoundly affected than others. People with insulin-treated
diabetes are frequently exposed to hypoglycaemia as a result of the limitations of their
insulin therapy. It is probable that these individuals will be subject to a similar
impairment of memory functions during hypoglycaemia, which could have important
practical implications for daily activities and working ability. The detrimental effect of
hypoglycaemia on delayed memory also suggests that the ability to learn during




Short-Term, Delayed and Working Memory are Impaired
During Hypoglycaemia in People with Type 1 Diabetes
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INTRODUCTION
Hypoglycaemia is a common side-effect of treatment with insulin in people with
diabetes (1,33). Acute neuroglycopenia causes a rapid deterioration in cognitive
function in humans with, and without, diabetes (235). In general, tests that involve
attention, concentration, psychomotor skill, the accessing of long term memory and the
ability to ignore distracting information, deteriorate when arterial blood glucose declines
below about 3.0 mmol/1 (6,82,152,185,196,278).
Memory is one of the most important cognitive domains with respect to everyday
function and is the process of storing, encoding and retrieving information. However,
few studies have examined the effects of acute hypoglycaemia on memory function,
other than by including a heterogeneous assortment of memory measures as part of a
larger battery of cognitive tests. In some studies, memory functions were impaired
during acute hypoglycaemia (6,82,99,185,279), whereas in others, memory was
apparently unaffected (152,239,280). Variability of results may relate to methodological
differences. Many studies are limited by small sample size, application of a limited
selection of tests, and inadequate ascertainment of biomedical and psychosocial
variables that could affect the results. The method of induction of hypoglycaemia has
also varied between studies, with differing methods of blood sampling (e.g. arterialised
or venous blood). A common methodological error has been the induction of a stepwise
decline in blood glucose with estimation of cognitive function during the final 30
minutes of each blood glucose plateau, thus confounding glucose level with practise
effects.
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In our laboratory a comprehensive examination of the effects of moderate acute
hypoglycaemia on memory performance in healthy non-diabetic humans demonstrated
global impairment of all memory systems, with working memory and delayed memory
being most susceptible to the effects of neuroglycopenia (292). The present study was
designed to investigate the effects of experimentally-induced hypoglycaemia on verbal
and non-verbal tests of short-term, delayed and working memory in adults with type 1




Sixteen (9 male) adults with type 1 diabetes were studied. Subjects were
recruited from the diabetes out-patient clinics at the Royal Infirmary of Edinburgh.
Their median (range) age was 28.5 (20.0-38.2) years, with a Body Mass Index of 23.9
(20.1-24.8) kg/m2, duration of diabetes of 4.5 (1.2-8.4) years, ElbAlc 8.2 (6.9-8.7) %,
and insulin dose of 0.65 (0.25-1.1) u/kg. HbAlc was measured by High Performance
Liquid Chromatography (Variant II Haemoglobin Testing System, Biorad Diagnostics
Group, Hercules, California, USA). None of the participants had a history of
hypertension or chronic disease, previous head injury, seizure, blackouts, alcohol or drug
abuse, or psychiatric illness. They had no intercurrent illness and were not taking any
regular medication (with the exception of insulin and the oral contraceptive pill).
Subjects were excluded if they had any evidence of microvascular disease. The
presence of retinopathy was ascertained by ophthalmoscopy, neuropathy by clinical
examination, and nephropathy was defined by the presence of microalbuminuria.
Subjects were excluded if they had a history of impaired awareness of hypoglycaemia,
or had suffered an episode of hypoglycaemia in the 48 hours preceding the study.
Ethical permission for the study was approved by the Lothian Research Ethics
Committee. All subjects gave written informed consent for participation in the study.
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Study Design
Each subject participated in two laboratory sessions that were separated by at
least two weeks (Figure 8.1). The studies were conducted in the Department of Diabetes
at the Royal Infirmary of Edinburgh. A modified hyperinsulinaemic glucose clamp
(238) was used to maintain the blood glucose at a predetermined level. In the
euglycaemia study, the arterialised blood glucose concentration was maintained at 4.5
mmol/1 and hypoglycaemia was not induced. In the hypoglycaemia study, the glucose
concentration was lowered to 2.5 mmol/1. The subjects were not informed which
experimental arm of the study was being undertaken on each occasion and the two
experimental sessions were performed in a randomized and counterbalanced fashion.
Procedure
The hyperinsulinaemic glucose clamp procedure (238), as discussed in chapter 6,
was used to induce hypoglycaemia.
Cognitive Function Tests
Tests of immediate and delayed verbal memory, immediate and delayed visual
memory, and tests of working memory were administered during the study conditions.
In addition to the memory tests, the Trail Making B and Digit Symbol tests were also
administered. These are validated tests of general cognitive ability and were used to




The Edinburgh Hypoglycaemia Scale (276) was used to document the common
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Figure 8.1: Study design
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RESULTS
A stable blood glucose plateau was achieved during each study condition (Figure
8.2). The mean (SD) arterialised blood glucose concentration during the euglycaemia
condition was 4.55 (0.18) mmol/1, and during the hypoglycaemia condition was 2.51
(0.08) mmol/1. Statistical analysis revealed that no significant order effects had occurred
for any of the outcome variables of this study, and no significant gender differences
were evident.
Symptoms
Results of the hypoglycaemia symptom questionnaires confirmed that scores for
autonomic (p<0.0001), neuroglycopenic (p=0.001) and general malaise (p=0.008)
symptoms were all significantly elevated during hypoglycaemia compared to baseline
euglycaemia, and were unchanged from baseline levels during the euglycaemia study
condition.
Digit Symbol and Trail Making B
During hypoglycaemia, the time taken to complete the Trail Making B test
increased significantly from a mean (SD) of 33.7 (7.7) seconds during euglycaemia to
54.0 (10.7) seconds during hypoglycaemia (p<0.0001, eta2=0.68). The mean (SD) score
of the Digit Symbol test declined from 73.5 (11.2) during euglycaemia to 62.9 (16.9)
during hypoglycaemia (p=0.001, eta2=0.57).
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The results of the memory function tests are summarised in Table 8.1.
Immediate Verbal Memory
Acute hypoglycaemia caused a significant deterioration in tests of immediate
verbal memory as assessed by the AVLT (p=0.002, eta2=0.49) and Logical Memory
tests (p=0.008, eta2=0.41) (Figure 8.3).
Immediate Visual Memory
The Benton Visual Retention Test score declined during hypoglycaemia
(p=0.007, eta2=0.42). By contrast, the score for the Visual Reproduction test did not fall
significantly (p=0.093) (Figure 8.3).
Delayed Verbal Memory
Both the AVLT Delayed (pO.OOOl, eta2=0.68. Percent retained: pO.OOOl,
eta2=0.78) and Logical Memory Delayed (p<0.0001, eta2=0.83. Percent retained:
p<0.0001, eta2=0.73) scores were significantly worse during hypoglycaemia (Figure
8.4).
Delayed Visual Memory
During hypoglycaemia a significant decrement was observed in the Visual




Performance in the working memory tests is shown in Figure 8.5. Digit Span
Backwards (p=0.02, eta2=0.33), Letter/Number Sequencing (p=0.001, eta2=0.57) and
Validation Span (p<0.0001, eta =0.92) all demonstrated a significant decrement during
hypoglycaemia. The Validation Span test declined from a mean (SD) score of 20.7 (2.3)
during euglycaemia to 14.9 (2.2) during hypoglycaemia. However, performance in the
Digit Span Forwards test was not significantly affected (p=0.06, eta =0.23).
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DISCUSSION
Few previous studies have made a detailed examination of the effects of acute
hypoglycaemia on memory function in humans, with and without diabetes
(99,152,185,239,279), and earlier studies have given inconsistent results. Using an
identical study design, we have studied the effects of hypoglycaemia in young, healthy,
non-diabetic volunteers and demonstrated a profound impairment in memory function at
a blood glucose level that was similar to the present study (2.5 mmol/1) (292). In view
of the frequency with which mild hypoglycaemia is experienced by people with insulin-
treated diabetes, the present study has examined the effects of acute hypoglycaemia on a
wide range of memory functions in a group of adults with type 1 diabetes who had no
evidence of significant vascular complications.
The present study has demonstrated that in adults with type 1 diabetes acute
moderate hypoglycaemia caused a marked deterioration in performance in tests of short-
term, delayed and working memory, for both verbal and non-verbal material, with
working memory and delayed memory being affected most strongly (according to effect
size analysis). In addition, performance in the Trail Making B and Digit Symbol tests
was impaired significantly during hypoglycaemia. This is consistent with previous
observations (185,217,218,279,281), and confirms that the degree of hypoglycaemia
achieved was sufficient to affect other domains of cognitive function.
Short-term memory was significantly disrupted by hypoglycaemia in the present
study. The effect of hypoglycaemia on short-term verbal memory, assessed by the
AVLT and Logical Memory tests, and short-term visual memory, assessed by the
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Benton Visual Retention Test, was profound, with performance in the three tests being
significantly impaired. Earlier studies have demonstrated decrements in short-term,
verbal memory during hypoglycaemia (99,185). In the present study, the magnitude of
the impairment induced by hypoglycaemia was substantial, as indicated by the large
effect size. However, the immediate Visual Reproduction test was not significantly
affected by hypoglycaemia. This appeared to be a manifestation of a 'ceiling-effect'
(i.e. most subjects obtained near-to-perfect scores), indicating a lack of sensitivity of this
test to the stress of hypoglycaemia.
A significant deterioration in performance in tests of delayed verbal memory has
been shown during hypoglycaemia in previous human studies of non-diabetic (6) and
diabetic subjects (162). In the present study, all tests of delayed memory were markedly
affected by hypoglycaemia. Performance in the Delayed AVLT and Delayed Logical
Memory tests deteriorated significantly during hypoglycaemia, and the effects of
hypoglycaemia on delayed visual memory were also considerable. Analysis of the
'immediate' and 'delayed' Logical Memory, AVLT and Visual Reproduction test scores
allowed calculation of the percentage of information that was learned and retained
during the study. This revealed that, for tests of both verbal and visual memory, not
only was less information recalled immediately after having studied the information
during hypoglycaemia as compared to euglycaemia but that, over time, subjects forgot
more of what they had recalled immediately during hypoglycaemia, than during the
euglycaemic state.
Working memory was very susceptible to the effects of hypoglycaemia. The
Digit Span Lorwards test, the least difficult of the working memory tests, was the least
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affected and was not significantly impaired during hypoglycaemia. A small decrement
was observed in the scores during hypoglycaemia as compared to euglycaemia and the
effect size was modest, indicating that, although the effects of hypoglycaemia on this
test did not achieve significance in this study, hypoglycaemia did impair test
performance. Digit Span Backwards, Letter/Number Sequencing and Validation Span
were all more substantially impaired. The impact of hypoglycaemia on performance in
these tests was highly significant, and the extent of the decrements, as measured by the
effect size, was large.
Functional neuroimaging studies in humans have confirmed that medial temporal
lobe structures such as the hippocampus and adjacent parahippocampal regions are the
principal structures involved with memory performance (284,285). The hippocampus is
susceptible to a variety of toxic insults, including heavy metals (289), hypoxia (290),
and drugs (295,296). There is some evidence that this particular area of the brain is also
preferentially vulnerable to the adverse effects of hypoglycaemia. Neuropathological
observations have indicated that the brain is sensitive to neuroglycopenia in a
rostrocaudal direction with the cerebral cortex and hippocampus being most susceptible
and the brainstem and spinal cord being most resistant (91). The brains of human
subjects who have suffered an episode of severe hypoglycaemia have been studied and
are shown to have areas of cortical necrosis in the frontal lobes and hippocampus, with
relative sparing of the hindbrain (91,286). Anecdotal case reports of severe amnesia
following an episode of severe hypoglycaemia have identified a specific structural lesion
in the hippocampus in people with insulin-treated diabetes (92,287).
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The results of the present study have clearly demonstrated the short-term
detrimental effects of acute hypoglycaemia on memory and are consistent with these
earlier observations. We acknowledge that, with the administration of such an extensive
battery of cognitive tests, there is the potential for type 1 statistical error, and ideally this
should have been excluded using bonferroni statistical analysis. Working memory and
delayed memory appeared to be the most vulnerable components of memory to the
effects of hypoglycaemia. Many of the tests of working memory also engage other
cognitive processes, particularly attention. In the brain, the frontal lobes are important
for performance in tasks requiring attention (288,289). These areas of the brain are also
very sensitive to the effects of neuroglycopenia (91), and a different study in our own
centre has confirmed the detrimental effects of acute hypoglycaemia on attention (290).
In the present study, it is possible that the marked disruptive effect of hypoglycaemia on
working memory is a combination of the simultaneous adverse effects of hypoglycaemia
on memory and attention. The prefrontal lobe and medial temporal lobe structures are
important for performance in tasks ofworking memory (297,298).
In animals, working memory tasks have been shown to exert high demands on
brain extracellular glucose (299). In the brain, glucose is transported across the cell
membranes by facilitated diffusion, mediated by the glucose transport proteins GLUT1
and GLUT3 (300). It is possible that the vulnerability of working memory to the effects
of hypoglycaemia is a consequence of the interaction between local brain demands and
the regional distribution of GLUT1 and GLUT3 receptors. The profound impact of
hypoglycaemia on delayed memory is likely to be due to the disruption, by
neuroglycopenia, of the normal pathways of hippocampal neural activity that are
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responsible for the transfer of information from short-term memory to longer-term
memory.
The adverse effects of hypoglycaemia on impairment of memory in adults with
type 1 diabetes that have been demonstrated in the present study are very similar to the
effects of hypoglycaemia on memory function in non-diabetic humans that we have
shown previously (292). It is not known whether the effect of hypoglycaemia on
memory is sustained or protracted, and this will require further investigation. Many
aspects of cognitive function have been observed to return to normal within two hours
after euglycaemia is restored (95,100,301), and this is presumably similar for memory
function. The present study also demonstrated that other domains of cognition are
impaired during moderately severe hypoglycaemia, and it is feasible that the impairment
of memory performance observed in this study reflects a transient global brain
dysfunction induced by hypoglycaemia, rather than specific vulnerability of memory
processes to hypoglycaemia. The very large effect size associated with the validation
span test, in particular, may be a consequence of task complexity.
The effect of memory dysfunction during acute hypoglycaemia on performance
in activities during everyday life is difficult to quantify. It is known that there is
considerable inter-individual variability of susceptibility to the adverse cognitive effects
of acute hypoglycaemia and it is probable that some individuals are more profoundly
affected than others Many tasks of everyday life engage memory processes, especially
working memory. For example, before crossing a street, working memory is used by a
pedestrian to remember whether traffic is approaching after looking each way, working
memory is essential when taking rapid decisions while driving, and is fundamental to
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following directions such as reading a map. It is also of critical importance in the work
environment and is used continuously when operating machinery or computer
equipment. People with insulin-treated diabetes are frequently exposed to varying
degrees of hypoglycaemia, and current therapeutic policies that strive to achieve strict
glycaemic control may promote more frequent hypoglycaemic events. The results of the
present study demonstrate that many people with type 1 diabetes are subject to
impairment of memory functions during hypoglycaemia in their everyday lives, which
may have important practical implications for daily activities including effective
working ability and driving performance (76).
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Chapter 9
Working Memory Performance is Particularly Susceptible to
the Adverse Effects of Acute Hypoglycaemia
191
The effects of acute hypoglycaemia on the specific domain ofworking memory, in
both diabetic and non-diabetic subjects, was particularly marked. Working memory is the
mental capacity simultaneously to store and manipulate information (224). As has been
discussed, glucose is the brain's principal fuel and mental function deteriorates when
arterial glucose falls below 3 mmol/1. Tasks that are complex and performed under time
pressure are particularly affected, the usual finding being a modest reduction in
performance (175). The effect of acute hypoglycaemia on working memory has not been
studied previously.
Memory performance was studied in 16 (9 men) healthy, non-diabetic humans,
aged 26 and 34 years, under conditions of euglycaemia (4.5 mmol/1) and hypoglycaemia
(2.5 mmol/1), using the hyperinsulinaemic glucose clamp technique to achieve precise
control of arterialised plasma glucose (238).
The 'Four-Term Order' working memory test is from Kyllonen's well-validated
cognitive battery (302). Subjects listen to three rules read aloud by the experimenter and
then choose which of eight response options correctly accords with the rules. Eight
response alternatives are then displayed on a card and the subject is required to identify
the correct sequence as determined by the preceding commands. Twenty four different
items were used in each condition.
Performance on the Four-Term Series task fell from 11.5 (4.9) during euglycaemia
to 2.5 (1.5) during hypoglycaemia (p < .0001). A range of individual differences during
euglycaemia, from chance to near-perfect performance, was reduced to near-uniform
chance responding during hypoglycaemia (Figure 9.1). Figure 9.1 also demonstrates the
performance of the same subjects under the same conditions in the digit symbol task, a test
that has been used extensively under the conditions of acute hypoglycaemia. Performance
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in this particular test was, as expected, significantly poorer during moderate
hypoglycaemia (a mean (SD) of 70.1 (13.0) during euglycaemia fell to 59.6 (14.4) during
hypoglycaemia) but the range of impairment was substantially greater amongst
individuals, with considerable individual variation in response, and considerable overlap
in scores between the two conditions.
Unlike other mental functions, working memory performance, as indexed by the
Four Term Order task, was reduced to chance levels. Performance in this working memory
task was almost obliterated during moderate hypoglycaemia in young, healthy humans.
Working memory is a pillar of human mental performance, almost indistinguishable from
reasoning and general intelligence (227,302) and such detrimental effects on this particular
cognitive domain may, therefore, have substantial detrimental effects on the everyday
lives of people with diabetes who are frequently exposed to similar levels of
hypoglycaemia. Animal studies suggest that working memory makes high demands on
brain extracellular glucose, specifically in the hippocampus (299), and it appears that the
hippocampus and other medial temporal lobe structures and the frontal lobes are especially
sensitive to the effects of neuroglycopenia (286). The dorsolateral prefrontal cortex is
frequently activated during memory and reasoning tasks that involve the evaluation of
externally generated information (303,304). A possible basis for the vulnerability of
working memory to the effects of hypoglycaemia, therefore, is the interaction of local
brain energy demands and the regional density of the cerebral glucose transporters GLUT1
and GLUT3 (300).
The degree of hypoglycaemia induced in this study, which occurs commonly in
people with type 1 (insulin-dependent) diabetes, does not affect conscious level. Although
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performance in many mental tasks show some deterioration in this state, such a deleterious
effect on such a fundamental cognitive domain has not been observed previously.
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Figure 9.1: The effect of hypoglycaemia on individual non-diabetic subjects' (a) digit

















































HYPERGLYCAEMIA AND COGNITIVE FUNCTION
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Chapter 10
Acute Hyperglycaemia Alters Mood State and Impairs
Cognitive Performance in People with Type 2 Diabetes
197
INTRODUCTION
Diabetes is frequently associated with acute metabolic disturbances and
fluctuations in glycaemic control. Hyperglycaemia commonly occurs as a
consequence of the relative or absolute insulin deficiency that is intrinsic to diabetes,
and hypoglycaemia is a common side effect of the treatment of diabetes with insulin,
and to a lesser extent with sulphonylureas (1). The brain is vitally dependent on
glucose as a source of fuel, and disturbance of blood glucose concentration can
impinge on cerebral function. Many studies have demonstrated the deleterious
effects of acute hypoglycaemia on cognitive function and on mood states, both in
non-diabetic subjects and in people with type 1 and type 2 diabetes (175,235). In
contrast, considerably less information is available on the effects of acute
hyperglycaemia on cognition. However, anecdotal descriptions by patients with
either type 1 or type 2 diabetes suggest that altered mood (such as increased
irritability and feelings of diminished well-being) and difficulties with rapid
cerebration are common when blood glucose is elevated.
Published data on the effects of hyperglycaemia on cognitive function reveals
conflicting results. One study (239) demonstrated impaired performance in verbal
cognitive tasks in 12 people with type 1 diabetes during acute hyperglycaemia (blood
glucose 16.6 mmol/1) and a further study in 12 children, mean age 12.4 years (240)
showed a reduction in performance IQ under conditions of controlled
hyperglycaemia (20 - 30mmol/l).
In contrast to this, other studies do not support these findings. A study of
adolescents with type 1 diabetes did not show any effect of acute hyperglycaemia on
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cognitive function (241), and Hoffman et al (278) also failed to demonstrate any
significant effect of acute hyperglycaemia on cognitive function in 18 adults with
type 1 diabetes. Two further studies examined the effects of acute hyperglycaemia
on cognitive function (99) and mood (242) in a cohort of 42 adult patients with type
1 diabetes. Neither cognitive function, nor self-reported mood were significantly
affected. However, the study cohort had poor metabolic control, with a mean HbAlc
of 10.1%. There may be potential for cerebral adaptation in response to a high
prevailing blood glucose concentrations.
A further study in non-diabetic volunteers utilised functional magnetic
resonance imaging to determine the effects of acute hyperglycaemia on activation of
the occipital cortex in response to a visual stimulus (305). The study demonstrated
that acute hyperglycaemia did not have a substantial effect on the size or intensity of
visual cortical activation in response to visual stimuli.
All previous studies on the effects of acute hyperglycaemia on cognitive
function have been in people with type 1 diabetes. To our knowledge, there are no
studies on the effects of acute hyperglycaemia on cognitive and non-cognitive
function in people with type 2 diabetes. There is increasing evidence that people
with type 2 diabetes are at an increased risk of cognitive dysfunction, especially of
verbal memory (243). It is probable that this dysfunction is a consequence of
synergistic interaction between metabolic derangements associated with diabetes and
the structural and functional changes that occur within the central nervous system as
part of the normal ageing process. Therefore, people with type 2 diabetes may be
more susceptible to cognitive dysfunction during acute glycaemic changes.
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The present study aimed to examine the effects of acute hyperglycaemia




Twenty (12 male) adults with type 2 diabetes were studied. Subjects were
recruited from the diabetes out-patient clinics at the Royal Infirmary of Edinburgh.
Their median (range) age was 61.5 (53.1-72.0) years, with a Body Mass Index of
29.8 (22.0-34.6) kg/m2, duration of diabetes of 5.9 (2.8-11.2) years, and HbAlc 7.5
(6.7-8.4) %. HbAlc was measured by High Performance Liquid Chromatography
(Variant II Haemoglobin Testing System, Biorad Diagnostics Group, Hercules,
California, USA) (non-diabetic reference range 4.3-6.5%). Three of the subjects
were taking insulin alone for the treatment of their diabetes, five subjects were taking
a single oral hypoglycaemic agent (OHA), nine were taking two OHAs, and three
subjects were taking a combination of insulin and an OHA. None of the participants
had a history of chronic disease, previous head injury, seizure, blackouts, alcohol or
drug abuse, or psychiatric illness. Subjects were excluded if they had any evidence
of microvascular disease, with the exception of background retinopathy. The
presence of retinopathy was ascertained by ophthalmoscopy, neuropathy by clinical
examination, and nephropathy was defined by the presence of microalbuminuria.
Ethical permission for the study was approved by the Lothian Research Ethics




Each subject participated in two laboratory sessions that were separated by at
least two weeks (Figure 10.1). The studies were conducted in the Department of
Diabetes at the Royal Infirmary of Edinburgh. A modified hyperinsulinaemic
glucose clamp (238) was used to maintain the blood glucose at a predetermined
level. In the euglycaemia study, the arterialized blood glucose concentration was
maintained at 4.5 mmol/1. In the hyperglycaemia study, the glucose concentration
was raised to 16.5 mmol/1. The subjects were not informed which experimental arm
of the study was being undertaken on each occasion and the two experimental
sessions were performed in a randomised and counterbalanced fashion.
Procedure
A hyperinsulinaemic glucose clamp was used to induce hyperglycaemia or
euglycaemia (238).
Cognitive Function Tests
Validated tests of information processing, tests of memory and tests of
attention were administered during each study condition.
Test of information processing included the Trail Making B test, the Digit
Symbol Test and the simple and four-choice reaction time tests. In this study, a
computerised version of the test on a hand-held computer was used (306).
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Tests of memory included verbal memory tests (Auditory Verbal Learning
Test (AVLT) - immediate and delayed, Logical Memory Test - immediate and
delayed), visual memory tests (Visual Reproduction - immediate and delayed,
Benton Visual Retention Test (BVRT)) and working memory tests (Digit Span -
Forwards and Backwards, Letter/Number Sequencing)
The Test of Everyday Attention (TEA) battery (274) was used to measure
attention.





~^ ^ and mood questionnaire
run-in baseline (30 mins)
I I 1 1
^ Euglycaemia (4.5 mmol/1)
insulin/dextrose
Figure 10.1: Study design
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RESULTS
A stable blood glucose plateau was achieved during each study condition
(Figure 10.2). The mean (SD) arterialised blood glucose concentration during the
euglycaemia condition was 4.5 (0.2) mmol/1, and during the hyperglycaemia
condition was 16.7 (0.6) mmol/1. Statistical analysis revealed that no significant
order effects had occurred for any of the outcome variables of this study, and no
significant gender differences were evident.
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Tests of Information Processing
The results of these tests are summarised in Table 10.1. During acute
hyperglycaemia, performance in both the Trail Making B (p=0.037, eta2=0.22) and
the Digit Symbol tests (p=0.029, eta =0.24) was significantly impaired. The Four
Choice Reaction Time score deteriorated during hyperglycaemia (p<0.0001,
eta =0.56). By contrast, the score for the Simple Reaction Time test was not
significantly affected (p=0.101).
Tests ofMemory
The results of the memory function tests are summarised in Table 10.2.
Immediate Memory
Acute hyperglycaemia had no significant effect on tests of immediate verbal
(AVLT: p=0.085, Logical Memory: p=0.162) or immediate visual memory (Visual
Reproduction: p=0.515, BVRT: p=0.296).
Delayed Memory
Tests of delayed verbal (AVLT Delayed: p=0.26, Logical Memory Delayed:
p=0.092) and delayed visual memory (Visual Reproduction Delayed: p=0.075) were
also not significantly impaired during hyperglycaemia.
Working Memory
Digit Span Backwards (p=0.013, eta2=0.3) and Letter/Number Sequencing
2
tests (p=0.023, eta =0.25) demonstrated a significant decrement during
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hyperglycaemia. Performance in the Digit Span Forwards test was not significantly
affected (p=0.33).
Tests of Attention
The results of the tests of attention are summarised in Table 10.3.
Visual Selective Attention
The mean number (SD) of map symbols circled during euglycaemia in one
minute was 35.0 (6.7) versus 32.2 (5.1) during hyperglycaemia (p=0.036, eta2=0.22).
The mean number (SD) of symbols circled in two minutes was also lower at 62.5
(8.7) during hyperglycaemia, compared with 64.8 (7.4) in the euglycaemia condition.
However, the difference did not achieve statistical significance (p=0.31). In the
telephone search task, no difference was demonstrated between euglycaemia and
hyperglycemia in the number of symbols located (Table 10.3). The mean (SD) time
taken to complete the task increased from 58.7 (8.3) seconds during euglycaemia, to
67.0 (13.1) seconds during hyperglycaemia (p=0.043, eta2=0.27) (Table 10.3).
Auditory Selective Attention
In the auditory elevator test with reversal, the achieved score declined from a
mean (SD) of 5.3 (1.7) during euglycaemia to 4.4 (1.4) during hyperglycaemia
(p=0.014, eta =0.29). By contrast, the score attained on the elevator test with
distraction did not deteriorate during hyperglycaemia, with a mean (SD) score of 8.8
(1.1) during euglycaemia compared to 8.3 (1.3) during hyperglycaemia (p=0.117).
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Sustained Attention
Sustained attention did not deteriorate during hyperglycaemia using either the
lottery ticket test or the elevator counting test (Table 10.3).
Attentional Switching
In the visual elevator task, no difference was observed in the raw score
between the two study conditions. The mean (SD) raw score during euglycaemia
was 8.9 (1.1) compared with 8.5 (0.9) during hyperglycaemia (p=0.173). However, a
significantly longer time was required to complete each switch of the visual elevator
task during hyperglycaemia with a mean (SD) time of 4.7 (0.9) seconds per switch,
compared to 4.3 (1.0) seconds per switch during euglycaemia (p=0.001, eta2=0.49).
Divided attention
In the task that involved search of a telephone directory while counting, no
significant difference was observed in the number of symbols that were located
during either study condition (Table 10.3). The time taken to complete the task was
higher during hyperglycaemia with a mean (SD) of 67.2 (17.1) seconds compared to
62.3 (9.5) seconds during euglycaemia, but this difference was not significant
(p=0.1). The time per target score, which is the ratio of the number of circled
symbols divided by the time taken for the task, was significantly higher during acute
hyperglycaemia, with a mean (SD) of 1.2 (0.6) seconds/target during hyperglycaemia
compared to 1.0 (0.6) seconds/target during euglycaemia (p=0.049, eta2=0.2).
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Table 10.1: Results of tests of information processing during euglycaemia and
hyperglycaemia in 20 adults with type 2 diabetes. Results are shown as mean (SD).
Subtest Euglycaemia Hyperglycaemia p value Eta2
Digit Symbol Substitution test 70.2 (8.4) 66.8 (7.8) .029 .24
Trail Making B test 40.9 (7.8) 43.9 (8.0) .037 .23
Simple Reaction Time test 359.9 (84.6) 373.7 (72.3) .101 .14
Four-Choice Reaction Time test 710.0(116.7) 775.7 (122.9) < .0001 .56
SD - Standard Deviation
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Table 10.2: Results of tests ofmemory during euglycaemia and hyperglycaemia in
20 adults with type 2 diabetes. Results are shown as mean (SD).
Subtest Euglycaemia Hyperglycaemia p value Eta
Immediate Logical Memory 27.2 (4.3) 26.1 (4.1) .162 .11
Immediate AVLT 35.0 (5.7) 32.4 (4.9) .085 .16
Benton Visual Retention test 6.2(1.2) 5.9 (0.9) .296 .06
Visual Reproduction 76.9 (7.6) 77.9 (7.5) .515 .02
Digit Span Forwards 9.6(1.3 9.2(1.6) .33 .05
Digit Span Backwards 8.6(1.5) 7.9(1.3) .013 .30
Letter/Number Sequencing 10.4(1.9) 9.4(1.6) .023 .25
Delayed Logical Memory 13.2 (2.1) 12.3(2.2) .092 .15
Delayed AVLT 8.2 (2.2) 7.8 (1.9) .26 .07
Delayed Visual Reproduction 14.1 (9.2) 10.8 (8.2) .075 .17
AVLT - Auditory Verbal learning Test
SD - Standard Deviation
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Table 10.3: Results of tests of attention during euglycaemia and hyperglycaemia in
20 adults with type 2 diabetes. Results are shown as mean (SD).
Subtest Euglycaemia Hyperglycaemia p value Eta2
Map Search 1 minute 35.0(6.7) 32.2 (5.1) .036 .22
Map Search 2 minutes 64.8 (7.4) 62.5 (8.7) .314 .06
Elevator Counting 6.6 (0.68) 6.7 (0.67) .795 .01
Elevator Counting with distraction 8.8 (1.1) 8.3 (1.3) .117 .13
Elevator Counting with reversal 5.3 (1.7) 4.4(1.4) .014 .29
Visual Elevator raw score 8.9(1.1) 8.5 (0.9) .173 .10
Visual Elevator switch time 4.3 (1.0) 4.7 (0.9) .001 .49
Telephone Search raw score 3.6 (0.7) 3.7 (0.6) .340 .05
Telephones Search total time 58.7(8.3) 67.0(13.1) .043 .27
Telephone Search with counting 1.0(0.6) 1.2 (0.6) .049 .20
Telephone Search with counting
total time
62.3 (9.5) 67.2(17.1) .100 .12
Telephone Search with counting
time per target
1.0(0.6) 1.2 (0.6) .049 .20
Lottery 9.6 (0.7) 9.7 (0.6) .630 .01
SD - Standard Deviation
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Mood
The results of the mood questionnaire are shown in Figure 10.3. Hedonic
Tone (p=0.004, eta2=0.38) and Energetic Arousal (p=0.001, eta2=0.49) scores were
significantly lower during hyperglycaemia, while feelings of Tense Arousal were
greater (pO.OOOl, eta2=0.56).
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Figure 10.3: Graph showing mean (SD) scores of the UWIST mood adjective
checklist during euglycaemia and hyperglycaemia.
Euglycaemia
■ Hyperglycaemia
HedonicTone Energetic Arousal Tense Arousal
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DISCUSSION
Relatively few studies have examined in detail the effects of acute
hyperglycaemia on cognitive function, and non-cognitive functions such as mood, in
people with diabetes (99,239-242,278). Earlier studies have provided inconsistent
results. In view of the paucity of data on the effects of hyperglycaemia on these
important aspects of everyday life, the present study has attempted a broad
examination of the effects of hyperglycaemia on an extensive battery of cognitive
tests, and mood state.
The present study has demonstrated that acute hyperglycaemia significantly
impairs cognitive function and has a significant effect on mood in people with type 2
diabetes. We acknowledge that, with the administration of such an extensive battery
of cognitive tests, there is the potential for type 1 statistical error, and ideally this
should have been excluded using bonferroni statistical analysis.
The changes in mood that were observed during acute hyperglycaemia
included increased feelings of agitation and anxiety (increased tense arousal),
increased feelings of tiredness and lethargy (decreased energetic arousal) and
decreased feelings of happiness (decreased hedonic tone). Changes in mood can
influence cognitive performance. Further analysis of the cognitive test results with
mood as a covariate demonstrated that the impairment in cognitive function occurred
independently of changes in mood state.
In tests of information processing, performance in the Digit Symbol and Trail
Making B tests was significantly impaired during acute hyperglycaemia. In the
reaction time test there was no significant decrement in performance in the Simple
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Reaction Time test. However, performance in the more complex Four-Choice
Reaction Time test deteriorated very significantly during hyperglycaemia.
There was no significant disruption of test performance in the relatively
simple tests of short-term verbal (Logical Memory, AVLT) and short-term visual
(Visual Reproduction, BVRT) memory during hyperglycaemia. Tests of delayed
memory were also unaffected.
The Digit Span test is a test of working memory. Digit Span Forwards test
performance was not significantly impaired during acute hyperglycaemia. However,
performance in the more complicated Digit Span Backwards test showed a
significant decrement during hyperglycaemia. Performance in the Letter/Number
Sequencing test, another complicated test of working memory, was also significantly
worse during acute hyperglycaemia.
Scores in the Lottery and Elevator Counting tests, tests of sustained attention,
were not significantly affected by hyperglycaemia. However, there was a significant
reduction in performance in the more difficult task of Elevator Counting with
Reversal during acute hyperglycaemia.
In the Map Search, a test of visual selective attention, significantly fewer
symbols were marked after one minute during hyperglycaemia compared to
euglycaemia. There was no significant difference in the overall two minute score.
This was due to a 'ceiling effect' after two minutes. There was no difference in the
total number of symbols located in the Telephone Search test, but the time taken to
complete the task was significantly longer during hyperglycaemia compared to
euglycaemia. Similarly, in the Telephone Search While Counting test, although
there was no significant difference in the total number of symbols located during
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either study condition, the time taken to complete the test was significantly longer
during hyperglycaemia. In the Visual Elevator task, no significant difference was
observed in the raw score during hyperglycaemia compared to euglycaemia.
However, the time taken to complete each switch was significantly longer during
hyperglycaemia.
The adverse effects of acute hypoglycaemia on cognitive function are well
established. The results of the present study indicate that acute hyperglcaemia also
has a significant deleterious effect on neuropsychological function. With the
exception of the Four-Choice Reaction Time test, the eta2 values for the tests of
cognitive function are modest. Nevertheless, the effects of hyperglycaemia on mood
and some tests of cognitive function were significant. From the cognitive function
test results it was apparent that acute hyperglycaemia caused impairment in
performance of complex tasks of cognitive function in people with type 2 diabetes.
This finding is in agreement with the results from an earlier study by Davis et al
(240), who demonstrated that the impairment of cognitive function in children with
type 1 diabetes during acute hyperglycaemia was limited to complex tests of
cognitive ability. We have also demonstrated impairment of performance during
acute hyperglycaemia in tests that require a speeded response, suggesting that
accuracy is preserved at the expense of speed. It is not known whether the effect of
hyperglycaemia on cognitive function or mood is sustained or protracted, and this
will require further investigation. The effects of acute hypoglycaemia on cognitive
function have been observed to return to normal within two hours after euglycaemia
is restored (95,100).
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The precise mechanism by which acute hyperglycaemia may cause cognitive
dysfunction is unclear. It is possible that acute hyperglycaemia may cause structural
or functional changes in the blood brain barrier, may influence synthesis or re-uptake
of neurotransmitters, including neurotoxic neurotransmitters such as glutamate, or
acute hyperglycaemia may induce cytotoxic osmotoic changes within neurones.
There is already some indirect evidence to suggest that hyperglycaemia has
adverse affects on cerebral function. There is increasing evidence to suggest that
chronic hyperglycaemia, as indicated by surrogate markers such as polyneuropathy
or retinopathy, is involved in the pathogenesis of the cognitive impairment associated
with diabetes (186,307,308), and acute hyperglycaemia has been shown to enhance
cerebral damage resulting from ischemic stroke (308).
Our findings are in concordance with anecdotal reports from people with
diabetes, and are supported by a recent study conducted by Cox et al (309) who have
demonstrated changes in mood and impairment in cognitive function during acute
hyperglycaemia in people with both type 1 or type 2 diabetes. The findings of our
study are of considerable practical importance to people with type 2 diabetes in
whom moderate hyperglycaemia is common. Such effects of hyperglycaemia on
cognitive function may significantly interfere with many activities of daily living and







Vessel Wall Stiffness in Type 1 Diabetes, and the Central
Haemodynamic Effects of Acute Hypoglycaemia
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INTRODUCTION
Central arterial pressure and waveform convey important information about
cardiovascular status (244,249). Arterial blood pressure is usually recorded non-
invasively from the brachial artery by sphygmomanometry. It is assumed that the
pressure is the same throughout the arterial tree and that it represents an accurate
index of aortic peak pressure and of left ventricular systolic pressure, and so of left
ventricular afterload. However, pressure values in the peripheral circulation are an
inaccurate measure of central pressure because of amplification of the pressure pulse
between central and peripheral arteries (245,265).
Each left ventricular contraction generates a pressure wave which travels
along the major arteries until it meets peripheral resistance, at which point the wave
is reflected back to the heart. Arterial stiffness influences the velocity of the reflected
pressure wave. Normally, the reflected wave reaches the heart during diastole and,
by increasing diastolic pressure, coronary perfusion is enhanced. However, where
arterial stiffening develops, the increased pulse wave velocity of the stiffened arteries
leads to an earlier reflection of the wave so that it reaches the heart during late
systole (249,261). The increase in systolic pressure that results from earlier
reflection of the pressure wave is referred to as "augmentation". The Augmentation
Index (AIx) is the augmentation pressure expressed as a percentage of the pulse
pressure. AIx increases with increasing age, and also increases in disease states such
as hypertension (262). It is also influenced by heart rate; a decrease in AIx is
observed with increasing heart rate (264).
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Arterial stiffness, is an independent predictor of cardiovascular morbidity,
especially for myocardial infarction (249-253). The development of pulse wave
analysis has allowed the measurement of central arterial pressure, and the degree of
its augmentation by pulse wave reflection, to be studied reliably and non-invasively
(254-256). The system utilises applanation tonometry, with the external application
of a micromanometer-tipped probe to record peripheral pulse waveforms. The radial
artery is usually used for these measurements because of its close proximity to, and
support provided by, nearby bony structures (258,259).
Diabetes is a chronic disorder, associated with the development of
microvascular and macrovascular disease as a result of long-term exposure to
hyperglycaemia (310,311). Hence, diabetes is associated with a high prevalence of
macrovascular disease causing life-threatening vascular events, such as acute
myocardial infarction and stroke.
Several studies have examined arterial stiffness in people with diabetes.
Arterial stiffness has consistently been found to be increased in people with Type 2
diabetes (312,313), and also in their relatives (310), but the results of studies that
have examined arterial stiffness in people with Type 1 diabetes have been
inconsistent. Some studies have demonstrated increased levels of arterial stiffness in
people with Type 1 diabetes compared to non-diabetic controls (315-317), whereas
other studies have shown either no difference (318) or reduced arterial stiffness (319)
in people with Type 1 diabetes. The discrepancy between results may be due to
methodological differences between studies. Participants have varied in their
duration of diabetes, their age and gender, smoking status, peripheral blood pressure
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and serum cholesterol concentration and have differed in the presence or absence of
microvascular complications.
Hypoglycaemia is a common side-effect of insulin therapy in people with
diabetes (1,173). To protect the function and integrity of the central nervous system,
a hierarchy of responses are activated when blood glucose falls below 4.0 mmol/1
which help to restore normoglycaemia (6,320). A fall in blood glucose activates the
autonomic system via hypothalamic autonomic centres in the brain, so stimulating
the sympatho-adrenal system and the secretion of catecholamines, particularly
adrenaline (epinephrine). This profound autonomic stimulus provokes
haemodynamic changes, including an increase in heart rate and stroke volume,
increased myocardial contractility and a rise in cardiac output (50). Left ventricular
ejection fraction has been shown to increase by almost a third in response to acute
hypoglycaemia (48). In addition, peripheral blood pressure is affected with an
increase in systolic and decrease in diastolic pressure, while mean arterial pressure
remains unchanged.
There is some evidence that insulin per se has a direct effect on large artery
function. In non-diabetic humans, intravenous infusion of insulin has been observed
to be associated with a reduction in AIx, suggesting that insulin increases the
distensibilty (i.e. reduces the stiffness) of large arteries (321). In subjects with
insulin resistance, a characteristic of Type 2 diabetes, the ability of insulin to
decrease arterial stiffness is impaired (322).
The present study aimed to examine arterial wall stiffness in people with and
without Type 1 diabetes of varying duration, to determine the central haemodynamic
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responses to intravenous insulin and acute hypoglycaemia in these subjects, and to




To avoid potential gender differences in the counterregulatory hormonal
responses to hypoglycemia (320), three groups of male subjects, matched for age,
body mass index (BMI) and peripheral blood pressure, were studied. 10 non-diabetic
volunteers (Group 1), 10 subjects with Type 1 diabetes of short duration (<5 years)
(Group 2) and 10 subjects with Type 1 diabetes of longer duration (>15 years)
(Group 3). Subjects with diabetes were matched for HbAlc, and were recruited from
the out-patient clinic at the Department of Diabetes at the Royal Infirmary of
Edinburgh. Blood pressure and plasma cholesterol concentration were measured
before inclusion in the study. HbAlc was measured by high performance liquid
chromatography (Variant II Hemoglobin Testing System, Biorad Diagnostics Group,
Hercules, California, USA), with a local DCCT-adjusted non-diabetic reference
range of 4.3-6.5%. Subjects were excluded from the study if there was a history of
hypertension (BP>140/80mmHg), hypercholesterolemia (total cholesterol
>5.0mmol/l) or other chronic disease, or a history of previous head injury, alcohol or
drug abuse, seizure or blackouts. All the subjects were non-smokers, had no
intercurrent illness and were not taking any regular medication (other than insulin for
diabetes). Subjects with diabetes were excluded if they had any evidence of
microvascular disease, other than background diabetic retinopathy (two subjects in
Group 2 and five subjects in Group 3). The presence of retinopathy was determined
by direct ophthalmoscopy, peripheral neuropathy by clinical examination, and
nephropathy by the presence of microalbuminuria (albuminxreatinine ratio >2.5
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mg/mmol for women and >3.5 mg/mmol for men). All potential subjects underwent
standard autonomic function testing (323) prior to inclusion in the study and any with
autonomic dysfunction were excluded. Subjects were also excluded if they had a
history of impaired awareness of hypoglycemia.
Studies were postponed if a subject had experienced hypoglycemia in the
preceding 48 hours, and subjects were required to measure their blood glucose
frequently during this period, including bedtime tests on the evening before the study
to identify biochemical hypoglycemia. Ethical permission for the study was given by
the Lothian Research Ethics Committee. All subjects gave their written informed
consent.
Procedure
Each study session began at 08.00 after a 10-12 hour overnight fast. The
subjects with type 1 diabetes omitted their insulin on the morning of the study. The
study design is shown in Figure 11.1. A hyperinsulinaemic glucose clamp (238) was
used, initially, to maintain euglycaemia (blood glucose concentration 4.0-7.0 mmol/1)
for 20 mins before the induction of acute hypoglycemia. As the purpose of inducing
acute hypoglycemia was to provoke an acute autonomic reaction with profound
activation of the sympatho-adrenal system, a rapid fall in blood glucose was then
induced by infusing insulin intravenously at a rate of 2mU/kg/min. This caused a
controlled decline in blood glucose to a level which triggered the autonomic reaction
associated with hypoglycemia. This method of inducing hypoglycemia stimulates
the development of hypoglycemia under everyday conditions and can not be induced
using the hyperinsulinaemic glucose clamp technique. Any variability between
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subjects in the rate of fall in blood glucose and the depth of the hypoglycemia
achieved is inconsequential as the intention is to lower blood glucose to the blood
glucose threshold at which autonomic activation is stimulated.
The autonomic reaction (designated as R) was identified by an abrupt rise in
heart rate (15% above baseline), the rapid onset of autonomic symptoms, such as
sweating and tremor, and a rapid rise in peripheral systolic blood pressure. When the
autonomic reaction occurred the clock timer was reset to zero and all subsequent
measurements were timed relative to this point. This accommodates the variable
time interval that occurs between non-diabetic and diabetic individuals in
development of the autonomic reaction using the insulin infusion technique (324).
As soon as R had occurred, the insulin infusion was discontinued and hypoglycemia
was reversed using an intravenous infusion of 20% dextrose to restore
normoglycaemia. All subjects consumed a meal on completion of the study.
Measurements:
During the study, arterialised blood glucose was measured at the bedside
(Yellow Springs Instrument 2300 Stat, Yellow Springs, Ohio, USA) every 5 minutes
until R, and every 15 minutes thereafter until R+30 minutes. The maximal
haemodynamic changes in response to hypoglycemia occur in the 30 minutes
following the onset of the autonomic reaction (R) (48). Pulse wave analysis at the
radial artery was therefore performed every 5 minutes until R, and every 5 minutes
thereafter until R+30 minutes. Heart rate was monitored continuously using a pulse
oximetry probe. Peripheral blood pressure was recorded every 5 minutes using a
digital automated sphygmomanometer.
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The Edinburgh Hypoglycaemia Scale (276), a validated subjective self-rating
questionnaire, was used to document the symptoms of hypoglycemia experienced by
the subjects during the study. The symptoms of hypoglycemia were classified as
autonomic (hunger, palpitations, sweating, shaking), neuroglycopenic (drowsiness,
confusion, inability to concentrate, speech difficulty, blurred vision) and non-specific
(malaise, nausea, headache). Each symptom was graded on a Likert Scale of 1 to 7 (1
= not present, 7 = very intense). The questionnaire was applied at baseline and at 5
minute intervals thereafter until the onset of the autonomic reaction. It was repeated
at R+30 minutes.
Statistics
A general linear model (repeated measures analysis of variance) was used to
compare means within individual groups. Between groups, an ANOVA with post-
hoc t-tests was used. Correlation analyses for changes in AIx and insulin dose were
performed using Pearson's correlation. A p value < 0.05 was considered to be
significant. All analyses were performed using SPSS version 11.0 for Windows. All
results are expressed as mean ± SD.
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Figure11.1:St dydesign. Groups2&3 Hyperinsulinaemic glucoseclamp Group1
Insulininfusio (2mU/kg/min) (autonomicreact on)
RESULTS
The clinical characteristics of the subjects in the study are shown in Table
11.1.
Changes in blood glucose concentration
The blood glucose concentrations (mean±SD) at baseline were 4.3±0.5
mmol/1 in Group 1 (non-diabetic) and 8.4±2.1 mmol/1 and 8.9+3.1 mmol/1 in Groups
2 and 3 (diabetic), respectively. Following application of the euglycaemic clamp, the
blood glucose concentrations were stabilised at 4.2±0.1 mmol/1 (Group 1), 4.3±0.2
mmol/1 (Group 2) and 4.3±0.2 mmol/1 (Group 3). The nadir blood glucose
concentrations at R were 2.9±0.3 mmol/1 (Group 1), 2.8±0.3 mmol/1 (Group 2) and
2.6±0.3 mmol/1 (Group 3).
Peripheral blood pressure
No significant differences were observed in the peripheral systolic, diastolic,
and mean arterial pressures between the three groups at baseline. In all three groups
of subjects an increase in peripheral systolic blood pressure and a decrease in
peripheral diastolic pressure occurred at R, compared to baseline (Table 11.2).
Systolic and diastolic pressures had returned to baseline levels by R+30 minutes in
all three groups (Table 11.2).
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Central arterial pressure
Central systolic blood pressure at baseline was significantly higher in Group
3 compared to Groups 1 and 2 (Table 11.1). A small, but significant, reduction in
central systolic pressure was observed at R in all three groups, compared to the
respective baseline levels (Table 11.2). No change in central diastolic blood pressure
was observed throughout the study in any of the three groups (Table 11.2).
Heart rate and autonomic symptom score
The induction of hypoglycaemia and the onset of the autonomic reaction (R)
was associated with significant increments of heart rate and autonomic symptom
score in all three groups compared to baseline levels (Table 11.2). In all groups, the
heart rate and the autonomic symptom score had returned to baseline values at R+30
minutes.
Augmentation index (AIx)
At baseline, no difference in AIx was discernible between Group 1 and Group
2, whereas the AIx in Group 3 was higher than in either of these groups (Table 11.1).
All three groups exhibited a progressive decline in AIx between baseline and
the development of hypoglycaemia at R (Figure 11.2). At R+30 minutes, AIx had
risen to approach baseline levels in all three groups.
Changes in AIx and insulin dose
There was no significant difference between the amount of insulin infused
during the studies in the three different groups (Table 11.1). However, amongst the
231
separate groups, there was a significant correlation between changes in AIx and
insulin exposure. A greater decrement in AIx was associated with greater insulin
exposure (Group 1 r = 0.30 p = 0.05, Group 2 r = 0.34 p = 0.04, Group 3 r = 0.3 p =
0.03).
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Table 11.1: Patient characteristics. Group 1: Non-diabetic subjects. Group 2: Type









Age (years) 29.4 (4.4) 30.2 (7.9) 31.1 (4.7) T3IIp 00
Duration of diabetes (years) 3.0(1.1) 18.4 (0.7) p=0.3
HbAlc 7.6 (0.7) 8.1 (0.3) p=0.2
Body Mass Index (kg/m2) 24.0(1.2) 24.2(1.1) 24.4(1.4) xs IIo
Total plasma cholesterol (mmol/1) 4.5 (0.8) 4.7 (0.6) 4.8 (0.6) p=0.4
Peripheral systolic BP (mmHg) 121.7(10.5) 123.3 (6.5) 125.9(9.8) p=0.3
Peripheral diastolic BP (mmHg) 65.6 (7.4) 69.4 (7.7) 72.7 (6.7) p=0.2
Mean arterial pressure (mmHg) 92.4 (8.7) 87.5 (9.1) 92.5 (9.1) p=0.4
Central systolic BP (mmHg) 114.4(14.9) 110.9(8.0) 121.5 (9.7) p<0.05
Central Diastolic BP (mmHg) 77.2(10.5) 74.8 (8.4) 79.0 (8.7) xs llp ON
Augmentation index (AIx) 9.3 (12.4) 10.0(8.3) 21.8 (6.9) p<0.05
Total insulin dose (Units) 14.6 (4.4) 12.7(3.1) 15.7(4.8) p = 0.6
Post hoc t tests
Central systolic pressure: Group 3 vs. Group 1 p = i0.04, Group 3 vs. Group 2 p = 0.047
Augmentation index: Group 3 vs. Group 1 p = 0.02, Group 3 vs. Group 2 p = 0.002
BP = blood pressure HbAlc = glycated haemoglobin (non-diabetic range 4.3-6.5%)
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Table 11.2: Haemodynamic measurements. Group 1: Non-diabetic subjects. Group
2: Type 1 diabetes <5 years. Group 3: Type 1 diabetes >15 years. Results are
expressed as mean (SD). Results marked * represent a significant within group
difference (p<0.05). EC = euglycaemic clamp commenced. 0 = start of insulin




























































































































Arterial stiffness is increased in people with Type 2 diabetes
(312,313,325,326), in their non-diabetic relatives (314) and in people with impaired
glucose tolerance (327). In people with Type 1 diabetes results have been discrepant.
Some studies have shown increased arterial stiffness compared to non-diabetic
controls (315-317), whereas others have shown either no difference (318), or reduced
arterial stiffness (319). These differences may relate to the methodologies used and
to patient selection, with participants differing in their duration of diabetes, age and
gender, smoking status, peripheral blood pressure, serum cholesterol concentrations
and the presence or absence ofmicrovascular disease.
Here, arterial stiffness and central arterial pressure were studied in both non-
diabetic adults and in people with type 1 diabetes of differing duration, using radial
artery pulse wave analysis and calculation of augmentation index, and the subjects,
all ofwhom were non-smokers, were matched for age, gender, blood pressure, serum
cholesterol and body mass index. The results showed no difference in vessel wall
stiffness or central arterial pressure between a group with well-controlled type 1
diabetes of short duration and a matched cohort of healthy non-diabetic volunteers.
However, the people with type 1 diabetes of longer duration had greater stiffness of
the arterial vessel wall and an elevated central arterial pressure compared to non-
diabetic controls. This suggests that the duration of exposure to chronic
hyperglycemia influences vessel wall stiffness, rather than the presence of type 1
diabetes itself. This may possibly result from structural changes caused by the
gradual deposition of advanced glycation endproducts (AGEs) within the walls of
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large blood vessels (328). The endothelium (329,330) and arterial wall smooth
muscle bulk and tone (331) (the latter under the control of the endothelium) also
influence the elasticity of arteries, and it is also possible, therefore, that increased
vessel wall stiffness in people with type 1 diabetes of long duration is the result of
functional changes that occur within the endothelium with increasing duration of
diabetes.
In the present study, the rise in peripheral systolic blood pressure that is
known to accompany acute insulin-induced hypoglycaemia was accompanied by a
reduction of central systolic blood pressure. These findings highlight the potential
for divergent responses of central and peripheral arterial pressures, and support the
premise that the measurement of peripheral blood pressure by conventional methods
does not provide a accurate measure of the central arterial pressure load on the left
ventricle. Specifically, the results show how the changes of central and peripheral
arterial pressures differ in response to the stress provoked by acute hypoglycaemia
and mediated by sympatho-adrenal stimulation. In the present study the difference
that was observed between the responses of peripheral and central systolic blood
pressures to insulin-induced hypoglycemia may be a consequence of the observed
changes in augmentation index; a reduction in AIx produces diminished
amplification of the systolic pressure wave and so causes a net reduction overall in
central arterial systolic blood pressure. It is possible that this observed change in
augmentation index had resulted either from changes in heart rate (264) or from the
actions of vasoactive hormones that are secreted in response to hypoglycemia (332),
or as a combination of both effects. An increment in heart rate of 10 beats per
minute, causes a fall in augmentation index of around 4% (264), and the infusion of
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noradrenaline promotes an increase in augmentation index (333). However, in the
present study, the augmentation index was observed to fall initially during
euglycaemia, before any stimulated changes in heart rate, autonomic symptom score
or peripheral blood pressure. Insulin per se may have a direct effect on the
functional integrity of large blood vessels. In support of this, it was observed that
amongst individuals within each study group, there was a significant correlation
between changes in AIx and the amount of insulin infused. The early changes in AIx
may therefore be a consequence of the direct action of insulin on endothelial function
or smooth muscle tone of large arteries. This interpretation would be consistent with
the results of other studies that have demonstrated that the intravenous administration
of insulin increases the distensibility of large arteries (321,322).
The decrement of augmentation index was less in the group who had Type 1
diabetes of longer duration compared with those with diabetes of short duration and
to non-diabetic subjects. This would be consistent with greater stiffness and reduced
elasticity of the vessel walls of large arteries in people with Type 1 diabetes of long
duration. Consistent with this, Westerbacka et al (334) have shown that the effect of
insulin to reduce vessel wall stiffness in large arteries is diminished in people with
Type 1 diabetes who have no vascular complications. The mean duration of Type 1
diabetes in their participants was 18 years (334), which is similar to the duration of
diabetes in Group 3 of the present study. We acknowledge that the algorithm for
relating peripheral and central pressures by applanation tonometry was derived in
non-diabetic subjects. However, in this study, the changes in the central
haemodynamic responses to insulin infusion and the induction of acute
hypoglycemia were similar amongst both the non-diabetic and the diabetic groups.
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Type 1 diabetes is associated with an increased prevalence of cardiovascular
disease, and vessel wall stiffness is an independent predictor of cardiovascular
morbidity and mortality. The present study has demonstrated that a greater duration
of type 1 diabetes was associated with an increase in vessel wall stiffness, before the
development of overt macrovascular disease. Central systolic pressure at rest was
also greater in people with type 1 diabetes of longer duration, although no apparent
difference was observed in peripheral blood pressure between the three study groups.
Changes in brachial pressure may, therefore, underestimate changes in aortic pulse
pressure and the response of left ventricular systolic function to haemodynamic stress
in people who have had Type 1 diabetes for several years. These vascular changes
and the attendant rise in central arterial blood pressure may contribute to the
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Hypoglycaemia is a very common occurrence in people with insulin-treated
diabetes and, because the human brain is vitally dependent on glucose as its main
source of energy, cerebral deprivation of glucose rapidly causes cognitive
dysfunction through the direct effects of acute neuroglycopenia.
Hypoglycaemia, therefore, affords the unique opportunity to study cognitive
processes under controlled deprivation of the brain's energy supply. Russell & Rix-
Trot, in 1975 (237), observed that blood glucose concentrations below 3.0 mmol/1,
occurring as a consequence of an intravenous bolus injection of insulin, were
associated with impairment of cerebral function, and since then a large literature on
the cognitive effects of acute hypoglycaemia has developed. Tasks that are complex,
attention demanding and require a rapid response are more impaired during
neuroglycopenia. In general, tests that involve attention, concentration, psychomotor
skill, the accessing of long term memory and the ability to ignore distracting
information, tend to deteriorate when blood glucose declines below about 3.0
mmol/L. Memory, one of the most important cognitive domains with respect to
everyday function, has not, until now, been examined in detail during acute
hypoglycaemia. In view of the relative lack of data on the effects of hypoglycaemia
on this important cognitive domain, the present studies have attempted a
comprehensive examination of the effects of acute hypoglycaemia on short-term,
delayed and working memory using verbal and non-verbal materials.
These studies have conclusively demonstrated that acute hypoglycaemia
significantly impairs a broad spectrum ofmemory functions both in people with, and
in people without Type 1 diabetes. The domains of working memory and of delayed
memory were particularly susceptible to the adverse effects of acute hypoglycaemia.
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The results of these studies form a foundation for research which examines
the biological and practical aspects ofmemory function in more detail. In the brain,
the medial temporal lobe, the hippocampus and the parahippocampal apparatus are
the principal structures involved with memory performance. It is known that the
brain is susceptible to neuroglycopenia in a rostrocaudal direction; the cerebral
cortex and hippocampus appear to be the areas most sensitive to the deleterious
effects of acute hypoglycaemia. It could be hypothesised, therefore, that the
hippocampus and memory processes would be particularly vulnerable to the harmful
effects of hypoglycaemia. The results of the present study would support this
postulation. Working memory tasks have been shown to exert high demands on
brain extracellular glucose. The vulnerability of working memory to the effects of
hypoglycaemia, therefore, may be a consequence of an interaction between local
energy demands of the brain and the regional distribution of the glucose transport
receptors GLUT1 and GLUT3.
The results of these studies also lays a foundation for more psychological
research which should inquire, for example, whether the process of consolidating
(laying down) new memories or retrieving already-established memories are
particularly sensitive to the effects of hypoglycaemia.
Rehearsal of information allows material to be transferred from short-term
memory to long-term memory. This process is referred to as consolidation. Through
rehearsal, the neural activity responding to sensory stimulation can be sustained.
Sustained activity causes permanent structural changes in the brain which are
responsible for the formation of long-term memory. The profound impact of
hypoglycaemia on delayed memory that has been demonstrated is likely to be a
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consequence of the disruption, by neuroglycopenia, of the normal pathways of
hippocampal neural activity that are responsible for the transfer of information from
short-term to longer-term memory. It is possible, therefore, that short-term exposure
to relatively moderate hypoglycaemia may disrupt the recent memory of events
occurring immediately before exposure to hypoglycaemia.
Functional magnetic resonance imaging (fMRI) is a very sensitive form of
neuroimaging that has the ability to detect subtle signs of neuronal activation and
dysfunction. The technique of fMRI utilises Blood Oxygen Level Dependent
(BOLD) contrast to measure blood flow and, indirectly, neural activity. It is able to
detect changes in blood flow and oxygen consumption and this correlates closely
with definable alterations in neuronal activity (335). During cognitive stimulation,
blood flow and metabolism increase in specific areas of the brain and these changes
can be detected using fMRI (336-340). Recently, the development of sophisticated
and sensitive functional neuroimaging techniques in humans has confirmed the
importance ofmedial temporal lobe structures, such as the hippocampus and adjacent
parahippocampal regions, to memory function in normal individuals
(284,285,341,342).
The neuroanatomical correlates of human memory can be examined using
fMRI which can be applied to examine the brain regions involved in selective
memory processes. A limited number of studies have utilised fMRI to study the
effects of hypoglycaemia and one study has used fMRI to study patterns of brain
activation in response to cognitive testing during hypoglycaemia (343). fMRI could
therefore, be used to examine functional impairment of the medial temporal lobe, and
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correlate brain activation aspects of memory, following exposure to acute
hypoglycaemia.
Many studies have demonstrated the deleterious effects of acute
hypoglycaemia on cognitive function and on mood states, but considerably less
information is available on the effects of acute hyperglycaemia on cognitive
function. Hyperglycaemia, however, commonly occurs as a consequence of the
relative or absolute insulin deficiency that is intrinsic to diabetes and, therefore, any
potential detrimental effects of hyperglycaemia on cognition would be of huge
importance. In study 3, we have demonstrated that acute hyperglycaemia
significantly impairs cognitive function and also has a significant effect on mood in
people with type 2 diabetes. Performance in tasks of cognitive function that are
particularly complex was most significantly impaired during acute hyperglycaemia.
The changes in mood that were observed during acute hyperglycaemia included
increased feelings of agitation and anxiety, increased feelings of lethargy and
decreased feelings of happiness. Such effects of hyperglycaemia on cognitive
function may significantly interfere with many activities of daily living for many
people with diabetes. The findings from our study would suggest that the
detrimental effects of acute hyperglycaemia are modest and it would be useful,
therefore, to correlate this degree of cognitive impairment with performance in
everyday tasks encountered in daily life.
Other potential areas of future research could include the ascertainment of the
duration of cognitive impairment caused by acute hyperglycaemia, the precise
mechanism by which acute hyperglycaemia causes cognitive dysfunction,
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determination of whether there is a particular threshold of blood glucose above
which the adverse effects of acute hyperglycaemia on cognitive function are
manifest, and the potential impact of recent preceding exposure to acute
hyperglycaemia. There may be potential for cerebral adaptation to occur in
response to high prevailing blood glucose concentrations. The effect of recent
antecedent hyperglycaemia, or of more prolonged exposure to hyperglycaemia in
subjects with longstanding poor glycaemic control, may influence cognitive
performance during acute hyperglycaemia.
In studies 4, 5 and 6 we have addressed the potential effect ofType 1 diabetes
on arterial wall stiffness, which is an independent predictor of cardiovascular
morbidity and mortality. Arterial stiffness has been studied previously in people with
type 1 diabetes but the results have been inconsistent and variable. The present
studies have demonstrated that people with well-controlled type 1 diabetes of short
duration, who had no evidence of significant microvascular disease, had no
demonstrable difference in vessel wall stiffness compared to a matched cohort of
healthy volunteers. However, people with type 1 diabetes of longer duration did have
greater stiffness of vessel walls compared to non-diabetic controls. This finding
suggests that increasing duration of exposure to chronic hyperglycaemia results in
increased vessel wall stiffness. The mechanism by which this is manifest is unclear,
but it is possible that increased vessel wall stiffness is a consequence of the
deposition of advanced glycation endproducts (AGEs) within the vessel wall. This
may cause endothelial dysfunction or may promote the premature development of
occult atherosclerosis.
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Arterial blood pressure is usually recorded non-invasively from the brachial
artery by sphygmomanometry. It is assumed that the pressure is the same throughout
the arterial tree, that peripheral blood pressure is an accurate reflection of left
ventricular afterload, and that it can be used therefore as an index of cardiovascular
risk. The present study demonstrated that central systolic pressure was greater in
people with type 1 diabetes of long duration, despite no apparent difference in the
changes in peripheral blood pressure between the three study groups. Changes in
brachial pressure may, therefore, underestimate changes in aortic pulse pressure and
of left ventricular systolic stress in people with type 1 diabetes of long duration, and
may therefore underestimate cardiovascular risk. These vascular changes may
contribute to the increased cardiovascular risk of people with type 1 diabetes and
determination of central arterial pressure and vessel wall stiffness may, therefore,
provide a more accurate index of cardiovascular risk in patients with diabetes.
The results of the present study suggest that, in type 1 diabetes, it is the length
of exposure to hyperglycaemia that influences vessel wall stiffness, rather than type 1
diabetes per se. It would be of interest to examine central arterial pressure and
arterial wall stiffness in individuals with Type 1 diabetes who had developed
microvascular complications. Assuming the presence ofmicrovascular disease to be
a surrogate of exposure to more profound hyperglycaemia, it could be hypothesised
that such individuals would exhibit greater levels of arterial stiffness and central
arterial pressure when compared to individuals with Type 1 diabetes with no
microvascular complications, when subjects are matched for duration of diabetes. It
is probable that the deleterious effects of hyperglycaemia on vessel wall stiffness are
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cumulative and relate to both the duration of exposure to hyperglycaemia and the
magnitude of hyperglycaemia.
Blood glucose is tightly regulated in health, and spontaneous hypoglycaemia
in the non-diabetic individual is very rare. The majority of episodes of
hypoglycaemia occur in people with insulin-treated diabetes and, for most people
with insulin-treated diabetes, acute hypoglycaemia is a very common occurrence.
Patients with type 1 diabetes attempting to achieve strict glycaemic control suffer
countless episodes of asymptomatic hypoglycaemia; plasma glucose concentrations
may be less than 3.3 mmol/1 10% of the time. In humans the most important organ to
be affected by fluctuations in blood glucose is the brain. The human brain is
dependent upon glucose as its main source of energy and rapidly malfunctions if
deprived of this substrate. In order to protect the function and integrity of the central
nervous system, blood glucose levels are normally very strictly controlled. It is
known that progressive neuroglycopenia causes cognitive impairment and the present
studies have demonstrated the profound impact of acute hypoglycaemia on the
crucially important cognitive domain of memory. We have also shown that acute
/ryper-glycaemia can have a harmful effect on neuropsychological function and this
is naturally of major concern to people with diabetes who, intrinsically, are exposed
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Moderate Hypoglycemia Impairs Multiple Memory Functions
in Healthy Adults
Andrew J. Sommerfield Ian J. Deary
Royal Infirmary of Edinburgh University of Edinburgh
Vincent McAulay and Brian M. Frier
Royal Infirmary of Edinburgh
The effects of acute insulin-induced hypoglycemia on short-term, delayed, and working
memory were examined in healthy adults. A hyperinsulinemic glucose clamp was used to
maintain arterialized blood glucose at either 4.5 (euglycemia) or 2.5 (hypoglycemia) mmol/L
on 2 separate occasions in 16 healthy volunteers. Tests of immediate and delayed verbal
memory, immediate and delayed visual memory, and working memory were administered
during each experimental condition. All memory systems were impaired during acute hypo¬
glycemia, with working memory and delayed memory being particularly susceptible. These
findings are informative concerning the metabolic basis of adequate memory function and are
of practical importance to people with insulin-treated diabetes, in whom hypoglycemia is
common.
Acute hypoglycemia is a common side effect of treatment
with insulin in people with diabetes (Tattersall, 1999). The
nonphysiological doses of insulin that are used in standard
treatment regimens often lead to a mismatch between blood
glucose and plasma insulin concentrations, resulting in hy¬
poglycemia. Hypoglycemia can be subdivided into mild
(self-treated) and severe episodes. In the latter, external
assistance is required for recovery. A recent study has
confirmed the high frequency of hypoglycemia among peo¬
ple with Type 1 diabetes (Pramming et al., 2000). The mean
rate of mild hypoglycemia was 2.0 episodes/patient/week,
and the mean rate of severe hypoglycemia was 1.3 episodes/
patient/year. Hypoglycemia is considerably less common in
people with Type 2 diabetes. Although hypoglycemia can
also be associated with sulphonylurea therapy, this occurs
much less frequently than insulin-induced hypoglycemia
and is seldom severe.
The human brain is dependent on a continuous supply of
glucose as its main source of energy. Cerebral deprivation
of glucose, therefore, rapidly causes cognitive dysfunction
through the direct effects of acute neuroglycopenia (Deary,
1993, 1998). Early observations noted that blood glucose
concentrations below 3.0 mmol/L, as a consequence of
either natural glucose fluctuations (Flender & Lifshitz,
1976) or bolus injection of insulin (Russell & Rix-Trot,
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1975), were associated with impaired motor coordination
and mental speed. Since then, a large literature on the
cognitive effects of acute hypoglycemia has developed,
with recent interest focusing on the particular cognitive
domains that are affected and the clinical relevance of the
cognitive decrements that occur.
Two main techniques have been used to induce hypogly¬
cemia experimentally: the insulin infusion technique and the
hyperinsulinemic glucose clamp. The former involves the
intravenous infusion of insulin at various rates to reach the
desired blood glucose concentration, whereas the hyperin¬
sulinemic clamp technique uses a fixed intravenous infusion
rate of insulin with a variable intravenous infusion of dex¬
trose to maintain blood glucose concentrations at the deter¬
mined level (DeFronzo, Tobin, & Andres, 1979). However,
in many clamp studies, a common methodological error has
been to induce hypoglycemia by glucose clamp using a
stepwise decline in blood glucose, with tests of cognitive
function being administered during the final 30 min of each
blood glucose plateau. This allows a practice effect to occur,
which is confounded with the level of hypoglycemia.
Hypoglycemia affords the opportunity to study cognitive
processes under controlled deprivation of the brain's energy
supply. Tasks that are complex, are attention demanding,
and require a rapid response are more impaired during
neuroglycopenia, compared with simple cognitive and mo¬
tor tasks, which are relatively preserved. In general, tests
that involve attention, concentration, psychomotor skill, the
accessing of long-term memory, and the ability to ignore
distracting information tend to deteriorate when blood glu¬
cose declines below about 3.0 mmol/L (Hoffman et al.,
1989; Kerr, Macdonald, & Tattersall, 1991; Mitrakou et al.,
1991; Pramming, Thorsteinsson, Theilgaard, Pinner, &
Binder, 1986; Widom & Simonson, 1990; Wirsen, Tallroth,
Lindgren & Agardh, 1992).
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Memory is one of the most important cognitive domains
with respect to everyday function, yet it has seldom been
examined in detail during acute hypoglycemia. A still useful
classification recognized three main memory systems—sen¬
sory, short-term, and long-term memory (Baddeley, 1996).
Although the measurement of sensory memory presents
practical problems, the effect of hypoglycemia on this mem¬
ory system has been examined in studies conducted in the
Royal Infirmary of Edinburgh (Ewing, Deary, McCrimmon,
Strachan, & Frier, 1998; McCrimmon, Deary, & Frier,
1997; McCrimmon, Deary, Huntly, MacLeod, & Frier,
1996). Less is known about the effects of hypoglycemia on
other aspects of memory. Short-term memory capacity is
limited in terms of the number of items that can be stored,
and it lasts for a duration measured in seconds. Rehearsal of
information allows material to be transferred from short-
term memory to long-term memory by the process of con¬
solidation (Fuster, 1995; Hebb, 1949; Horn, 1998).
Working memory is a short-term memory system that
allows the retention and manipulation of information con¬
currently. Working memory comprises a phonological loop
(a store of phonetic, verbal information), a visuospatial
scratchpad (a store of spatial information and memories for
movement), and a central executive, which supervises and
updates the content of working memory (Baddeley, 1986,
1992; Baddeley & Hitch, 1974). Working memory is used,
for example, to remember what has been said at the begin¬
ning of a sentence and retain this until the sentence has been
completed; it allows a telephone number to be remembered
long enough for it to be dialed and enables the calculation of
simple mental arithmetic. Multivariate modeling and com¬
puter simulation studies show that working memory corre¬
lates highly with individual differences in the general factor
derived from a battery of psychometric intelligence tests
(Deary, 2001; Engle, Tuholski, Laughlin, & Conway, 1999;
Kyllonen & Christal, 1990; Stauffer, Ree, & Carretta,
1996). To our knowledge, the effect of hypoglycemia on
this key cognitive area has not explicitly been studied pre¬
viously, and there are no systematic studies involving short-
and longer term memory processes.
Previous studies of acute hypoglycemia used a heteroge¬
neous assortment of memory measures as part of a larger
battery of cognitive tests. Short-term memory, as tested by
word and story recall, can deteriorate during hypoglycemia
(Draelos et al., 1995; Holmes, Koepke, Thompson, Gyves,
& Weydert, 1984; Pramming et ah, 1986; Widom & Simon-
son, 1990; Wirsen et ah, 1992). Other tests that assess
memory can be identified in cognitive batteries that have
been used to study the effects of acute insulin-induced
hypoglycemia in subjects with and without diabetes. Some
studies have shown impaired memory functions (Draelos et
ah, 1995; Holmes et ah, 1984; Mitrakou et ah, 1991; Pram¬
ming et ah, 1986; Wirsen et ah, 1992), whereas, in others,
tests of memory were unaffected (Harrad et ah, 1985;
Holmes, Hayford, Gonzalez, & Weydert, 1983; Widom &
Simonson, 1990). Variation in results may relate to meth¬
odological differences among studies. Many of the studies
reported previously suffer from small sample sizes, appli¬
cation of a limited selection of tests, and an inadequate
ascertainment of biomedical and psychosocial variables that
may affect the results. In addition, the method of induction
of hypoglycemia has varied among studies, and the method
of blood sampling (e.g., arterialized or venous blood) has
differed. As a result of these problems, definitive evidence
regarding the effects of acute hypoglycemia on learning and
memory is not available. There is a particular lack of
information concerning the effect of hypoglycemia on
working memory.
The present study was designed to investigate the effects
of experimentally induced hypoglycemia on verbal and
nonverbal tests of short-term, delayed, and working mem¬
ory in young, healthy humans.
METHOD
Subjects
Sixteen (9 male) healthy adult volunteers were studied. Their
mean age was 29.6 years (SD = 2.9), and they had a mean body
mass index of 24.1 kg/m2 (SD = 1.1). None of the subjects had
diabetes or a family history of diabetes, a history of chronic
disease, previous head injury, seizure, blackouts, or psychiatric
illness. They had no intercurrent illness and were not taking any
regular medication (with the exception of the oral contraceptive
pill). Ethical permission for the study was approved by the Lothian
Research Ethics Committee. All subjects gave written, informed
consent for the study.
Study Design
Each subject participated in two laboratory sessions, represent¬
ing two different experimental conditions, that were separated by
at least 2 weeks. The studies were conducted in the Department of
Diabetes at the Royal Infirmary of Edinburgh. A modified hyper-
insulinemic glucose clamp was used to maintain the blood glucose
at a predetermined level. In the euglycemia condition, the arteri¬
alized blood glucose concentration was maintained at 4.5 mmol/L
and hypoglycemia was not induced. In the hypoglycemia condi¬
tion, the glucose concentration was lowered to 2.5 mmol/L. The
subjects were not informed of which experimental arm of the study
was being performed on each occasion, and they underwent the
two experimental sessions in a randomized and counterbalanced
fashion.
Procedure
Each session commenced at 8 a.m. following a 10-12-hr over¬
night fast. An intravenous cannula was inserted in a retrograde
direction into a vein on the dorsum of the nondominant hand for
regular blood sampling. The hand was placed in a heated blanket
to arterialize the venous blood. A second intravenous cannula was
inserted into a vein in the antecubital fossa of the same arm for
infusion of human soluble insulin (Humulin S; Eli Lilly, Indianap¬
olis, IN) and 20% dextrose. Intradermal lignocaine (1%) was used
for insertion of each cannula. Insulin was infused at a constant rate
of 60 mU/m2/min using an IMED Gemini PCI pump (Alaris
Medical Systems, San Diego, CA). A variable intravenous infusion
of 20% dextrose was given simultaneously. The rate of dextrose
infusion was varied according to the arterialized blood glucose
concentration. This was measured at the bedside using the glucose
oxidase method (Yellow Springs Instrument 2300 Stat, Yellow
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Springs, OH). Blood glucose concentration was measured every 3
min initially and then every 5 min once a stable level had been
achieved.
In each study condition, the arterialized blood glucose concen¬
tration was stabilized initially at 4.5 mmol/L (baseline) for a period
of 30 min. In the euglycemia condition, the blood glucose con¬
centration was thereafter maintained at 4.5 mmol/L throughout the
study. In the hypoglycemia condition, blood glucose was lowered
over a 20-min period to 2.5 mmol/L. The blood glucose concen¬
tration was maintained at the predetermined target level for a
further 10 min before we commenced the cognitive tests and was
maintained at this level for a further 70 min while the tests were
administered. At the end of the hypoglycemia study, the blood
glucose level was restored to 4.5 mmol/L. Subjects were provided
with a meal after completion of each study session.
Cognitive Function Tests
Tests of immediate and delayed verbal memory, immediate and
delayed visual memory, and working memory were administered
during the study conditions. In addition to the memory tests, the
Trail Making B Test (Reitan, 1958) and the Digit Symbol Substi¬
tution Test (Wechsler, 1998) were also administered. These latter
tests were used to confirm the effect of hypoglycemia on cognitive
function, as has been shown in previous studies (Ewing et al.,
1998; Holmes et ah, 1984; McCrimmon et ah, 1997; Stevens et ah,
1989; Wirsen et ah, 1992).
Memory Tests
Verbal Memory Tests
Auditory Verbal Learning Test—Immediate and delayed. The
Auditory Verbal Learning Test (AVLT; Lezak, 1995) is a test of
immediate memory span, retrieval efficiency, and learning. The
delayed component measures longer term retention (Lezak, 1995).
It consists of a list of 15 words that are read to the subject at a rate
of 1 word per second. The subject is asked to try to recall words
immediately in any order from the list. This procedure is repeated
five times with the same list. The total of words remembered
correctly is designated the immediate score. Each subject is in¬
structed to try to remember the words on the list and is informed
that recall of words from the list will be requested after a period
of 1 hr. The delayed score is the number of words that are recalled
correctly at that time. The number of words that were remembered
(i.e., percentage retained) from the immediate test is also
calculated.
Logical Memory Test—Immediate and delayed. The Logical
Memory Test (Wechsler, 1987) is a test of verbal learning. It
measures immediate free recall following auditory presentation as
well as delayed recall. The subject is asked to recount a short story
immediately after it is read to him or her, to remember the story,
and to recall it again after a delay of 1 hr. The story incorporates
a number of specific points or story elements, each of which the
subject must recall to obtain credit. The immediate and delayed
scores are the sum of the number of points remembered by the
subject during immediate and delayed recall, respectively. From
these scores, the percentage of information retained from the
immediate to the delayed presentation is calculated.
Visual Memory Tests
Visual Reproduction Test—Immediate and delayed. The Vi¬
sual Reproduction Test (Wechsler, 1987) measures immediate and
delayed recall following nonverbal, visual presentation. A design
(line drawing) is presented to the subject. The subject is allowed to
study the design for 10 s. The design is then removed, and the
subject is instructed to draw the design from memory. The next
design follows, and so on for a total of five designs. The subject is
asked to draw the designs again after a delay of at least 1 hr. The
designs are scored according to their accuracy. The total score is
the sum of the scores of all five designs. Immediate and delayed
scores are calculated separately, and from these the percentage
retained score is also derived.
Benton Visual Retention Test. The Benton Visual Retention
Test (BVRT; Sivan, 1992) is a test of immediate visual recall. A
series of 10 designs of increasing complexity are presented to the
subject, the designs are removed, and the subject is then asked to
draw the designs from memory. The test is scored according to the
accuracy with which the designs are drawn. The total score is the
sum of the scores of all 10 designs.
Working Memory Tests
Working Digit Span Test—Forward and backward. In the
Working Digit Span Test (Wechsler, 1987), a series of lists of
numbers is presented verbally to the subject. The standard Wechs¬
ler Working Digit Span Test was modified for this experiment to
more fully test working memory. The subjects were asked to recall
the numbers in ascending numerical order (forward) or reverse
numerical order (backward). For example, for the sequence 2, 6, 1,
5, 3, the correct response for the Working Digit Span Test-forward
is 1, 2, 3, 5, 6, and for the Working Digit Span Test-backward, it
is 6, 5, 3, 2, 1. The test score is the number of lists that are
remembered correctly.
Letter/Number Sequence Test. In the Wechsler (1987) Letter/
Number Sequence Test, a series of lists of numbers mixed with
letters is presented verbally. The subject must recall the list, stating
the numbers in ascending numerical order followed by the letters
in alphabetical order. For example, for the sequence 2, D, 6, A, 1,
G, the correct response is 1,2, 6, A, D, G. The test score is the
number of lists that are recounted correctly.
Validation Span Test. This test examined working memory in
the context of numerical reasoning and was provided by Kyllonen
(1993; Kyllonen & Christal, 1990). This test is based on Badde-
ley's (1986) original working memory tasks, but the material has
been altered to be less abstract. In this test, the subject is presented
visually with a simple arithmetical problem. The subject is re¬
quired to perform the calculation and to determine whether the
sum is correct or incorrect. On the left side of the page, adjacent to
the problem, is placed an isolated and unrelated number. In addi¬
tion to performing the simple mental arithmetic, the subject must
remember this isolated number. Each problem is presented for 5 s.
The problems are presented in sets of three, four, and five. After
completion of each set, the subject must recall the isolated left-
sided numbers in the correct order. The score is based on how
many of the isolated numbers are remembered correctly. An ex¬
ample of a set of three is given below:
5 3 + 2—1=4 (correct)
2 1-5+8=7 (false)
3 2 + 4 + 6= 12 (correct)
For this example, the correct sequence of numbers is 5, 2, 3.
Parallel versions of the tests are available for Logical Memory,
AVLT, BVRT, and Validation Span, and in the present study these
were used to minimize a learning effect between the two study
conditions. Throughout the study, the battery of tests was carried
out in a fixed order.
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Nonmemory Tests
Trail Making B
In the Trail Making B Test (Reitan, 1958), the subject is pre¬
sented with a grid containing randomly positioned numbers and
letters. The subject must connect consecutive numbers in numer¬
ical order and consecutive letters in alphabetical order, alternating
between numbers and letters. The score is the time taken to
complete the task.
Digit Symbol Substitution Test
The Digit Symbol Substitution Test (Wechsler, 1998) consists
of four rows containing, in all, 100 small blank squares, each
paired with a randomly assigned number from 1 to 9. Above these
rows is a printed key that pairs each number with a different
symbol. The subject is asked to fill in as many of the blank squares
as possible with the appropriate symbol that matches the number
above the box, in a time limit of 120 s. The score is the number of
squares that are successfully completed within the 120-s time limit.
Symptoms of Hypoglycemia
The Edinburgh Hypoglycemia Scale (Deary, Hepburn, Mac¬
Leod, & Frier, 1993), a validated, subjective self-rating question¬
naire, was used to document the symptoms of hypoglycemia
experienced by the subjects during the two studies. The symptoms
of hypoglycemia were classified as autonomic (e.g., hunger, pal¬
pitations, sweating, shaking), neuroglycopenic (e.g., drowsiness,
confusion, inability to concentrate, speech difficulty, blurred vi¬
sion), and nonspecific (e.g., nausea, headache). Each symptom was
graded on a Likert scale ranging from 1 (not present) to 7 {very
intense).
Statistical Analysis
A general linear model (repeated measures analysis of variance)
was used, with order of session (euglycemia-hypoglycemia or
hypoglycemia-euglycemia) as a between-subjects factor and con¬
dition (euglycemia or hypoglycemia) as a within-subject factor. A
p value of less than .05 was considered to be significant. Effect size
was calculated using eta squared. All analyses were performed
using SPSS Version 10.0 for Windows.
RESULTS
A stable blood glucose plateau was achieved during both
study conditions. The mean blood glucose concentration
during the euglycemia condition was 4.5 mmol/L
(.SD = 0.2), and during the hypoglycemia condition it
was 2.5 mmol/L (SD = 0.1). Statistical analysis revealed
that no significant order effects had occurred for any of the
outcome variables of this study, and no significant gender
differences were evident on any test.
Symptoms
Results of the hypoglycemia symptom questionnaires
confirmed that scores for autonomic, F(l, 14) = 21.24, p <
.0001, neuroglycopenic, F(l, 14) = 31.78, p < .0001, and
general malaise, F(l, 14) = 4.34, p = .05, symptoms were
all significantly higher during hypoglycemia, compared
with baseline euglycemia, and were unchanged from base¬
line levels during the euglycemia study condition.
Tests of Nonmemory Function
During hypoglycemia, the time taken to complete the
Trail Making B Test increased significantly, from a mean
of 41.5 s (SD = 7.9) during euglycemia to 62.6 s
(SD = 11.0) during hypoglycemia, F(l, 14) = 58.5, p <
.0001, r\2 = .81. The mean score of the Digit Symbol
Substitution Test deteriorated from 70.1 (SD = 13.0) during
euglycemia to 59.6 (SD = 14.4) during hypoglycemia, F( 1,
14) = 19.01, p = .001, t}2 = .58.
Tests of Memory
The results of the memory function tests are summarized
in Table 1.
Immediate Verbal Memory
Acute hypoglycemia caused a significant deterioration in
tests of immediate verbal memory as assessed by the AVLT,
F(l, 14) = 16.12,p = .001, q2 = .54, and Logical Memory
Test, F(l, 14) = 11.57,/? = .004, q2 = .45.^
Immediate Visual Memory
The BVRT score declined during hypoglycemia, F(l,
14) = 5.09, p = .041, t)2 = .27. By contrast, the results for
the Visual Reproduction Test did not demonstrate a signif¬
icant deterioration, F(l, 14) = 4.23, p = .059.
Delayed Verbal Memory
Performance in both the AVLT-delayed, F(l, 14) =
96.18,/? < .0001, t}2 = .87 (percentage retained, F(l, 14) =
53.65, p < .0001, q2 = .79), and the Logical Memory
Test-delayed, F(l, 14) = 19.04, p = .001, tj2 = .58
(percentage retained, F(l, 14) = 37.31, p < .0001, q2 =
.73), was significantly impaired during hypoglycemia.
Delayed Visual Memory
The Visual Reproduction Test-delayed demonstrated a
significant decrement during hypoglycemia, F(l, 14) =
18.96,/? = .001, q2 = -58 (percentage retained, F(l, 14) =
12.49, p = .003, q2 = .47).
Working Memory
All working memory test scores deteriorated significantly
during hypoglycemia: Working Digit Span-forward, F(l,
14) = 5.00, p = .042, q2 = .26; Working Digit Span-
backward, F(l, 14) = 28.90, p < .0001, t;2 = .67; Letter/
Number Sequencing, F(l, 14) = 9.44,/? = .008, q2 = .40;
Validation Span, F(l, 14) = 225.36,/? < .0001, q2 = .94.
Validation Span deteriorated from a mean score of 22.0
(SD = 2.3) during euglycemia to 13.4 (SD = 2.5) during
hypoglycemia.
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Table 1
Results of Tests ofMemory Function During Euglycemia and Hypoglycemia
in 16 Healthy Adults
Memory system and subtest
Euglycemia Hypoglycemia
















Working Digit Span forward
Working Digit Span backward
Letter/Number Sequence
27.7 5.9 24.4 5.0 .004 .45
43.6 7.0 33.9 7.7 .001 .53
6.3 1.7 5.1 1.6 .041 .26
85.6 8.3 81.7 8.0 .059 .23
15.1 4.0 8.1 3.9 .001 .58
88.2 10.0 55.6 19.7 <.0001 .73
10.3 2.1 4.5 1.6 <.0001 .87
88.2 8.9 50.6 18.3 <.0001 .79
21.5 16.5 7.6 5.5 .001 .57
25.9 20.3 10.0 7.3 .003 .47
22.0 2.3 13.4 2.5 <.0001 .94
10.2 2.4 9.3 1.7 .042 .26
8.8 1.9 6.8 1.2 <.0001 .67
13.1 3.1 10.5 1.8 .008 .40
Note. AVLT = Auditory Verbal Learning Test.
DISCUSSION
The present study has demonstrated that acute hypogly¬
cemia significantly impaired multiple memory functions in
young, healthy humans. The results indicate that all of the
memory systems tested were impaired during hypoglyce¬
mia, with working memory and delayed memory being
particularly susceptible. The effect sizes (eta squared) for
working memory and delayed memory were large; the ef¬
fect of moderate hypoglycemia on some of these processes
was profound. Performance in the Trail Making B and Digit
Symbol Substitution Tests was also significantly impaired
during hypoglycemia, consistent with the results of previous
studies (Ewing et al., 1998; Holmes et al., 1984; McCrim-
mon et al., 1997; Stevens et al., 1989; Wirsen et al., 1992),
confirming that the degree of hypoglycemia achieved was
sufficient to impair other domains of cognitive function
simultaneously.
Few studies have examined in detail the effects of acute
hypoglycemia on memory function in humans with and
without diabetes (Draelos et al., 1995; Holmes et al., 1983,
1984; Widom & Simonson, 1990; Wirsen et al., 1992), and
earlier studies have given inconsistent results. In view of the
paucity of data on the effects of hypoglycemia on this
important cognitive domain, the present study has attempted
a broad examination of the effects of hypoglycemia on
short-term, delayed (longer term), and working memory
using verbal and nonverbal materials.
The present study has shown that short-term memory is
significantly disrupted by hypoglycemia. The effect of hy¬
poglycemia on short-term verbal memory, assessed by the
AVLT and Logical Memory Test, was considerable. Per¬
formance in both tests was significantly impaired, consistent
with the results of earlier studies (Draelos et al., 1995;
Wirsen et al., 1992). In the present study, the extent of the
deterioration induced by hypoglycemia was substantial, as
indicated by the large effect size. The extent of deterioration
appeared to be slightly greater in the AVLT compared with
the Logical Memory Test. The capacity of short-term mem¬
ory to retain verbal material depends on how much meaning
the information confers to the recipient. A list of random,
unrelated words is therefore more difficult to remember than
a story in which the words are organized into meaningful
sentences with a structured and logical progression. Short-
term visual memory was also impaired during hypoglyce¬
mia. The BVRT score decreased significantly during hypo¬
glycemia, although this test was impaired to a lesser degree
than were tests of verbal memory. This may reflect an
integral difference in the degree of susceptibility to hypo¬
glycemia of these two different modalities, or it may indi¬
cate a relative insensitivity of this specific test in detecting
changes in cognitive performance. The Visual Reproduction
Test-immediate was not significantly affected by hypogly¬
cemia. Although a small decrement was observed in the
scores during hypoglycemia as compared with euglycemia,
this difference was not significant.
All tests of delayed memory were greatly affected by
hypoglycemia. Performance in the AVLT-delayed and the
Logical Memory Test-delayed decreased substantially,
with the AVLT-delayed appearing to be more vulnerable to
the effects of hypoglycemia. A significant deterioration in
performance in tests of delayed verbal memory has been
shown in earlier studies of nondiabetic (Mitrakou et al.,
1991) and diabetic humans (Fanelli et al., 1998). In the
present study, the effects of hypoglycemia on delayed visual
memory were also considerable. Analysis of the immediate
and delayed Logical Memory Test, AVLT, and Visual Re¬
production Test scores allowed calculation of the percent¬
age of information that was learned and retained during the
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study. This revealed that, for tests of both verbal and visual
memory, not only did subjects recall less information im¬
mediately after having studied the information during hy¬
poglycemia compared with euglycemia, over time, they
forgot more of what they had recalled immediately during
hypoglycemia than during the euglycemic state.
Working memory was very susceptible to the effects of
hypoglycemia, with all tests being affected severely. The
Working Digit Span Test-forward, the easiest of the work¬
ing memory tests, was the least affected. Working Digit
Span-backward, Letter/Number Sequencing, and Valida¬
tion Span were all impaired more substantially. The impact
of hypoglycemia on performance in the Validation Span
Test, in particular, was highly significant, and the size of the
decrement, as measured by effect size, was very large, with
the glycemic manipulation accounting for almost all of the
variance in the test scores.
In the brain, the medial temporal lobe and, in particular,
the hippocampus are the principal structures involved with
memory performance (Gabrielli, Brewer, Desmond, &
Glover, 1997; Parkin, 1996; Scoville & Milner, 1957; Stern
et al., 1996). Neuropathological observations have indicated
that the brain is susceptible to neuroglycopenia in a rostro-
caudal direction, with the cerebral cortex and hippocampus
being most sensitive and the brainstem and spinal cord
being most resistant (Auer, Wieloch, Olsson & Siesjo,
1984). The brains of human subjects who have suffered an
episode of severe hypoglycemia have been studied and are
shown to have areas of cortical necrosis in the frontal lobes
and hippocampus, with relative sparing of the hindbrain
(Auer et al., 1984; Fujioka et al., 1997). Anecdotal case
reports of severe amnesia following an episode of severe
hypoglycemia have identified a specific structural lesion in
the hippocampus in people with insulin-treated diabetes
(Chalmers et al., 1991; Holemans, Dupuis, Misson & Van-
derijst, 2001). The hippocampus, therefore, may be partic¬
ularly vulnerable to the adverse effects of hypoglycemia.
This premise is supported by the results of the present
study, which clearly demonstrate the detrimental effects of
short-term acute hypoglycemia on memory. Working mem¬
ory and delayed memory appear to be the components of
memory most vulnerable to the induction of neuroglycope¬
nia. Functional magnetic resonance imaging studies have
shown that prefrontal brain activity is associated with the
performance of tasks very similar to those performed in
working memory tests (Carpenter, Just, & Reichle, 2000;
Fletcher & Henson, 2001; Mcintosh, 1999). In addition,
many of the tests of working memory also engage other
cognitive processes, particularly attention, that also use the
frontal lobe (Cohen et al., 1988; Pardo, Fox, & Raichle,
1991). These areas of the brain are also very sensitive to the
effects of neuroglycopenia (Auer et al., 1984; Pramming et
al., 1986), and a study in the Royal Infirmary of Edinburgh
has confirmed the detrimental effects of acute hypoglycemia
on attention (McAulay, Deary, Ferguson, & Frier, 2001). In
the present study, it is possible that the disruptive effect of
hypoglycemia on working memory was enhanced by the
simultaneous adverse effect of hypoglycemia on attention.
In the brain, glucose is transported across the cell mem¬
branes by facilitated diffusion, mediated by the glucose
transport proteins GLUT1 and GLUT3 (Duelli & Kuschin-
sky, 2001). These are localized in the membranes of brain
endothelial cells, astrocytes, and neurones. In animals,
working memory tasks have been shown to exert high
demands on brain extracellular glucose (McNay, Fries, &
Gold, 2000), and it is possible that the vulnerability of
working memory to the effects of hypoglycemia is a con¬
sequence of the interaction between local energy demands
of the brain and the regional distribution of GLUT1 and
GLUT3 receptors. The profound impact of hypoglycemia
on delayed memory is likely to be a consequence of the
disruption, by neuroglycopenia, of the normal pathways of
hippocampal neural activity that are responsible for the
transfer of information from short-term to longer term
memory.
In summary, the present study is novel in examining three
major aspects of memory for both verbal and nonverbal
stimuli. In particular, it has systematically studied and un¬
equivocally demonstrated the extent to which working
memory processes are affected by moderate hypoglycemia,
and it forms a foundation for research that examines the
biological and practical aspects of these findings. It also lays
a foundation for more psychological research, which should
inquire, for example, whether the processes of consolidating
(laying down) new memories or retrieving already-estab¬
lished memories are particularly sensitive to the effects of
hypoglycemia. The present study also demonstrates that
other cognitive processes are impaired during moderately
severe hypoglycemia. It could be argued that the impair¬
ment of memory performance is a reflection of a diffusely
distributed transient brain dysfunction induced by hypogly¬
cemia and that the very large effect size associated with the
Validation Span Test, in particular, is a consequence of task
complexity rather than specific vulnerability of memory
processes to hypoglycemia.
In addition to contributing to knowledge about the bio¬
logical bases of intact memory function, the present results
have practical importance. Working memory shows a strong
connection to fluid intelligence (Engle et al., 1999; Kyl-
lonen & Christal, 1990; Stauffer et al., 1996) and is neces¬
sary for performance of such complex cognitive tasks as
language comprehension and reasoning (Baddeley, 1992;
Carpenter, Just, & Shell, 1990; Kyllonen, 1993). Many
tasks in everyday life engage memory processes, especially
working memory. For example, working memory is used to
remember whether traffic is proceeding along a street after
one looks to either side before crossing, is used in making
rapid decisions while one is driving or operating machinery
or computer equipment, and is fundamental to following
instructions or reading a map. People with insulin-treated
diabetes are frequently exposed to hypoglycemia as a side
effect of insulin therapy. These individuals may be subject
to impairments of multiple memory functions during hypo¬
glycemia. This may have important practical implications
for daily activities and working ability. The detrimental
effect of hypoglycemia on delayed memory also suggests
that the ability to learn during hypoglycemia could be
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substantially impaired and could influence academic perfor¬
mance, such as during examinations. Whether these findings
are of practical importance to people with insulin-treated
diabetes remains to be established. It is possible that people
with diabetes may develop compensatory mechanisms to
enable them to cope with the adverse effects of hypoglyce¬
mia. Further studies are currently investigating the effects of
hypoglycemia on memory in people with Type 1 (insulin-
dependent) diabetes.
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Short-Term, Delayed, and Working
Memory Are Impaired During
Hypoglycemia in Individuals With Type 1
Diabetes
Andrew J. Sommerfield, mrcp (uk) Vincent McAulay, mrcp (uk)
Ian J. Deary, phd2 Brian M. Frier, md1
OBJECTIVE— To examine the effects of acute insulin-induced hypoglycemia on short-term,
delayed, and working memory in individuals with type 1 diabetes.
RESEARCH DESIGN AND METHODS— A hyperinsulinemic glucose clamp was used
to maintain arterialized blood glucose level at either 4.5 mmol/1 (euglycemia) or 2.5 mmol/1
(hypoglycemia) on two separate occasions in 16 adults with type 1 diabetes. The participants
completed tests of immediate and delayed verbal memory, immediate and delayed visual mem¬
ory, and workingmemory during each experimental condition. Two othermental tests, the Trail
Making B Test and the Digit Symbol Test, were also administered.
RESULTS— Performance in tests of immediate verbal and immediate visual memory was
significantly impaired during hypoglycemia. The effect of hypoglycemia on working memory
and delayed memory was more profound. Performance in the nonmemory tests, the Trail
Making B Test, and the Digit Symbol Test also deteriorated during hypoglycemia.
CONCLUSIONS— All of the memory systems examined in the present study were affected
significantly by acute hypoglycemia, particularly working memory and delayed memory. Mild
(self-treated) hypoglycemia is common in individuals with insulin-treated diabetes; therefore,
these observed effects of hypoglycemia on memory are of potential clinical importance because
they could interfere with many everyday activities.
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Hypoglycemia is a common adverseeffect of treatment with insulin inindividuals with diabetes (1,2).
Acute neuroglycopenia causes rapid dete¬
rioration of cognitive function in humans
with and without diabetes (3). Complex
and attention-demanding tasks, as well as
those that require a rapid response, are
more affected by neuroglycopenia,
whereas simple motor and cognitive tasks
are relatively preserved. In general, results
of tests that involve attention, concentra¬
tion, psychomotor skills, accessing of
long-term memory, and ability to ignore
distracting information deteriorate when
arterial blood glucose level declines below
~3.0 mmol/1 (4-9).
Memory is one of the most important
cognitive domains with respect to every¬
day function and is the process of storing,
encoding, and retrieving information.
Different forms of memory are recog¬
nized, including sensory, short-term,
long-term, and working memory (10). In
sensory memory, representations of the
physical features of a stimulus are stored
for a very brief time (<1 s), and it is dif¬
ficult to distinguish from the process of
perception. The deleterious effect of hy¬
poglycemia on this memory system has
been demonstrated in previous studies
conducted in our center (11-14). It seems
that the principal function of sensory
memory is to retain information for a pe¬
riod of time sufficient to allow its transfer
to short-term memory. Short-term mem¬
ory refers to the function that temporarily
retains stimuli that have just been per¬
ceived. Its capacity is limited in terms of
the number of items that can be stored
and lasts for ~20 s. Through repetition,
information may be transferred from
short-term memory to long-term mem¬
ory. Long-term memory refers to infor¬
mation that is represented on a more
permanent basis. Unlike short-term
memory, long-term memory has no
known limits to capacity and is relatively
durable.
Working memory is a short-term
memory system that allows concurrent
retention and manipulation of informa¬
tion (15). It is used for thinking about
what is already known and for deriving
conclusions on the basis of that knowl¬
edge; therefore, working memory is fun¬
damental to successful completion of
many activities. For example, it is used to
remember what has been said at the be¬
ginning of a sentence and retain this until
the sentence has been completed and is
essential for the calculation of mental
arithmetic. It allows spatial relations to be
updated in our mental map as we move
through a new geographical location.
Few studies have examined the effects
of acute hypoglycemia on memory func¬
tion, other than by including a heteroge¬
neous assortment ofmemory measures as
part of a larger battery of cognitive tests,
fn some studies (6,7,9,16,17), memory
functions were impaired during acute hy¬
poglycemia, whereas in other studies
(8,18,19), memory was apparently unaf¬
fected. Variability of results may relate to
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methodological differences. Many studies
are limited by small sample size, applica¬
tion of a limited selection of tests, and
inadequate ascertainment of biomedical
and psychosocial variables that could af¬
fect the results. The method of induction
of hypoglycemia has also varied between
studies, with differing methods of blood
sampling (e.g., arterialized or venous
blood). A common methodological error
has been induction of a stepwise decrease
in blood glucose level with estimation of
cognitive function during the final 30 min
of each blood glucose plateau, thus con¬
founding glucose level with practice ef¬
fects. In addition, in a study by Holmes et
al. (18), the blood glucose nadir was only
3.3 mmol/1, and the studies by Widom
and Simonson (8) and Harrad et al. (19)
used only a single test to assess memory
function. These factors may also help ex¬
plain the discrepancy in results between
different studies.
In our laboratory, a more comprehen¬
sive examination of the effects of moder¬
ate acute hypoglycemia on memory
performance in healthy nondiabetic hu¬
mans demonstrated impairment of all
memory systems; working memory and
delayed memory weremost susceptible to
the effects of neuroglycopenia (20). The
present study was designed to investigate
the effects of experimentally induced hy¬
poglycemia on verbal and nonverbal tests
of short-term, delayed, and working
memory in adults with type 1 diabetes,





A total of 16 adults with type 1 diabetes (9
men, 7 women) were studied. Subjects
were recruited from the diabetes outpa¬
tient clinics at the Royal Infirmary of Ed¬
inburgh. The median (range) data for the
study participants were as follows: age
28.5 years (20.0-38.2), BMI 23.9 kg/m2
(20.1-24.8), duration of diabetes 4.5
years (1.2-8.4), HbAlc 8.2% (6.9-8.7),
and insulin dose 0.65 U/kg (0.25-1.1).
HbAlc was measured by high-perfor¬
mance liquid chromatography (Variant II
Hemoglobin Testing System; Biorad Di¬
agnostics, Hercules, CA) (nondiabetic ref¬
erence range 4.3-6.5%). None of the
participants had a history of hypertension
or chronic disease, previous head injury,
seizure, blackouts, alcohol or drug abuse,
or psychiatric illness. They had no inter¬
current illness and were not taking any
regular medication (except for insulin and
oral contraceptives). Subjects were ex¬
cluded from the study if they had any ev¬
idence of microvascular disease. Presence
of retinopathy was ascertained by oph¬
thalmoscopy, neuropathy was deter¬
mined by clinical examination, and
nephropathy was defined by presence of
microalbuminuria. Subjects were ex¬
cluded if they had a history of impaired
awareness of hypoglycemia or had suf¬
fered an episode of hypoglycemia in the
48 h preceding the study. All subjects
gave written informed consent for partic¬
ipation in the study.
Study design
Each subject participated in two labora¬
tory sessions that were separated by at
least 2 weeks. The studywas conducted in
the Department of Diabetes at the Royal
Infirmary of Edinburgh. A modified hy-
perinsulinemic glucose clamp (21) was
used to maintain blood glucose at a pre¬
determined level. In the euglycemia con¬
dition, the arterialized blood glucose
concentration was maintained at 4.5
mmol/1 and hypoglycemia was not in¬
duced. In the hypoglycemia condition,
the glucose concentration was decreased
to 2.5 mmol/1. The subjects were not in¬
formed which experimental condition of
the study was being undertaken on each
occasion, and the two experimental ses¬
sions were performed in a randomized
and counterbalanced fashion.
Procedure
Each session commenced at 8:00 a.m. af¬
ter a 10- to 12-h overnight fast, and the
subjects omitted theirmorning dose of in¬
sulin. An intravenous cannula for regular
blood sampling was inserted retrogradely
into a vein on the dorsum of the non-
dominant hand, which was placed in a
heated blanket to arterialize the venous
blood. A second intravenous cannula was
inserted into a vein in the antecubital
fossa of the same arm for infusion of hu¬
man soluble insulin (Humulin S; Eli Lilly,
Indianapolis, IN) and 20% dextrose. In¬
tradermal lidocaine (1%) was used for
insertion of the cannulae. Insulin was in¬
fused at a constant rate of 60 mU • m~2 •
min-1 using an IMED Gemini PCI pump
(Alaris Medical Systems, San Diego, CA).
A variable intravenous infusion of 20%
dextrose was given simultaneously. The
rate of dextrose infusion was varied ac¬
cording to the arterialized blood glucose
concentration, which was measured at
the bedside using the glucose oxidase
method (2300 Stat; Yellow Springs In¬
strument, Yellow Springs, OH). Blood
glucose concentration was measured ev¬
ery 3 min until a stable level was achieved
and then at 5-min intervals.
In each study condition, the arterial¬
ized blood glucose concentration was sta¬
bilized initially at 4.5 mmol/1 (baseline)
for a period of 30 min. In the euglycemia
condition, the blood glucose concentra¬
tion was maintained thereafter at 4.5
mmol/1 throughout the study. In the hy¬
poglycemia condition, blood glucose was
lowered over a 20-min period to 2.5
mmol/1. The blood glucose concentration
was maintained at the predetermined tar¬
get level for an additional 10 min before
commencement of the cognitive tests and
was maintained at this level for an addi¬
tional 70 min during administration of
the tests. At the end of the hypoglycemia
condition, the blood glucose level was re¬
stored to 4.5 mmol/1. Subjects were given
a meal after completion of each study.
Cognitive function tests
Tests of immediate and delayed verbal
memory, immediate and delayed visual
memory, and tests of working memory
were administered during the study con¬
ditions. In addition to the memory tests,
the Trail Making B Test and the Digit
Symbol Test were also administered.
These tests were used to confirm the effect
of hypoglycemia on cognitive function, as
has been shown in previous studies
(9,11,12,17,22).
Verbal memory tests
Auditory Verbal Learning Test: imme¬
diate and delayed. The Auditory Verbal
Learning Test (AVLT) is a test of immedi¬
ate memory capacity, retrieval efficiency,
and learning. The delayed component
measures longer-term retention (23). It
consists of a list of 15 words that are read
to the subject at a rate of one word per
second. The subject is asked to try to re¬
call words immediately in any order from
the list. This procedure is repeated five
times. The total of words remembered
correctly is designated as the "immediate"
score. Each subject is instructed to try to
remember the words on the list and is
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informed that recall of words from the list
will be requested after a period of 1 h. The
"delayed" score is the number of words
that are recalled correctly at that time. The
percentage of words that were retained
from the immediate to the delayed score
("percent retained") was also calculated.
Logical Memory Test: immediate and
delayed. The Logical Memory Test, a
subtest from theWechslerMemory Scales
(24), is a test of verbal learning. It mea¬
sures immediate free recall after auditory
presentation and delayed recall. The sub¬
ject is asked to recount a short story im¬
mediately after it is read to them, to
remember the story, and to recall it again
after a 1-h delay. The story incorporates
25 specific points or "story elements,"
each of which the subject must recall to
obtain credit. The immediate and de¬
layed scores are the sum of the number of
points remembered by the subject during
immediate and delayed recall, respec¬
tively. From these scores, the percentage
of information retained from the immedi¬
ate to the delayed presentation was also
calculated.
Visual memory tests
Visual Reproduction Test: immediate
and delayed. This Wechsler Memory
Scales subtest measures immediate and
delayed recall after nonverbal, visual pre¬
sentation (24). A design (line drawing) is
presented to the subject, who is allowed
to study the design for 10 s. The design is
then removed and the subject is in¬
structed to draw the design frommemory.
The next design follows, for a total of five.
The subject is asked to draw the designs
again after a delay of at least 1 h. The
designs are scored according to their ac¬
curacy. The total score is the sum of the
scores of all five designs. Immediate and
delayed scores are calculated separately,
and from these the percent retained score
was also derived.
Benton Visual Retention Test. The
Benton Visual Retention Test (BVRT) is a
test of immediate visual recall. A series of
10 designs of increasing complexity are
presented to the subject, the designs are
removed, and the subject is then asked to
draw the designs from memory (25). The
test is scored according to the accuracy
with which the designs are drawn. The
total score is the sum of the scores of all 10
designs.
Working memory tests
Working Digit Span Test: forward and
backward. In the digit span test, a series
of lists ofnumbers is presented verbally to
the subject. The standard Wechsler Mem¬
ory Scales Digit Span Test (24) was mod¬
ified for this experiment to test working
memory more fully. The subjects were
asked to recall the numbers in ascending
numerical order (forward) or reverse nu¬
merical order (backward). For example,
for the sequence 2-6-1-5-3, the correct
response for working digit span forward
is 1-2-3-5-6, and for working digit span
backward, the correct response is 6-5-3-
2-1. The test score is the number of lists
that are remembered correctly.
Letter/Number Sequencing Test. In
the Letter/Number Sequencing Test from
the Wechsler Memory Scales, a series of
lists of numbers mixed with letters is pre¬
sented verbally (24). The subject must re¬
call the list, stating the numbers in
ascending numerical order followed by
the letters in alphabetical order. For ex¬
ample, for the sequence 2-D-6-A-1-G, the
correct response is 1-2-6 A-D-G. The test
score is the number of lists that are re¬
membered correctly.
Validation Span Test. In the Validation
Span Test from the Kyllonen's Cognitive
Abilities Measurement battery (26), the
subject is presented visually with a simple
arithmetical problem. The subject is re¬
quired to perform the calculation and to
determine whether the sum is correct or
incorrect. On the left side of the page, ad¬
jacent to the problem, an isolated and un¬
related number is placed. In addition to
performing the simple mental arithmetic,
the subject must remember this isolated
number. Each problem is presented for
5 s. The problems are presented in sets of
three, four, and five. After completion of
each set, the subject must recall the iso¬
lated left-sided numbers in the correct or¬
der. The score is based on how many of
the isolated numbers are remembered
correctly. An example of a set of three is
given below:
5 3 + 2—1=4 (correct)
2 1 — 5 + 8 = 7 (incorrect)
3 2 + 4 + 6 = 12 (correct)
For this example, the correct sequence of
numbers is 5-2-3.
Parallel versions of the Logical Mem¬
ory Test, AVLT, BVRT, and Validation
Span Test are available; in the present
study, these were used to minimize a
learning effect between the two study
conditions. Throughout the study, the
battery of tests was performed in a fixed
order.
Other mental tests
Trail Making B Test. The Trail Making
B Test from the Halstead Reitan battery
(27) assesses complex visual scanning
and has a motor component that mea¬
sures visual conceptual and visual motor
tracking. An electronic version of the test,
performed on a handheld computer, was
used for this study (28). In this test, the
subject is presented with a grid contain¬
ing randomly positioned numbers and
letters. The subject is to connect consec¬
utive numbers in numerical order and
consecutive letters in alphabetical order,
alternating between numbers and letters.
The score is the time taken to complete
the task.
Digit Symbol Test. This Digit Symbol
Test from theWechsler Adult Intelligence
Scale is a test of coding performed at
speed. It consists of four rows containing
at total of 100 small blank squares, each
paired with a randomly assigned number
from 1 to 9. Above these rows, a printed
key is shown, which pairs each number
with a different symbol. The subject is
asked to fill in as many of the blank
squares with the appropriate symbol that
matches the number above the box, in a
time limit of 120 s (29). The score is the
number of squares that are successfully
completed within 120 s.
Symptoms of hypoglycemia
The Edinburgh Hypoglycemia Scale (30),
a validated subjective self-rating ques¬
tionnaire, was used to document the
common symptoms of hypoglycemia ex¬
perienced by the subjects during the two
studies. The symptoms of hypoglycemia
were classified as autonomic (hunger, pal¬
pitations, sweating, shaking), neurogly-
copenic (drowsiness, confusion, inability
to concentrate, speech difficulty, blurred
vision), and nonspecific (nausea, head¬
ache). Each symptom was graded using a
Likert Scale of 1 (not present) to 7 (very
intense).
Statistical analysis
The results were analyzed independently
for each memory test. A general linear
model (repeated-measures ANOVA) was
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Table 1—Results of tests ofmemory function during euglycemia and hypoglycemia in 16 adults with type 1 diabetes
Memory system Subtest Euglycemia Hypoglycemia P value Tl2
Immediate verbal memory
Immediate Logical Memory Test 26.8 ± 4.8 21.3 ± 6.9 0.008 0.41
Immediate AVLT 39.4 ± 7.7 34.0 ± 5.1 0.002 0.49
Immediate visual memory
Benton Visual Retention Test 6.5 ± 1.7 4.7 ± 1.5 0.007 0.42
Visual Reproduction Test 81.3 ± 7.2 78.2 ± 9.5 0.093 0.19
Delayed memory
Delayed Logical Memory Test 13.6 ± 2.1 6.1 ± 3.7 <0.0001 0.83
Percent retained 78.4 ± 6.0 47.0 ± 21.3 <0.0001 0.73
Delayed AVLT 9.1 ± 1.9 5.3 ± 1.9 <0.0001 0.68
Percent retained 79.1 ± 6.9 47.8 ± 16.0 <0.0001 0.78
Delayed Visual Reproduction 15.9 ± 8.7 7.1 ± 7.3 0.002 0.52
Percent retained 18.6 ± 9.8 9.1 ± 9.0 0.004 0.46
Working memory
Validation Span Test 20.7 ± 2.3 14.9 ± 2.2 <0.0001 0.92
Modified Digit Span Forward Test 9.56 ± 2.4 8.6 ± 1.4 0.06 0.23
Modified Digit Span Backward Test 8.3 ± 1.9 7.2 ± 1.2 0.02 0.33
Letter/Number Sequencing Test 11.8 ± 1.9 9.7 ± 1.6 0.0001 0.57
Data are means ± SD.
used; order of session (euglycemia-
hypoglycemia or hypoglycemia-
euglycemia) was a "between subjects"
factor, and condition (euglycemia or hy¬
poglycemia) was a "within subjects" fac¬
tor. A P value <0.05 was considered
significant. Effect size was calculated us¬
ing t|2. An ti2 score of 0.25-0.5 was con¬
sidered amoderate effect size. All analyses
were performed using SPSS statistical
software (version 10.0 for Windows;
SPSS, Chicago, IL).
RESULTS— A stable blood glucose
plateau was achieved during each study
condition. The mean (SD) arterialized
blood glucose concentration during the
euglycemia condition was 4.55 mmol/1
(0.18) and during the hypoglycemia con¬
dition was 2.51 mmol/1 (0.08). Statistical
analysis showed that no significant order
effects had occurred for any of the out¬
come variables of this study and no sig¬
nificant sex differences were evident.
Symptoms
Results of the hypoglycemia symptom
questionnaires confirmed that scores for
autonomic (P < 0.0001), neuroglyco-
penic (P = 0.001), and general malaise
(P = 0.008) symptoms were all signifi¬
cantly elevated during hypoglycemia
compared with baseline euglycemia and
were unchanged from baseline levels dur¬
ing the euglycemia study condition.
Digit Symbol and Trail Making B
Tests
During hypoglycemia, the time taken to
complete the Trail Making B Test in¬
creased significantly from a mean (SD) of
33.7 s (7.7) during euglycemia to 54.0 s
(10.7) during hypoglycemia (P < 0.0001,
t|2 = 0.68). The mean (SD) score of the
Digit Symbol Test declined from 73.5
(11.2) during euglycemia to 62.9 (16.9)
during hypoglycemia (P = 0.001, T|2 =
0.57).
Tests of memory
The results of the memory function tests
are summarized in Table 1.
Immediate verbal memory. Acute hy¬
poglycemia caused a significant deteriora¬
tion in immediate verbal memory as
assessed by the AVLT (P = 0.002, t)2 =
0.49) and the Logical Memory Test (P =
0.008, T|2 = 0.41).
Immediate visual memory. The BVRT
score decreased during hypoglycemia
(P = 0.007, T)2 = 0.42). By contrast, the
score for the visual reproduction test did
not decrease significantly (P = 0.093).
Delayed verbal memory. Scores for
both the Delayed AVLT (P < 0.0001,
"q2 = 0.68; percent retained, P < 0.0001,
t|2 = 0.78) and the Delayed Logical Mem¬
ory Test (P < 0.0001, T| = 0.83; percent
retained, P < 0.0001, q2 = 0.73) were
significantly worse during hypoglycemia.
Delayed visual memory. During hypo¬
glycemia, a significant decrement was
observed in the Delayed Visual Repro¬
duction Test (P = 0.002, ti2 = 0.52; per¬
cent retained, P = 0.004, T|2 = 0.46).
Working memory. The Working Digit
Span Backward Test (P = 0.02, r\2 =
0.33), Letter/Number Sequencing Test
(P = 0.001, T)2 = 0.57), and Validation
Span Test (P < 0.0001, -q2 = 0.92) all
demonstrated a significant decrement
during hypoglycemia. The Validation
Span Test decreased from a mean (SD)
score of 20.7 (2.3) during euglycemia to
14.9 (2.2) during hypoglycemia. How¬
ever, performance in the Working Digit
Span Forward Test was not significantly
affected (P = 0.06, rj2 = 0.23).
CONCLUSIONS— Few previous
studies have made a detailed examination
of the effects of acute hypoglycemia on
memory function in humans, with and
without diabetes (8,9,16-18), and earlier
studies have given inconsistent results.
Using an identical study design, we have
studied the effects of hypoglycemia in
young, healthy, nondiabetic volunteers
and demonstrated a profound impair¬
ment in memory function at a blood glu¬
cose level that was similar to the present
study (2.5 mmol/1) (20). In view of the
frequency with which mild hypoglycemia
is experienced by individuals with in¬
sulin-treated diabetes, the present study
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has examined the effects of acute hypogly¬
cemia on a wide range of memory func¬
tions in a group of adults with type 1
diabetes who had no evidence of signifi¬
cant vascular complications.
The present study has demonstrated
that in adults with type 1 diabetes, acute
moderate hypoglycemia caused a marked
deterioration in performance in tests of
short-term, delayed, and working mem¬
ory, for both verbal and nonverbal mate¬
rial; working memory and delayed
memory were most strongly affected (ac¬
cording to analysis of effect size). In addi¬
tion, performance in the Trail Making B
Test and the Digit Symbol Test was im¬
paired significantly during hypoglycemia.
This is consistent with previous observa¬
tions (9,11,12,17,22) and confirms that
the degree of hypoglycemia achieved was
sufficient to affect other domains of cog¬
nitive function.
Short-term memory was significantly
disrupted by hypoglycemia in the present
study. The effect of hypoglycemia on
short-term verbal memory, assessed by
the AVLT and the Logical Memory Test,
and short-term visual memory, assessed
by the BVRT, was profound; performance
on all three tests was significantly im¬
paired. Earlier studies (9,16) have dem¬
onstrated decrements in short-term
verbal memory during hypoglycemia. In
the present study, the magnitude of the
impairment induced by hypoglycemia
was substantial, as indicated by the large
effect size. However, the immediate Vi¬
sual Reproduction Test was not signifi¬
cantly affected by hypoglycemia. This
seemed to be a manifestation of a "ceiling
effect" (i.e., most subjects obtained near-
to-perfect scores), indicating a lack of
sensitivity of this test to the stress of
hypoglycemia.
A significant deterioration in perfor¬
mance on tests of delayed verbal memory
has been shown during hypoglycemia in
previous human studies of nondiabetic
(6) and diabetic subjects (31). In the
present study, all tests of delayed memory
were markedly affected by hypoglycemia.
Performance on the Delayed AVLT and
Delayed Logical Memory Tests deterio¬
rated significantly during hypoglycemia,
and the effects of hypoglycemia on de¬
layed visual memory were also consider¬
able. Analysis of the immediate and
delayed Logical Memory Test, AVLT, and
the Visual Reproduction Test scores al¬
lowed calculation of the percentage of in¬
formation that was learned and retained
during the study. This revealed that, for
tests of both verbal and visual memory,
not only was less information recalled
immediately after having studied the in¬
formation during hypoglycemia as com¬
pared with euglycemia, but over time,
subjects forgot more of what they had re¬
called immediately during hypoglycemia
than during euglycemia.
Working memory was also very sus¬
ceptible to the effects of hypoglycemia.
The Working Digit Span Forward Test,
the least difficult of the working memory
tests, was least affected and was not sig¬
nificantly impaired during hypoglycemia.
A small decrement was observed in the
scores during hypoglycemia as compared
with euglycemia, and the effect size was
modest, indicating that although the ef¬
fects of hypoglycemia on this test did not
achieve significance in this study, hypo¬
glycemia did impair test performance.
The Working Digit Span Backward Test,
the Letter/Number Sequencing Test, and
the Validation Span Test were all more
substantially impaired. The impact of hy¬
poglycemia on performance in these tests
was highly significant, and the extent of
the decrements, as measured by the effect
size, was large.
The adverse effects of hypoglycemia
on impairment of memory in adults with
type 1 diabetes that have been demon¬
strated in the present study are very sim¬
ilar to the effects of hypoglycemia on
memory function in nondiabetic humans
that we have shown previously (20). A
previous study (9) has suggested that in¬
dividuals with diabetes may be more sus¬
ceptible to cognitive impairment during
hypoglycemia. However, comparison of
the results of the nondiabetic and diabetic
groups showed no significant differences
between the two groups. This may be at¬
tributable to the fact that the subjects with
diabetes in our study were all young,
had diabetes of short duration, and had
normal hypoglycemia awareness. In addi¬
tion, subjects in the diabetic and nondia¬
betic groups were matched for cognitive
function. It is not known whether the ef¬
fect of hypoglycemia on memory is sus¬
tained or protracted, and this will require
further investigation. Many aspects of
cognitive function have been observed to
return to normal within 2 h after euglyce¬
mia is restored (32-34), and this is pre¬
sumably similar for memory function.
Functional neuroimaging studies in
humans (35,36) have confirmed that
medial temporal lobe structures such
as the hippocampus and adjacent para-
hippocampal regions are the principal
structures involved with memory perfor¬
mance. The hippocampus is susceptible
to a variety of toxic insults, including
heavy metals (37), hypoxia (38), and
drugs (39,40). There is some evidence
that this particular area of the brain is also
preferentially vulnerable to the adverse
effects of hypoglycemia. Neuropathologi-
cal observations have indicated that the
brain is sensitive to neuroglycopenia in a
rostrocaudal direction and that the cere¬
bral cortex and hippocampus are most
susceptible, whereas the brainstem and
spinal cord are most resistant (41). Brains
of human subjects who have suffered an
episode of severe hypoglycemia have
been studied (41,42) and were shown to
have areas of cortical necrosis in the fron¬
tal lobes and hippocampus as well as rel¬
ative sparing of the hindbrain. Anecdotal
case reports of severe amnesia after an ep¬
isode of severe hypoglycemia have iden¬
tified a specific structural lesion in the
hippocampus in individuals with insulin-
treated diabetes (43,44).
The results of the present study have
clearly demonstrated the short-term det¬
rimental effects of acute hypoglycemia on
memory and are consistent with these ob¬
servations. However, the present study
also demonstrated that other domains of
cognition are impaired during moderately
severe hypoglycemia, and there is now
considerable evidence that acute neuro¬
glycopenia causes rapid deterioration in
psychomotor performance across a wide
range of cognitive domains (3). It is feasi¬
ble, therefore, that the impairment of
memory performance observed in this
study reflects a transient global brain dys¬
function induced by hypoglycemia rather
than specific vulnerability of memory
processes to hypoglycemia. The very large
effect size associated with the Validation
Span Test, in particular, may be a conse¬
quence of task complexity. However, per¬
formance in another test of working
memory was also very significantly im¬
paired, to chance levels, in the same dia¬
betic and nondiabetic subjects (45).
Individuals with insulin-treated dia¬
betes are frequently exposed to varying
degrees of hypoglycemia, and current
therapeutic policies that strive to achieve
strict glycemic control may promote more
frequent hypoglycemic events. The re-
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suits of the present study demonstrate
that many individuals with type 1 diabe¬
tes are subject to substantial impairments
ofmemory function during hypoglycemia
in their everyday lives, which may have
important practical implications for daily
activities, including effective working
ability and driving performance (46).
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Acute Hyperglycemia Alters Mood State
and Impairs Cognitive Performance in
People With Type 2 Diabetes
Andrew J. Sommerfield, mrcp (uk)
Ian J. Deary, phd2
Brian M. Frier, md1
OBJECTIVE— To examine the effects of acute hyperglycemia on cognitive function and
mood in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS— Twenty subjects with type 2 diabetes, me¬
dian age 61.5 years (range 53.1-72.0), known duration of diabetes 5.9 years (range 2.8-11.2),
BMI 29.8 kg/m2 (range 22.0-34.6), and HbAlc 7.5% (range 6.7-8.4) were studied. Treatment
modalities varied from antidiabetic medications to insulin. A hyperinsulinemic glucose clamp
was used to maintain arterialized blood glucose at either 4.5 (euglycemia) or 16.5 mmol/l
(hyperglycemia) on two occasions in a randomized and counterbalanced fashion. Tests of infor¬
mation processing, immediate and delayed memory, working memory, and attention were
administered, along with a mood questionnaire, during each experimental condition.
RESULTS— Speed of information processing, working memory, and some aspects of atten¬
tion were impaired during acute hyperglycemia. Subjects were significantly more dysphoric
during hyperglycemia, with reduced energetic arousal and increased sadness and anxiety.
CONCLUSIONS— During acute hyperglycemia, cognitive function was impaired and
mood state deteriorated in a group of people with type 2 diabetes. These findings are of practical
importance because intermittent or chronic hyperglycemia is common in people with type 2
diabetes and may interfere with many daily activities through adverse effects on cognitive func¬
tion and mood.
Diabetes Care 27:2335-2340, 2004
Diabetes is associated with rapid fluc¬tuations in blood glucose. Hyper¬glycemia is a frequent consequen e
of the relative or absolute insulin defi¬
ciency that is intrinsic to diabetes, and
hypoglycemia is a common side effect of
treatment with insulin and some antidia¬
betic medications (1). Because the brain is
dependent on a continuous supply of glu¬
cose as its principal source of energy,
changes in blood glucose concentration
rapidly affect cerebral function. The ad¬
verse effects of acute hypoglycemia on
cognitive function and on mood are rec¬
ognized (2,3). However, less is known
about the effects of acute hyperglycemia
on cerebral function. Anecdotal descrip¬
tions by patients with diabetes suggest
that when blood glucose is elevated,
changes in mood (such as increased irri¬
tability and feelings of diminished well-
being) occur and rapid thinking is more
difficult.
Published data on the effects of acute
hyperglycemia on cognitive function are
contradictory. Two studies (4,5) have
demonstrated impaired language skills
and reduced IQ during hyperglycemia
compared with euglycemia. Other studies
have shown no effect of acute hyperglyce¬
mia on cognitive function (6-8) or mood
(9). However, in the study by Gschwend
et al. (6), only two tests were used to as¬
sess cognitive function, and in the studies
by Draelos et al. (8) andWeinger et al. (9)
the study cohorts had chronically poor
metabolic control, which may have al¬
lowed cerebral adaptation to occur in re¬
sponse to prevailing high blood glucose
concentrations. A further study by Sin-
drup et al. (10) showed that short-term
hyperglycemia (blood glucose concentra¬
tion 17.1 mmol/1) with physiological hy-
perinsulinemia was associated with
increased sensory nerve conduction ve¬
locity and decreased motor latency in
nondiabetic subjects.
Earlier studies have been confined to
people with type 1 diabetes. Evidence is
accumulating that people with type 2 di¬
abetes are at risk of developing cognitive
impairment (11,12). This is probably a
consequence of synergistic interaction be¬
tween metabolic derangements associ¬
ated with diabetes and the structural and
functional changes that occur within the
central nervous system as part of the nor¬
mal aging process. People with type 2 di¬
abetes may be susceptible to cognitive
dysfunction during short-term changes in
blood glucose concentration. The present
study examined the effects of acute hyper¬
glycemia on a range of important cogni¬
tive function and key mood states in a
group of people with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Twenty adults (12
men) with type 2 diabetes were studied,
following recruitment from the diabetes
outpatient clinic at the Royal Infirmary of
Edinburgh. Baseline characteristics in¬
cluded median age 61.5 years (range
53.1-72.0), BMI 29.8 kg/m2 (range
22.0-34.6), known duration of diabetes
of 5.9 years (range 2.8-11.2), and HbAlc
7.5% (range 6.7-8.4). HbAlc, recorded
in the month before the study, was mea¬
sured by high-performance liquid chro¬
matography (Variant II Hemoglobin
From the department ofDiabetes, Royal Infirmary ofEdinburgh, Edinburgh, U.K.; and the department of
Psychology, University of Edinburgh, Edinburgh, U.K.
Address correspondence and reprint requests to Professor Brian M. Frier, Department of Diabetes, Royal
Infirmary of Edinburgh, Edinburgh EH16 4ES, Scotland, U.K. E-mail: brian.frier@luht.scot.nhs.co.uk.
Received for publication 16 January 2004 and accepted in revised form 19 July 2004.
B.M.F. has received grant support from Eli Lilly.
A table elsewhere in this issue shows conventional and Systeme International (SI) units and conversion
factors for many substances.
© 2004 by the American Diabetes Association.
Diabetes Care, volume 27, number 10, October 2004 2335
Cognitive function during acute hyperglycemia
Testing System; BioRad Diagnostics
Group, Hercules, CA) with a local nondi-
abetic reference range of4.3-6.5%. Three
of the subjects required insulin to treat
their diabetes, five were taking a single
antidiabetic drug, nine were taking a
combination of antidiabetic drugs, and
three were taking an antidiabetic drug
and once-daily isophane (NPH) insulin.
None of the participants had a history of
any other chronic disease, previous head
injury, seizure, blackouts, alcohol or drug
abuse, or psychiatric illness. Subjects
were screened for diabetes complications
and were excluded if they had evidence of
microvascular disease, with the exception
of background retinopathy. The presence
of retinopathy was ascertained using
direct ophthalmoscopy, peripheral neu¬
ropathy by clinical examination, and
nephropathy was presumed by the pres¬
ence of established microalbuminuria.
Ethical permission for the study was
approved by the local medical research
ethics committee. All subjects gave
written informed consent for participa¬
tion in the study.
Each subject participated in two lab¬
oratory sessions that were separated by at
least 2 weeks. A modified hyperinsuline-
mic glucose clamp (13) was used to main¬
tain blood glucose at a predetermined
level. In each study condition, the arteri-
alized blood glucose concentration was
initially stabilized at 4.5 mmol/1 for a pe¬
riod of 30 min. In the euglycemia condi¬
tion, the blood glucose concentrationwas
thereafter maintained at 4.5 mmol/1
throughout the study. In the hyperglyce¬
mia condition, blood glucose was raised
to 16.5 mmol/1 over a period of 20 min.
The blood glucose concentration was
maintained at the predetermined target
level for a further 10 min before com¬
mencing cognitive testing and was kept at
this level for a further 80 min while the
tests were administered. The subjects were
not informed which arm of the study was
being undertaken on each occasion, and
the two sessions were performed in a ran¬
domized and counterbalanced fashion.
Cognitive function tests
Validated tests of information processing,
tests of memory, and tests of attention
were administered during each study
condition.
Test of information processing
Trail Making B. This test, which was run
on a handheld computer (14,15), assesses
complex visual scanning and has a motor
component.
Digit Symbol test. This is a test of coding
performed at speed (16).
Reaction Time test. This is a test of psy¬
chomotor speed and information pro¬
cessing (17). SDs of the Simple and Four-
Choice Reaction Times were also
calculated, providing a measure of intra-
individual variability, and the coefficient
of variation was calculated.
Tests of memory. The memory and
learning tests that were used in this study
were chosen because they have previously
been shown (18) to be sensitive to meta¬
bolic disturbances such as hypoglycemia.
Verbal memory tests. 1) Auditory Verbal
Learning Test, immediate and delayed.
This is a test of immediate memory capac¬
ity, retrieval efficiency, and learning. The
delayed component measures longer-
term retention (19). 2) Logical Memory
Test, immediate and delayed. The Logical
Memory test (20), a test ofverbal learning,
measures immediate and delayed recall
following auditory presentation.
Visual memory tests. 1) Visual Reproduc¬
tion, immediate and delayed. This test
measures immediate and delayed recall fol¬
lowing nonverbal visual presentation (20).
2) Benton Visual Retention Test. This is a
test of immediate visual recall (21).
Working memory tests. 1) Digit Span For¬
wards and Backwards. In this test, a series
of lists ofnumbers is presented verbally to
the subject, and the lists progressively in¬
crease in length (20). 2) Letter/Number Se¬
quencing. A series of lists ofnumbers mixed
with letters is presented verbally (20).
Tests ofattention. The Test ofEveryday
Attention battery (22) was used to mea¬
sure attention and includes tests of visual
selective, auditory selective, divided, and
sustained attention and of attention
switching.
Parallel versions of the tests are avail¬
able for the Auditory Verbal Learning Test,
Logical Memory, the Benton Visual Reten¬
tion Test, and the Test of Everyday Atten¬
tion battery, and in the present study these
were used to minimize a learning effect be¬
tween the two study conditions. Through¬
out the study, the battery of testswas carried
out in a fixed order.
Mood questionnaire
The University of Wales Institute of Sci¬
ence and Technology (UWIST) mood ad¬
jective checklist was used to document
changes in mood experienced by the sub¬
jects during the two studies (23). There
are three main mood states: energetic
arousal (feeling lively/active versus tired/
sluggish), tense arousal (feeling anxious/
nervous versus relaxed/calm), and
hedonic tone (feeling happy versus sad).
Statistical analysis
The results were analyzed independently
for each test. A general linear model (re¬
peated-measures ANOVA) was used with
order of session (euglycemia-hyperglyce-
mia or hyperglycemia-euglycemia) as a
fixed effect, and condition (euglycemia or
hyperglycemia) as a within-subjects fac¬
tor. The above models were repeated with
the following variables added singly and
separately: sex as a fixed effect and with
age, glucose infusion rate, HbAlc, and the
three mood states as covariates. The order
effect was retained in the models when
reported in the results. A P value <0.05
was considered to be significant. The P
values reported in the tables for the core
model (including only condition and or¬
der) were generated from analyses with¬
out including sex and the covariates. The
P value reported in the tables for the ad¬
ditional fixed effect of sex and the covari¬
ates refers to analyses in which these were
added singly to the core model. Effect size
was calculated using Eta2. An Eta2 score
of 0.25-0.5 indicates a moderate effect
size. Power was calculated using nQuery,
which gives S2-based power for univariate
repeated-measures ANOVA. a was set at
0.05 (n = 20). Between-level correlation
was set at zero, which offers a conserva¬
tive power estimate because correlations
are generally modest and positive. The
power to detect an effect size of 0.25 =
85% and to detect an effect size of 0.50 =
98%. All analyses were performed using
SPSS version 11.0 for Windows.
RESULTS—- A stable blood glucose
plateau was achieved during each study
condition. The mean (±SD) arterialized
blood glucose concentration during the
euglycemia condition was 4.5 ± 0.2
mmol/1 and during the hyperglycemia
condition was 16.7 ± 0.6 mmol/1. Statis¬
tical analysis revealed that no significant
order effects had occurred for any of the
outcome variables of this study. The sig¬
nificant effects of acute hyperglycemia on
cognitive function remained significant in
all analyses after controlling for sex, age,
HbAlc, and glucose infusion rate.
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Table 1—Results of tests of information processing during euglycemia and hyperglycemia in 20 adults with type 2 diabetes
Subtest Euglycemia Hyperglycemia P F Eta2 Age Sex GIR HbAlc TA EA HT
Digit Symbol Substitution test 70.2 ± 8.4 66.8 ± 7.8 0.03 5.64 0.24 0.38 0.26 0.65 0.71 0.64 0.57 0.96
Trail Making B test 40.9 ± 7.8 43.9 ± 8.0 0.04 4.77 0.23 0.74 0.77 0.34 0.32 0.38 0.39 0.39
Simple Reaction Time test
Mean 359.9 ± 84.6 373.7 ± 72.3 0.10 2.99 0.14 0.81 0.43 0.76 0.33 0.41 0.28 0.08
SD 73.3 ± 11.2 77.5 ± 17.6 0.10 0.47 0.15 0.96 0.18 0.98 0.81 0.50 0.45 0.68
Coefficient of variation 21.09 ± 6.86 21.82 ± 6.01 0.38 0.82 0.01 0.92 0.19 0.82 0.65 0.31 0.09 0.16
Four-Choice Reaction Time test
Mean 710.0 ± 116.7 775.7 ± 122.9 <0.0001 23.05 0.56 0.55 0.12 0.48 0.92 0.46 0.76 0.74
SD 133.1 ± 23.6 139.5 ± 41.2 0.09 0.68 0.18 0.09 0.48 0.60 0.70 0.67 0.34 0.26
Coefficient of variation 18.73 ± 2.77 18.22 ± 4.02 0.64 0.23 0.01 0.06 0.76 0.61 0.68 0.80 0.41 0.95
Number of errors 0.5 ± 0.1 0.4 ± 0.1 0.43 0.54 0.09 0.54 0.65 0.36 0.62 0.51 0.22 0.31
Data are means ±SD. The effects of age, sex, glucose infusion rate (GIR), HbAlc, and mood as covariates are also shown (all P values). EA, energetic arousal; HT,
hedonic tone;TA, tense arousal.
Tests of information processing
The results of these tests are summarized
in Table 1. During acute hyperglycemia,
performance was significantly impaired
in the Trail Making B, Digit Symbol, and
Four-Choice Reaction Time tests. Perfor¬
mance in the Simple Reaction Time test
was not significantly impaired during hy¬
perglycemia. The coefficient of variation
for the Simple and Four-Choice Reaction
Time tests was not significantly different
between the euglycemia and hyperglyce¬
mia conditions.
Tests of memory
The results of the memory function tests
are summarized in Table 2. Acute hyper¬
glycemia had no significant effect on tests
of immediate or delayed memory. Perfor¬
mance in two tests of working memory
(Digit Span Backwards, Letter/Number
Sequencing) was impaired during acute
hyperglycemia.
Tests of attention
The results of the tests of attention are
summarized in Table 3.
Visual selective attention. The mean
number (±SD) ofmap symbols circled in
1 min was significantly fewer during hy¬
perglycemia. The number of symbols cir¬
cled in 2 min was also lower during
hyperglycemia, but the difference did not
achieve statistical significance. In the tele¬
phone search task, no difference was
demonstrated between euglycemia and
hyperglycemia in the number of symbols
located. The mean (±SD) time taken to
complete the task during euglycemia
was significantly faster than that during
hyperglycemia.
Auditory selective attention. The audi¬
tory elevator test with reversal was signif¬
icantly affected by hyperglycemia.
However, performance in the elevator
with distraction test was not impaired.
Sustained attention. Sustained atten¬
tion was not affected by hyperglycemia.
Attention switching. In the visual ele¬
vator task, no difference was observed in
the raw score between the two study con¬
ditions. However, a significantly longer
time was required to complete each
switch of the visual elevator task during
hyperglycemia.
Divided attention. In the task that in¬
volved search of a telephone directory
while counting, no significant difference
was observed in the number of symbols
that were located during either study con¬
dition. The time taken to complete the task
was longer during hyperglycemia corn-
Table 2—Results of tests ofmemory during euglycemia and hyperglycemia in 20 adults with type 2 diabetes
Subtest Euglycemia Hyperglycemia P F Eta2 Age Sex GIR HbAlc TA EA HT
Immediate memory
Immediate Logical Memory 27.2 ± 4.3 26.1 -t- 4.1 0.16 2.13 0.11 0.93 0.16 0.67 0.41 0.52 0.47 0.88
Immediate AVLT 35.0 ± 5.7 32.4 4.9 0.09 3.33 0.16 0.78 0.12 0.43 0.56 0.46 0.46 0.38
Benton Visual Retention Test 6.2 ± 1.2 5.9 + 0.9 0.30 1.16 0.06 0.82 0.88 0.31 0.32 0.21 0.63 0.18
Visual Reproduction 76.9 ± 7.6 77.9 + 7.5 0.51 0.44 0.02 0.64 0.95 0.79 0.39 0.30 0.12 0.66
Working memory
Digit Span Forwards 9.6 ± 1.3 9.2 -4- 1.6 0.33 0.99 0.05 0.53 0.18 0.53 0.41 0.48 0.54 0.61
Digit Span Backwards 8.6 ± 1.5 7.9 -4- 1.3 0.01 5.01 0.30 0.13 0.09 0.49 0.36 0.61 0.55 0.89
Letter/Number Sequencing 10.4 ± 1.9 9.4 -4- 1.6 0.02 6.94 0.25 0.24 0.10 0.60 0.38 0.17 0.31 0.87
Delayed memory
Delayed Logical Memory 13.2 ± 2.1 12.3 -4- 2.2 0.09 3.16 0.15 0.54 0.18 0.78 0.51 0.85 0.68 0.72
Delayed AVLT 8.2 ± 2.2 7.8 -4- 1.9 0.26 6.23 0.07 0.25 0.46 0.94 0.26 0.62 0.40 0.06
Delayed Visual Reproduction 14.1 ± 9.2 10.8 -4- 8.2 0.08 3.58 0.17 0.41 0.31 0.36 0.76 0.59 0.31 0.70
Data are means ± SD. The effects of age, sex, glucose infusion rate (GIR), HbAlc, and mood as covariates are also shown (all P values). AVLT, AuditoryVerbal Learning
Test; EA, energetic arousal; HT, hedonic tone; TA, tense arousal.
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Table 3—Results of tests of attention during euglycemia and hyperglycemia in 20 adults with type 2 diabetes
Subtest Euglycemia Hyperglycemia P F Eta2 Age Sex GIR HbAIC TA EA HT
Visual selective attention
Map Search (1 min) 35.0 -t- 6.7 32.2 + 5.1 0.04 3.36 0.22 0.17 0.21 0.39 0.44 0.31 0.26 0.41
Map Search (2 min) 64.8 + 7.4 62.5 + 8.7 0.31 1.07 0.06 0.60 0.57 0.57 0.41 0.27 0.44 0.72
Telephone Search (raw score) 3.6 0.7 3.7 + 0.6 0.34 0.95 0.05 0.11 0.19 0.30 0.62 0.44 0.51 0.96
Telephone Search (total time) 58.7 8.3 67.0 + 13.1 0.04 2.91 0.27 0.43 0.24 0.56 0.71 0.61 0.16 0.76
Auditory selective attention
Elevator Counting (with distraction) coco ■+- 1.1 8.3 -e 1.3 0.12 2.71 0.13 0.56 0.50 0.83 0.47 0.32 0.28 0.06
Elevator Counting (with reversal) 5.3 -t- 1.7 4.4 + 1.4 0.01 7.44 0.29 0.12 0.08 0.49 0.50 0.38 0.24 0.17
Attention switching
Visual Elevator (raw score) 8.9 a- 1.1 8.5 0.9 0.17 2.01 0.10 0.69 0.85 0.08 0.90 0.19 0.87 0.59
Visual Elevator (switch time) 4.3 1.0 4.7 0.9 0.001 17.44 0.49 0.15 0.43 0.60 0.26 0.09 0.63 0.20
Divided attention
Telephone Search (with counting 62.3 -t- 9.5 67.2 + 17.1 0.10 2.71 0.12 0.56 0.25 0.78 0.53 0.42 0.21 0.60
total time)
Telephone Search (with counting 1.0 + 0.6 1.2 a- 0.6 0.05 4.45 0.20 0.31 0.37 0.59 0.62 0.46 0.54 0.68
time per target)
Sustained attention
Elevator Counting 6.6 0.68 6.7 + 0.67 0.79 0.07 0.01 0.1 0.18 0.68 0.38 0.30 0.31 0.27
Lottery 9.6 h- 0.7 9.7 + 0.6 0.63 0.24 0.01 0.48 0.18 0.93 0.67 0.27 0.82 0.26
Data are means ±SD. The effects of age, sex, glucose infusion rate (GIR), HbAlc, and mood as covariates are also shown (all P values). EA, energetic arousal; HT,
hedonic tone; TA, tense arousal.
pared with during euglycemia, but this
difference was not significant. The time-
per-target score, which is the ratio of the
number of circled symbols divided by the
time taken for the task, was significantly
higher during acute hyperglycemia.
Mood
The results of the mood questionnaire are
shown in Fig. 1. Hedonic Tone and Ener¬
getic Arousal scores were significantly
lower during hyperglycemia (decreased
happiness and alertness), whereas feel¬
ings of Tense Arousal were greater (in¬
creased agitation).
CONCLUSIONS— The present study
demonstrated that acute hyperglycemia
in people with type 2 diabetes significant¬
ly impaired speed of information process¬
ing, working memory, and some aspects
of attention. It also had a profound detri¬
mental effect on key mood states.
It was apparent from the results of
the present study that performance was
impaired during acute hyperglycemia in
tests that required a speedy response,
suggesting that accuracy was preserved
at the expense of speed. For example, in
the Map Search, a test of visual selective
attention, significantly fewer symbols
were identified after 1 min during hy¬
perglycemia when compared with eug¬
lycemia. However, in the overall 2-min
score no significant difference was ob¬
served, which indicates that a "ceiling
effect" is reached after 2 min. In the
Telephone Search test and the Tele¬
phone Search While Counting test, no
significant difference could be dis¬
cerned in the total number of symbols
located during either study condition, but
the time taken to complete these tests was
significantly longer during hyperglycemia.
In the Visual Elevator task no significant dif¬
ference in the raw score was observed dur¬
ing hyperglycemia compared with
euglycemia, but the time taken to complete
each switch was significantly greater during
hyperglycemia.
The cognitive domains that were
Hedonic Tone Energetic Arousal Tense Arousal
Figure 1—Graph showing mean (±SD) scores of the UWIST mood adjective checklist during
euglycemia (11) and hyperglycemia (■).
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most adversely affected by hyperglycemia
in people with type 2 diabetes were infor¬
mation processing speed and working
memory. Performance in three of the four
processing speed tests was significantly
impaired during hyperglycemia. In the
memory domain, the only two tests af¬
fected were of working memory; acute
hyperglycemia did not have a significant
detrimental effect on tests of immediate
and delayed memory. This suggestion is
supported by the "attention" results,
which also demonstrated a reduction in
speed of information processing (rather
than accuracy), and this was particularly
apparent in tests of attention that made
demands onworkingmemory, e.g., visual
elevator switch time, which requires stor¬
age and manipulation of information.
In addition to the specific cognitive
demands of the tasks affected by hyper¬
glycemia, impairment of performance in
these tests may reflect their relative com¬
plexity. Davis et al. (5) demonstrated that
in children with type 1 diabetes cognitive
function was impaired during acute hy¬
perglycemia but that this was limited to
complex tests of cognitive ability. In the
present study, performance in relatively
simple tests of information processing
(Simple Reaction Time), memory (tests of
immediate and delayed verbal and visual
memory, Digit Span Forwards), and at¬
tention (Lottery and Elevator Counting)
was not affected by acute hyperglycemia.
However, during acute hyperglycemia a
significant decrement in performance was
observed in comparatively more difficult
tasks, such as the Four-Choice Reaction
Time test, Digit Span Backwards, Letter/
Number Sequencing, and Elevator
Counting with Reversal.
Mood was also adversely affected by
acute hyperglycemia. The changes in
mood included increased feelings of agi¬
tation and anxiety (increased tense
arousal), increased feelings of tiredness
and lethargy (decreased energetic
arousal), and decreased feelings of happi¬
ness (decreased hedonic tone). Further
analysis of the cognitive function test re¬
sults with mood as a covariate demon¬
strated that the impairment in cognitive
function occurred independently of
changes in mood state.
The results of the present study indi¬
cate that acute hyperglycemia has a signif¬
icantly adverse effect on various aspects of
cognitive function and mood. However,
with the exception of the Four-Choice Re¬
action Time test, the Eta2 values for the
tests of cognitive function were modest.
The study had 80% power to detect an
effect size of 82 = 0.21. Therefore, we
were not able to detect small effect sizes.
However, at that level, they might not be
of great practical significance. The num¬
ber of subjects included in the study is
large by comparison with most glucose
clamp studies. Apart from giving more
confidence in the results, this was also
done because of the relatively large num¬
bers of cognitive outcomes, which were
included because they have been found to
be sensitive to the effects of hypoglyce¬
mia. These obviously carry the possibility
of type I errors, and it will be useful to
carry out a further study using a larger
sample to try and replicate these findings.
Nevertheless, it was important for this
first, systematic study of the cognitive ef¬
fects of hyperglycemia to include the
main domains of cognitive function. The
effects of acute hypoglycemia on cogni¬
tive function have been observed to re¬
turn to normal within 90 min of the
restoration ofeuglycemia (24,2 5). It is not
known whether the effect of hyperglyce¬
mia on cognitive function ormood is sus¬
tained or protracted, and this will require
further investigation.
Some indirect evidence suggests that
hyperglycemia may have adverse affects
on cerebral function. For example, acute
hyperglycemia has been shown (26) to
enhance cerebral damage resulting from
ischemic stroke. There is also accumulat¬
ing evidence to suggest that chronic hy¬
perglycemia, as indicated by surrogate
markers such as the presence of periphe¬
ral neuropathy or retinopathy, is involved
in the pathogenesis of the cognitive impair¬
ment associated with diabetes (27-29).
The findings of the present study are
in concordance with anecdotal reports
from people with type 2 diabetes and are
supported by the results of two recent
studies. Cox et al. (30) have demonstrated
changes in mood and impairment in cog¬
nitive function during acute hyperglyce¬
mia in people with type 1 and type 2
diabetes, and a study (31) in Canada has
shown impairment of cognitive function
in people with type 2 diabetes following
oral ingestion of 50 g of carbohydrate.
Taken together, these findings are of prac¬
tical importance to people with type 2 di¬
abetes in whom exposure to moderate
and intermittent hyperglycemia is com¬
mon. Working memory and processing
speed are fundamental aspects of cog¬
nition in everyday life. The deleterious
effects of hyperglycemia on cognitive
function and mood states may signifi¬
cantly interfere with many activities of
daily living and may influence therapeutic
strategies aimed at treating postprandial
hyperglycemia.
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}: 1 Sommerfield AJ, Wilkinson IB, Webb DJ, Frier BM. Vessel
wall stiffness in type 1 diabetes and the central hemodynamic
effects of acute hypoglycemia. Am J Physiol Endocrinol Metab
293: EOOO-EOOO, 2007. First published August 28, 2007;
doi: 10.1152/ajpendo.OOl 14.2007.—Objective: To examine the effects
of intravenous insulin and acute hypoglycemia on arterial wall stiff¬
ness and central hemodynamic responses in adults with and without
}:2 type 1 diabetes. Research Design and Methods: In 30 young male
volunteers [10 nondiabetic (Group 1); 10 with type 1 diabetes, <5 yr
duration (Group 2); 10 with type 1 diabetes, >15 yr duration (Group
5)], intravenous insulin was administered to provoke an acute auto¬
nomic reaction (R) to hypoglycemia. Heart rate, peripheral blood
}:3 pressure, and pulse wave analysis (radial artery) were monitored.
Augmentation index (AIx), a measure of arterial wall stiffness and
wave reflection, and central arterial pressure were recorded. Results:
At baseline, no significant differences were observed between Groups
1 and 2 in either AIx or in central arterial pressure, but in Group 3,
both measures were significantly higher. All three groups exhibited
similar responses to intravenous infusion of insulin and to hypogly¬
cemia: AIx fell progressively from baseline to R, peripheral systolic
blood pressure increased, and central systolic pressure decreased.
Conclusion: Compared with age- and sex-matched nondiabetic con¬
trols, people who had type 1 diabetes for a long duration had increased
stiffness of vessel walls. The opposing responses in peripheral and
central systolic pressures during hypoglycemia may be related to the
reduction in AIx, which causes diminished amplification of the sys¬
tolic pressure wave. Changes in AIx are probably mediated by a direct
action of insulin on arterial endothelium, or changes in heart rate.
These functional changes may contribute to the increased cardiovas¬
cular morbidity that is associated with type 1 diabetes of long
duration.
i:4 arterial wall stiffness; central arterial pressure; insulin
people with type l diabetes are frequently exposed to acute
hypoglycemia, which, in humans, is associated with profound
hemodynamic changes, including an increase in heart rate and
stroke volume, increased myocardial contractility, and a rise in
cardiac output (14, 15). Changes in peripheral blood pressure
include an increase in systolic and a decrease in diastolic
pressure, with no change in mean arterial pressure. The effects
on central arterial pressure are not known. Acute hypoglycemia
also has significant, albeit transient, effects on peripheral blood
that encourage hemostasis and increase blood viscosity (15).
These changes influence capillary blood flow and in some
tissues may predispose to intravascular stasis during hypogly¬
cemia. The hemodynamic and hematological changes that
occur during acute hypoglycemia do not appear to compromise
Address for reprint requests and other correspondence: B. M. Frier, Dept. of
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vascular perfusion in the normal healthy vasculature, but they
may have potentially adverse effects in people with diabetes, in
whom endothelial dysfunction and vascular disease are com¬
mon, and in whom premature atherosclerosis and cardiovascu¬
lar disease are often present. Indeed, acute hypoglycemia may
precipitate an acute vascular event or a dysrhythmia in people
who have preexisting coronary heart disease (15). Angina and
acute myocardial infarction have been documented, albeit
infrequently and anecdotally, as the direct consequences of
acute hypoglycemia (35).
Arterial blood pressure is usually recorded noninvasively at
the brachial artery by sphygmomanometry. It is assumed that
the pressure is the same throughout the arterial tree, and that it
represents an accurate index of aortic peak pressure and of left
ventricular systolic pressure, and so of left ventricular after-
load. However, blood pressure measured in the peripheral
circulation is not an accurate estimate of central pressure
because of amplification of the pressure pulse between central
and peripheral arteries (34, 43). Normally, there is amplifica¬
tion of the pulse pressure between the aorta and brachial artery
(24). It is the aortic, rather than the brachial, pressure that
determines left ventricular workload (42, 47).
Central arterial pressure and arterial wall stiffness, which are
independent predictors of cardiovascular morbidity (1,3, 20,
25, 31), can be studied noninvasively using pulse wave anal¬
ysis (30, 32, 44, 51), which requires the external application of
a micromanometer-tipped probe over a peripheral artery (6, 8).
Pulse wave analysis allows the measurement of central arterial
pressure, and the degree of its augmentation by pulse wave
reflection, to be studied reliably and noninvasively (32). The
system utilizes applanation tonometry, with the external appli¬
cation of a micromanometer-tipped probe to record peripheral
pulse waveforms. The radial artery is usually used for these
measurements because of its close proximity to and the support
provided by nearby bony structures (6, 8). Changes occur in the
pressure contour as it travels from the aorta to more peripheral
sites, so that pressures at the radial artery cannot be used
directly as a surrogate to predict central pressure in the aorta.
However, it is possible to estimate the central aortic pressure
wave from measurements of radial artery tonometry with the
use of a mathematical transformation (8). Several studies have
validated the accuracy and reliability of pulse wave analysis
(44, 51). Contraction of the left ventricle generates a pressure
wave that travels along the major arteries until it meets sites of
resistance (high-resistance arterioles), and then the wave is
reflected back to the heart (29). The stiffness of the arterial wall
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E2 HEMODYNAMIC RESPONSES TO HYPOGLYCEMIA
influences the velocity of the reflected wave. In healthy young
people, the reflected wave reaches the heart during diastole
and, by increasing diastolic pressure, enhances coronary per¬
fusion. However, when arterial stiffening has developed, the
increased pulse wave velocity of the stiffened arteries leads to
earlier reflection of the wave, so that it returns to the heart
during late systole (31, 33). The increase in systolic pressure
that results from this earlier reflection of the pressure wave is
known as "augmentation," with augmentation index (AIx)
}: s measured as the augmented pressure expressed as a percentage
of the pulse pressure. AIx increases with age and in disease
states such as hypertension (28) and hypercholesterolemia
(49). It is also influenced by heart rate; a decrease in AIx is
observed with an increase in heart rate (45). Central arterial
pressure and waveform convey important information about
cardiovascular status (21, 27, 31).
In view of the frequency of exposure to acute hypoglycemia
in people with diabetes and the potential effects of acute
hypoglycemia on the cardiovascular system, it is valuable to
establish the effects of acute hypoglycemia on central arterial
pressure and left ventricular load. The present study sought to
measure arterial wall stiffness and the central hemodynamic
responses to the administration of intravenous insulin and the
induction of acute hypoglycemia in people with type 1 diabetes
of varying duration and in nondiabetic subjects.
METHODS
Subjects. To avoid potential gender differences in the counterregu-
latory hormonal responses to hypoglycemia (10), three groups of male
subjects, matched for age, body mass index (BMI), and peripheral
blood pressure, were studied: 10 nondiabetic volunteers (Group 1), 10
subjects with type 1 diabetes of short duration (<5 yr) (Group 2), and
10 subjects with type 1 diabetes of longer duration (>15 yr) (Group
3). Subjects with diabetes were matched for glycated hemoglobin
•:6 (HbAlc) and were recruited from the outpatient clinic at the Depart¬
ment of Diabetes at the Royal Infirmary of Edinburgh. All patients
were receiving treatment with a basal-bolus insulin regimen consist¬
ing of a preprandial short-acting insulin analog and a long-acting
insulin analog, administered once daily. Blood pressure and plasma
cholesterol concentration were measured before inclusion in the study.
HbAlc was measured by HPLC (Variant II Hemoglobin Testing
System; Bio-Rad Diagnostics Group, Hercules, CA), with a local
Diabetes Control and Complications Trial-adjusted nondiabetic refer¬
ence range of 4.3-6.5%. Subjects were excluded from the study if
there was a history of hypertension (blood pressure >140/80 mmHg),
hypercholesterolemia (total cholesterol >5.0 mmol/1), or other
chronic disease or a history of a previous head injury, alcohol or drug
abuse, seizures, or blackouts. All of the subjects were nonsmokers,
had no intercurrent illness, and were not taking any regular medication
(other than insulin for diabetes). Subjects with diabetes were excluded
if they had any evidence of microvascular disease other than back¬
ground diabetic retinopathy (2 subjects in Group 2 and 5 subjects in
Group 3). The presence of retinopathy was determined by direct
ophthalmoscopy, peripheral neuropathy by clinical examination, and
nephropathy by the presence of microalbuminuria (albumin-to-creat-
inine ratio >2.5 mg/mmol for women and >3.5 mg/mmol for men).
All potential participants underwent standard autonomic function
testing (13) before inclusion in the study, and any with autonomic
dysfunction were excluded. Subjects were also excluded if they had a
history of impaired awareness of hypoglycemia.
Studies were postponed if a subject had experienced hypoglycemia
in the preceding 48 h, and subjects were required to measure their
blood glucose frequently during this period, including bedtime tests
on the evening before the study to identify biochemical hypoglycemia.
Ethical permission for the study was given by the Lothian Research
Ethics Committee. All subjects gave their written, informed consent.
Procedure. Each study session began at 0800 after a 10- to 12-h
overnight fast. The subjects with type 1 diabetes omitted their insulin
on the morning of the study. A hyperinsulinemic glucose clamp (12)
was used initially to maintain euglycemia (blood glucose concentra¬
tion 4.0-7.0 mmol/1) for 20 min before the induction of acute
hypoglycemia. Because of the variable fasting blood glucose level in
people with diabetes, it took a variable time to achieve euglycemia
(usually between 20 and 30 min). An intravenous cannula was
inserted retrogradely into a vein on the dorsum of the nondominant
hand for regular blood sampling. The hand was placed in a heated
blanket to arterialize the venous blood. A second intravenous cannula
was inserted into a vein in the antecubital fossa of the same arm for
infusion of human soluble insulin (Humulin S; Eli Lilly) and 20%
dextrose. Intradermal lignocaine (1%) was used for insertion of each
cannula. Insulin was infused at a constant rate of 60 mU-m~2-min_l
using an IMED Gemini PCI pump (Alaris Medical Systems, San
Diego, CA). A variable intravenous infusion of 20% dextrose was
given simultaneously. The rate of dextrose infusion was varied ac¬
cording to the arterialized blood glucose concentration. This was
measured at the bedside using the glucose oxidase method (Yellow
Springs Instrument 2300 Stat, Yellow Springs, OH). Blood glucose
concentration was measured every 3 min initially and then every 5
min once a stable level had been achieved.
Because the purpose of inducing acute hypoglycemia was to
provoke an acute autonomic reaction with profound activation of the
sympathoadrenal system, a rapid fall in blood glucose was then induced by
infusing insulin intravenously at a rate of 2 mU-kg^1 -min-1. This
caused a controlled decline in blood glucose to a level that triggered
the autonomic reaction associated with hypoglycemia. This method of
inducing hypoglycemia simulates the development of hypoglycemia
under everyday conditions and cannot be induced using the hyperin¬
sulinemic glucose clamp technique. Any variability among subjects in
the rate of fall in blood glucose and the depth of the hypoglycemia
achieved is inconsequential, as the intention is to lower blood glucose
to the blood glucose threshold at which autonomic activation is
stimulated.
The autonomic reaction (designated as R) was identified by an
abrupt rise in heart rate (15% above baseline), the rapid onset of
autonomic symptoms, such as sweating and tremor, and a rapid rise in
peripheral systolic blood pressure. When the R occurred, the clock
timer was reset to zero, and all subsequent measurements were timed
relative to this point. This accommodates the variable time interval
that occurs among individuals in the development of the R using the
insulin infusion technique (9). As soon as R had occurred, the insulin
infusion was discontinued, and hypoglycemia was reversed using
an intravenous infusion of 20% dextrose to restore normoglycemia.
All subjects consumed a meal on completion of the study.
Measurements. During the study, arterialized blood glucose was
measured at the bedside (Yellow Springs Instrument 2300 Stat) every
5 min until R and every 15 min thereafter until R+ 30 min. The
maximal hemodynamic changes in response to hypoglycemia occur in
the 30 min following the onset of the R (14). Pulse wave analysis at
the radial artery was therefore performed every 5 min until R and
every 5 min thereafter until R+30 min. Heart rate was monitored
continuously using a pulse oximetry probe. Peripheral blood pressure
was recorded every 5 min using a digital automated sphygmoma¬
nometer.
The Edinburgh Hypoglycemia Scale (11), a validated subjective
self-rating questionnaire, was used to document the symptoms of
hypoglycemia experienced by the subjects during the study. The
symptoms of hypoglycemia were classified as autonomic (hunger,
palpitations, sweating, shaking), neuroglycopenic (drowsiness, confu¬
sion, inability to concentrate, speech difficulty, blurred vision), and
nonspecific (malaise, nausea, headache). Each symptom was graded
on a Likert scale of 1 to 7 (1 = not present, 7 = very intense). The
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questionnaire was applied at baseline and at 5-min intervals thereafter
until the onset of the R. It was repeated at R+30 min.
Statistics. A general linear model (repeated-measures ANOVA)
was used to compare means within individual groups. Between
groups, an ANOVA with post hoc r-tests was used. Correlation
analyses for changes in AIx and insulin dose and duration of the study
were performed using the Pearson correlation. A P value <0.05 was
considered to be significant. All analyses were performed using SPSS
version 11.0 for Windows. All results are expressed as means ± SD.
RESULTS
The clinical characteristics of the subjects in the study are
shown in Table 1.
Changes in blood glucose concentration. The blood glucose
concentrations (means ± SD) at baseline were 4.3 ± 0.5
mmol/1 in Group 1 (nondiabetic) and 8.4 ±2.1 and 8.9 ± 3.1
mmol/1 in Groups 2 and 3 (diabetic), respectively. Following
application of the euglycemic clamp, the blood glucose con¬
centrations were stabilized at 4.2 ± 0.1 mmol/1 (Group 1),
4.3 ± 0.2 mmol/1 (Group 2), and 4.3 ± 0.2 mmol/1 (Group 3).
The nadir blood glucose concentrations at R were 2.9 ± 0.3
mmol/1 (Group 1), 2.8 ± 0.3 mmol/1 (Group 2), and 2.6 ± 0.3
mmol/1 (Group 3) (P — 0.2).
Peripheral blood pressure. No significant differences were
observed in the peripheral systolic, diastolic, and mean arterial
pressures among the three groups at baseline. In all three
groups of subjects, an increase in peripheral systolic blood
pressure and a decrease in peripheral diastolic pressure oc¬
curred at R compared with baseline (Table 2). Systolic and
diastolic pressures had returned to baseline levels by R+30
min in all three groups (Table 2).
Central arterial pressure. Central systolic blood pressure at
baseline was significantly higher in Group 3 compared with
Groups 1 and 2 (Table 1). A small, but significant, reduction in
central systolic pressure was observed at R in all three groups
compared with the respective baseline levels (Table 2). No
change in central diastolic blood pressure was observed
throughout the study in any of the three groups (Table 2).
Heart rate and autonomic symptom score. The induction of
hypoglycemia and the onset of the R were associated with
significant increments of heart rate and autonomic symptom
score in all three groups compared with baseline levels (Table
E3
2). In all groups, the heart rate and the autonomic symptom
score had returned to baseline values at R+30 min.
AIx. At baseline, no difference in AIx was discernible
between Group 1 and Group 2, whereas the AIx in Group 3
was higher than in either of these groups (Table 1).
All three groups exhibited a progressive decline in AIx
between baseline and the development of hypoglycemia at R
(Fig. 1). The fall in AIx from baseline to R was significantly Ft,
less in Group 3 compared with the reduction in AIx from AQ
baseline to R in Groups 1 (JP < 0.01) and 2 (P < 0.01). At
R+30 min, AIx had risen to approach baseline levels in all
three groups.
Changes in AIx, duration of insulin exposure, and insulin
dose. There was no significant difference in the duration of the
euglycemic clamp procedure or the time taken to induce
hypoglycemia among the three groups. The duration of the
euglycemic clamp [means (SD)] measured 37.3 (11.1) min in aq
Group 1, 44.2 (8.5) min in Group 2, and 46.9 (10.0) min in
Group 3 (P = 0.3). The time taken to induce the R measured
18.1 (6.4) min in Group 1, 22.4 (5.2) min in Group 2, and 20.7
(6.9) min in Group 3 (P = 0.5). However, among individuals
within the separate groups, a correlation was observed between
the time taken to induce hypoglycemia and changes in AIx,
with a longer duration being associated with a greater reduction
in AIx (Group 1, r — 0.25, P = 0.04; Group 2, r — 0.38, P =
0.3; Group 3, r = 0.28, P = 0.04). Similarly, no significant
difference was found in the amount of insulin infused during
the studies among the three different groups. The total insulin aq
dose administered was 14.6 (4.4) U in Group 1, 12.7 (3.1) U in
Group 2, and 15.7 (4.8) U in Group 3 (P = 0.6). However,
within the separate groups, a significant correlation was present
between changes in AIx and insulin exposure. A greater
decrement in AIx was associated with greater insulin exposure
(Group 1, r = 0.30, P = 0.05; Group 2, r = 0.34, P = 0.04;
Group 3, r = 0.3, P = 0.03).
DISCUSSION
Arterial stiffness is increased in people with type 2 diabetes
(5, 7, 16, 17), in their nondiabetic relatives (19), and in people
with impaired glucose tolerance (37). In people with type 1
diabetes, discrepant results have been reported. Some studies






(n = 10) ANOVA
Age, yr 29.4 (4.4) 30.2 (7.9) 31.1 (4.7) P = 0.8
Duration of diabetes, yr 3.0(1.1) 18.4(0.7) P = 0.3
HbAlc 7.6 (0.7) 8.1 (0.3) P = 0.2
Body mass index, kg/m2 24.0(1.2) 24.2(1.1) 24.4(1.4) P = 0.9
Total plasma cholesterol, mmol/1 4.5 (0.8) 4.7 (0.6) 4.8 (0.6) P = 0.4
Peripheral systolic BP, mmHg 121.7(10.5) 123.3 (6.5) 125.9(9.8) P = 0.3
Peripheral diastolic BP, mmHg 65.6 (7.4) 69.4 (7.7) 72.7 (6.7) P = 0.2
Mean arterial pressure, mmHg 92.4 (8.7) 87.5(9.1) 92.5(9.1) P = 0.4
Central systolic BP, mmHg 114.4(14.9) 110.9(8.0) 121.5(9.7) P < 0.05
Central diastolic BP, mmHg 77.2(10.5) 74.8 (8.4) 79.0(8.7) II O ON
Augmentation index* 9.3 (12.4) 10.0 (8.3) 21.8 (6.9) P < 0.05
Results are expressed as means (SD). Group 1, nondiabetic subjects; Group 2, type 1 diabetes, <5 yr duration; Group 3, type 1 diabetes, >15 yr duration.
BP, blood pressure; HbAlc, glycated hemoglobin (nondiabetic range 4.3-6.5%). *Measured as augmented pressure expressed as %pulse pressure. Post hoc r-test
results are as follows. Central systolic pressure: Group 3 vs. Group I, P — 0.04; Group 3 vs. Group 2, P = 0.047. Augmentation index: Group 3 vs. Group
1, P = 0.02; Group 3 vs. Group 2, P = 0.002.
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Table 2. Hemodynamic measurements in study participants
Group 1 Group 2 Group 3
(n = 10) (« = 10) (n = 10)
Peripheral systolic BP,
mmHg
EC 121.7(10.5) 123.3 (6.5) 125.9 (9.8)
0 121.1 (9.7) 117.8(9.4) 131.8 (11.2)
R *143.5(11.8) *137.8(9.8) *144.5(7.9)
R + 30 min 116.9(11.0) 114.6(12.2) 130.6 (8.1)
Peripheral diastolic BP,
mmHg
EC 65.6 (7.4) 69.4 (7.7) 72.7 (6.7)
0 68.1 (6.1) 68.7 (7.0) 72.5 (7.1)
R *61.6 (6.5) *63.6 (9.9) *68.7 (3.6)
R + 30 min 66.5(11.2) 67.4(14.6) 71.1 (6.7)
Mean arterial pressure,
mmHg
EC 92.4 (8.7) 87.5 (9.1) 92.5 (9.1)
0 92.6 (6.5) 88.1 (8.1) 92.9 (8.8)
R 92.3 (7.8) 87.7 (7.9) 93.9(11.2)
R + 30 min 92.3 (8.5) 87.43 (9.0) 89.6 (12.0)
Central systolic BP,
mmHg
EC 114.4(14.9) 110.9 (8.0) 120.5 (9.2)
0 114.2(12.6) 109.9 (7.2) 123.8 (6.4)
R *110.8(13.9) *108.1 (7.0) *118.0 (7.7)
R + 30 min 113.5 (5.6) 110.5 (9.2) 122.8 (7.8)
Central diastolic BP,
mmHg
EC 77.2(10.5) 74.8 (8.4) 79.0 (8.7)
0 77.3(11.1) 75.1 (7.4) 79.1 (8.1)
R 77.3(10.4) 74.8 (8.8) 78.7 (8.9)
R + 30 min 76.9 (8.9) 74.4 (9.0) 78.9 (8.2)
Heart rate, beats/min
EC 60.5(11.7) 66.5(7.1) 70.7 (7.8)
0 60.2(11.1) 66.3 (9.0) 68.4(10.1)
R *76.7(12.8) *82.2 (8.4) *79.0(7.1)
R + 30 min 59.1 (10.2) 66.2 (9.7) 66.8 (8.3)
Autonomic symptom
score
EC 0.2 (0.2) 0.5 (0.4) 0.2(0.1)
0 0.4 (0.6) 0.6 (0.3) 0.8 (0.6)
R *11.2(4.4) *9.9 (5.1) *7.9(1.4)
R + 30 min 0.5 (0.3) 0.8 (0.8) 0.9(1.1)
Results are expressed as means (SD). Group I, nondiabetic subjects; Group
2, type 1 diabetes, <5 yr duration; Group 3, type I diabetes, >15 yr duration.
EC, euglycemic clamp commenced; 0, start of insulin infusion to induce
hypoglycemia; R, autonomic reaction. *Significant within-group difference
(P < 0.05).
have demonstrated greater arterial stiffness compared with
nondiabetic controls (4, 36, 46), whereas others have shown
either no difference (23) or lower arterial stiffness (26). These
differences may relate to the methodologies used and to patient
selection, with participants differing in their duration of dia¬
betes, age and gender, smoking status, peripheral blood pres¬
sure, serum cholesterol concentrations, and the presence or
absence of microvascular disease.
In the present study, arterial stiffness and central arterial
pressure were studied both in nondiabetic adults and in people
with type 1 diabetes of differing duration, using radial artery
pulse wave analysis and calculation of the AIx, and the sub¬
jects, all of whom were nonsmokers, were matched for age,
gender, blood pressure, serum cholesterol, and body mass
index. The results showed no difference in vessel wall stiffness
or central arterial pressure between a group with well-con-
trolled type 1 diabetes of short duration and a matched cohort
of healthy nondiabetic volunteers. However, the people with
type 1 diabetes of longer duration had greater stiffness of the
arterial vessel wall and an elevated central arterial pressure
compared with nondiabetic controls. This suggests that the
duration of exposure to chronic hyperglycemia influences ves¬
sel wall stiffness rather than the presence of type 1 diabetes
itself. This may result from structural changes caused by the
gradual deposition of advanced glycation end products within
the walls of large blood vessels (18). The endothelium (22, 50)
and arterial wall smooth muscle bulk and tone (2) (the latter
under the control of the endothelium) also influence the elas¬
ticity of arteries, and it is also possible, therefore, that in¬
creased vessel wall stiffness in people with type 1 diabetes of
long duration is the result of functional changes that occur
within the endothelium with increasing duration of diabetes.
In the present study, the rise in peripheral systolic blood
pressure that is known to accompany acute insulin-induced
hypoglycemia was accompanied by a reduction of central
systolic blood pressure. These findings highlight the potential
for divergent responses of central and peripheral arterial pres¬
sures and support the premise that the measurement of periph¬
eral blood pressure by conventional methods does not provide
an accurate measure of the central arterial pressure load on the
left ventricle. Specifically, the results show how the changes of
central and peripheral arterial pressures differ in response to
the stress provoked by acute hypoglycemia and mediated by
sympathoadrenal stimulation. It could be speculated that the
reduction in central arterial pressure that was observed during
acute hypoglycemia may lead to a reduction of coronary
perfusion, which could potentially precipitate a vascular event
in people with vascular disease.
The difference that was observed between the responses of
peripheral and central systolic blood pressures to insulin-
induced hypoglycemia is indicated by the observed changes in
AIx; a reduction in AIx reflects diminished amplification of the
systolic pressure wave and so causes a net overall reduction in
central arterial systolic blood pressure. It is possible that this
observed change in AIx had resulted either from changes in
heart rate (45) or from the actions of vasoactive hormones that
are secreted in response to hypoglycemia (38), or as a combi¬
nation of both effects. An increment in heart rate of 10




Fig. 1. Mean change in augmentation index (AIx). Group 1, nondiabetic
subjects; Group 2, type 1 diabetes, <5 yr duration; Group 3, type 1 diabetes,
>15 yr duration. EC, euglycemic clamp commenced; 0, start of insulin
infusion to induce hypoglycemia; R, autonomic reaction; R—20, R—15,
R—10, and R—5, 20, 15, 10, and 5 min before R, respectively; R+30, 30 min
after R. *P < 0.0001 compared with values at 0.
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norepinephrine promotes an increase in AIx (48). However, in
the present study, the AIx initially was observed to fall during
euglycemia, before any stimulated changes in heart rate, auto¬
nomic symptom score, or peripheral blood pressure. Insulin per
se may have a direct effect on the functional integrity of large
blood vessels. In the present study, no significant differences
were observed in the duration of insulin exposure or in the total
insulin dose administered, but it was observed that, in individ¬
uals within each study group, a significant correlation existed
between changes in AIx and the duration of insulin exposure
and, consequently, the amount of insulin infused. This would
support the suggestion that the early changes in AIx may
therefore be a consequence of the direct action of insulin on
endothelial function or on smooth muscle tone of large arteries.
This interpretation would be consistent with the results of other
studies that have demonstrated that the intravenous adminis¬
tration of insulin increases the distensibility of large arteries
(39, 40).
The decrement of AIx was less in the group with type 1
diabetes of longer duration compared with that of subjects with
diabetes of short duration and nondiabetic subjects. This would
be consistent with greater stiffness and diminished elasticity of
the vessel walls of large arteries in people with type 1 diabetes
of long duration. Consistent with this observation, Wester-
): 11 backa et al. (41) have shown that the effect of insulin to reduce
vessel wall stiffness in large arteries is diminished in people
with type 1 diabetes who have no vascular complications. The
mean duration of type 1 diabetes in their participants was 18 yr
(41), which is similar to the duration of diabetes of Group 3 in
the present study. It has to be acknowledged that the algorithm
to relate peripheral and central pressures by applanation tonome¬
try was derived in nondiabetic subjects. However, in the present
study, the changes in the central hemodynamic responses to
insulin infusion and the induction of acute hypoglycemia were
similar in both the nondiabetic and the diabetic groups.
Type 1 diabetes is associated with an increased prevalence
of cardiovascular disease, and vessel wall stiffness is an inde¬
pendent predictor of cardiovascular morbidity and mortality.
The present study has demonstrated that a greater duration of
type 1 diabetes was associated with an increase in vessel wall
stiffness, before the development of overt macrovascular dis¬
ease. Central systolic pressure at rest was also greater in people
with type 1 diabetes of longer duration, although peripheral
blood pressure did not differ among the three study groups.
Changes in brachial pressure may therefore underestimate
changes in aortic pulse pressure and the response of left
ventricular systolic function to hemodynamic stress in people
who have had type 1 diabetes for several years. These vascular
changes and the attendant rise in central arterial blood pressure
may contribute to the increased risk of cardiovascular morbid¬
ity in people with type 1 diabetes.
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